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Amyotrophic Lateral Sclerosis (ALS) is a rapid and fatal neurodegenerative 
disease marked by progressive muscle weakness and wasting. Approximately 
50% of people with ALS experience changes in cognition and behaviour. 
Previous research has been mixed as to whether cognition declines over the 
course of ALS, or whether it is related to proxies of disease progression (e.g., 
functional disability scales). However, this research has suffered from limitations 
including the use of inappropriate measures of cognition, imprecise measures of 
disease progression, high attrition, practice effects, and biased analytic 
approaches. Fortunately, recent advances in clinical assessment have provided 
accurate measures of neuropsychological functioning and disease progression, 
namely, the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) and the 
King’s Clinical Disease Staging. 
The present study aims to utilise recent advances in ALS disease metrics 
to overcome previous limitations and explore the evolution of cognitive and 
behavioural dysfunction over the course of ALS. Specifically, the aims of the 
present project are to 1) develop alternate forms of the ECAS to accommodate 
repeated longitudinal assessment; 2) examine how cognition and behaviour 
relate to clinical disease stages in ALS; 3) evaluate how cognitive and 
behavioural symptoms evolve over the course of the disease in ALS; and 4) 
explore clinicians’ attitudes toward cognitive and behavioural screening in ALS. 
To achieve Aim 1, two new versions of the ECAS (ECAS-B and ECAS-C) 
were developed and administered to a group of age, education, and gender 
matched controls to that of the original ECAS-A validation study. Results 
demonstrate that the alternate forms of the ECAS (B and C) were equivalent to 
 
 ii 
the original ECAS-A, reducing practice effects and possessing excellent inter-
rater reliability. The ECAS forms were administered longitudinally to a separate 
group of healthy controls. Over an interval of 4 months, the ECAS-A-B-C showed 
no evidence of practice effects and excellent test-retest reliability validating their 
utility in the longitudinal monitoring of cognition in ALS.   
 The ECAS forms were then used in an international multi-centre clinical 
sample of 161 ALS patients and 80 matched controls to achieve Aim 2. Patients 
were grouped into their King’s Clinical Disease Stage at time of testing. Analysis 
revealed a significant cross-sectional relationship between disease stage and 
ALS-Specific cognitive functions, driven by a decline in verbal fluency 
performance. A significant relationship was also observed between disease stage 
and behavioural features. By end-stage disease 80% of patients demonstrated 
neuropsychological impairment.  
Participants were followed up longitudinally to explore the progression of 
cognitive and behavioural symptoms. Latent Growth Curve models of the ECAS 
subdomains (utilising the alternate versions) demonstrated a significant decline 
in ALS Specific cognitive, but not behavioural, functioning over time. This decline 
was explained by advancing disease stage, the presence of the C9orf72 repeat 
expansion, and years of education. Rate of change in ALS Non-Specific functions 
was dependent on baseline performance. Visuospatial functions and 
perseveration declined at similar rates and were distinct from language, fluency, 
apathy, and disinhibited behaviour. Cluster analysis of patients revealed a three-
cluster solution with one group demonstrating no significant decline, a second 
group with mild cognitive and behavioural decline, and a third group with more 
severe neuropsychological decline. When data was restructured by diseases 
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stage, rather than time, longitudinal results were similar to cross-sectional 
findings.  
To examine clinician’s attitudes to cognitive and behavioural screening. 
Fourteen Health Care Professionals (HCP) working in ALS (Neurologists, 
Psychologists, and Clinical Care Specialists) were interviewed. Thematic 
analysis revealed that HCPs recognised the importance of cognitive and 
behavioural screening in ALS, but that it is not common practice. Important 
barriers to screening were reported including other members of staff, a lack of 
resources, and issues concerning patients and their families. Participants 
suggested increasing training and psychology input, and making screening a 
standardised protocol to all patients may alleviate these barriers.  
 Cognition and behaviour are critically related to advancing disease stage, 
both cross-sectionally and longitudinally. Declining cognitive and behavioural 
symptoms has important implications for clinical practice, caregiver impact, and 
end-of-life decision making. However, clinicians report that cognitive and 
behavioural screening is not common practice and that significant barriers exist. 
The newly developed alternate forms of the ECAS provide an accurate, effective, 
and clinically useful means of monitoring cognitive function over the course of the 







Amyotrophic Lateral Sclerosis (ALS) is a rapid and fatal neurological disease. 
Approximately half of patients will experience changes in the way they think and 
behave. Some researchers have attempted to examine if these changes worsen 
as the disease progresses, with mixed results. However, this research has been 
limited by inaccurate research methods. These limitations include the use of tests 
that require intact motor speed, which is compromised in ALS. Practice effects 
are improvements in test performance due to familiarity with the test which may 
mask a decline and have not been accounted for previously. Furthermore, 
methods of measuring disease progression are highly variable between 
individuals. The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) was 
recently developed to overcome motor speed limitations in ALS, while the King’s 
Clinical Disease Staging was proposed as an accurate and standard measure of 
disease progression. The aim of this research was to further develop the ECAS 
to overcome practice effects and explore how thinking and behaviour changes 
evolve over the course of the disease in ALS. Finally, clinicians working in ALS 
will be interviewed regarding current attitudes and practices toward the 
assessment of thinking and behaviour changes.   
 Two alternate forms of the ECAS were developed to overcome practice 
effects. The new forms (ECAS-B and ECAS-C) were designed. The new ECAS 
forms were administered to a group of healthy adults who match the profile of 
ALS patients. Performance on the ECAS-B and ECAS-C was equivalent to the 
ECAS-A demonstrating that the new forms retain the same properties and level 
of difficulty as the original ECAS-A. When the ECAS-A was given to a different 
group of healthy adults over time, an improvement in scores was observed. 
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However, when the new forms (B and C) were given to healthy adults over time, 
no improvement in performance was observed. Finally, the new ECAS forms 
were given to a separate group of healthy adults to determine normal variation 
over time, so that cut-off scores of abnormal change over time can be determined. 
The evidence from this research suggests that the new ECAS forms provide an 
accurate way of measuring thinking abilities over time and provide a means of 
overcoming limitations with previous research.  
 These new ECAS forms were then administered to a group of people with 
ALS, recruited from Dublin, Edinburgh, and London. A group of healthy adults, 
matched by age, gender, and education were also recruited. Patients with ALS 
were divided into groups based on their King’s Clinical Disease Stage and their 
ECAS scores were compared. Results demonstrate that people in more 
advanced disease stages showed worse thinking abilities and behaviour, such 
that by late-stage disease 80% of people were impaired. This group of patients 
and healthy adults were followed up four times every four months to examine how 
their thinking and behaviour changes over the disease course. Results here 
demonstrate that thinking abilities decline with time. Thinking abilities and 
behaviour were related to advancing disease stage, years of education, and the 
presence of a gene (C9orf72) which forms a genetic overlap between ALS and 
dementia. 
Clinicians working in ALS were interviewed and they reported that 
assessment of thinking and behaviour is important, but not common. Significant 
barriers to assessment were reported including other members of staff, a lack of 
resources, and issues concerning patients and their families. Participants 
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suggested increasing training and psychology input and making assessment 
standard to all patients. 
This study demonstrated that thinking and behaviour does indeed worsen 
across the disease course. This finding is important for patients, their families, 
and clinicians due to the important decisions and care that is required in ALS as 
the disease advances. However, clinicians’ report that assessment of thinking 
and behaviour may not occur as often as it should due to important barriers. The 
new ECAS forms provides a means for clinicians to monitor patients’ thinking and 






CHAPTER 1: Introduction and background 
 
Cognitive and behavioural symptoms are now recognised as common features 
of amyotrophic lateral sclerosis (ALS). Where historically these functions were 
thought to be spared, it is now well documented that: 
 A significant proportion of people with ALS experience severe changes in 
behaviour and personality, presenting as frontotemporal dementia (FTD).  
 In addition to this, a larger proportion will experience milder cognitive and 
behavioural changes detectable through neuropsychological assessment.  
 The remaining patients with ALS will demonstrate no significant alteration 
in cognition or behaviour, and present with motor system involvement only.  
 
This chapter will begin with a description of ALS and introduce the concept 
of disease staging, important for tracking the progression of the disease. 
Following this, cognitive and behavioural symptoms in ALS will be explored, in 
addition to the methods currently available in assessing such symptoms.  
 
 
1.1. What is ALS?  
Motor Neuron Disease (MND) describes a group of conditions marked by 
degeneration of upper (UMN) and/or lower motor neurons (LMN) of the brain and 





only affects voluntary and autonomic movement, but also areas of the brain 
responsible for cognitive functioning and behaviour. Originating in the motor 
cortex, UMNs form synapses with LMNs in the motor nuclei of the brainstem and 
spinal cord (Kiernan et al. 2011; Figure 1.1). LMNs are required by the autonomic 
and voluntary nervous system to innervate muscle groups responsible for 
movement, including breathing, swallowing, and communication. Degeneration 
of the motor neurons interrupts this innervation, and over time, the muscles 
fatigue, weaken, and eventually paralyse (Kiernan et al. 2011). Degeneration of 
LMNs result in weakness, atrophy, and fasciculations, whereas degeneration of 
the UMNs results in weakness, brisk reflexes, and muscle stiffness. Under the 
umbrella of MND, there are several disease subtypes characterised by differential 
involvement of UMNs, LMNs, or both. Primary Lateral Sclerosis (PLS) presents 
with UMN signs only, such as spasticity of limbs, and brief reflexes, while 
Progressive Muscular Atrophy (PMA) predominantly affects the lower motor 
neurons causing muscle weakness. Amyotrophic Lateral Sclerosis (ALS) is the 
most common form of MND, with clear clinical signs of both UMN and LMN 
involvement (Elman et al. 2008).  
Approximately 80% of those with ALS will present with initial symptoms in 
the limbs (degeneration of motor neurones descending into and from the spine) 
and may go on to develop bulbar symptoms (progressive bulbar palsy for 
degeneration of the LMNs and pseudobulbar palsy for degeneration of the UMNs) 
as the disease progresses. Similarly, patients presenting with symptoms in bulbar 
muscles (degeneration of motor neurones descending into and from the 
brainstem) often go on to develop symptoms in the limbs (Kühnlein et al., 2008). 





PLS with a median survival of 2 to 3 years from symptom onset and death usually 
due to respiratory failure (Al-Chalabi & Hardiman, 2013). ALS affects more men 
than women, with a ratio of approximately 1:1.4, the incidence of which is 2.2 per 
100,000 for women and 3.1 for men (Logroscino et al. 2010).  
 
Figure 1.1. Corticospinal tract pathway 
 
 





1.2. Genetics of ALS 
Cases of ALS are classified as sporadic, accounting for 90-95%, or familial, 
accounting for the remaining 5-10% (Al-Chalabi et al., 2016; Byrne at al. 2011). 
Most genes associated with ALS are autosomal dominant, with over 20 being 
identified to date (Hardiman, Kiernan, & van den Berg, 2016). Of the 
approximately 10% of ALS cases where a genetic contribution can be identified, 
the most common finding is C9orf72 hexanucleotide repeat expansion, followed 
by superoxide dismuatase (SOD1) mutations, transactive response DNA binding 
protein 43 (TDP-43), and Fused in Sarcoma (FUS) (Chiò et al., 2008). C9orf72 
accounts for up to 50% of familial cases and 8% of sporadic ALS cases (De 
Jesus-Hernandez et al., 2011; Hardiman et al., 2016; Majounie et al., 2012). The 
presence of the C9orf72 mutation is associated with worse prognosis, possibly 
driven by spinal-onset males (Rooney et al., 2016a) and is population dependent, 
demonstrating significant geographic variability (Majounie et al., 2012; Sabatelli 
et al., 2012; van der Zee et al., 2013). Mutations in SOD1 account for 
approximately 15% of familial and 5% of sporadic cases of ALS. Mutations in 
DNA/RNA binding proteins, TDP-43 and FUS account for 10-15% of familial ALS. 
Most recently, NIMA (never in mitosis gene-A)-related kinase 1 (NEK1) variants 
have been associated with ALS, accounting for an additional 3% of cases (Kenna 
et al., 2016). 
 
1.3. Diagnosing ALS 
Definitive diagnostic tests for ALS are lacking. Presently, diagnosis is based on 
clinical and electromyographic results, and the exclusion of mimics. 





however, measurements of UMN involvement is more difficult. Patients with LMN 
disease (PMA) often go on to develop UMN signs later in the disease. Similarly, 
some patients who present with UMN signs (PLS), go on to develop LMN signs 
later in the disease (Ince et al., 2003; Gordon et al., 2006a; Tartaglia, et al., 2007). 
This may therefore cause diagnostic confusion between PMA, PLS, and ALS 
such that some authors question whether these conditions represent discrete 
phenotypes or a single disease continuum (Al-Chalabi et al., 2016). 
Nevertheless, ALS represents the majority of cases of MND in which both the 
UMN and LMN are involved.  
The El-Escorial diagnostic criteria were developed to facilitate the 
inclusion of ALS in clinical trials. The El-Escorial criteria (Brooks, 1994) and its 
revision (Brooks, Miller, Swash, & Munsat, 2000) propose a diagnosis of ALS 
based on the presence of LMN degeneration (by clinical, electrophysiological, or 
neuropathological examination), evidence of UMN degeneration (by clinical 
examination), and the progressive spread of symptoms or signs (within a 
particular region or to other regions). Additionally, there must be an absence of 
evidence of other disease processes that might explain the presence of UMN and 
LMN symptoms. Regarding diagnostic certainty, the El-Escorial criteria apply 
diagnoses under definite, probable, possible, and suspected ALS labels. The 
revised criteria (Airlie House Criteria) removed suspected ALS, and included 
laboratory supported probable ALS (see Table 1.1).  
However, a population-based study on the utility of the El-Escorial criteria 
and its revision suggested that it is overly restrictive with 10% of patients having 
possible or suspected ALS at the time of death. Unfortunately, the application of 





patients (Traynor et al., 2000). In 2008, a further revision to the criteria was 
employed, the Awaji-Shima criteria (Carvalho et al., 2008). The Awaji criteria 
(Table 1.1) modified the Airlie House criteria by allowing the concordant use of 
clinical and electrophysiological measurements in determining diagnostic 
certainty. The resulting criteria improved diagnostic sensitivity, particularly for 
bulbar onset patients (Carvalho & Swash, 2009). The improvement in diagnostic 
certainty has been externally validated (Boekestein et al., 2010; Geevasinga et 
al., 2016) with an improvement of 23% of patients being classified as having 
probable or definite ALS (Costa, Swash, & de Carvalho, 2012a). However, the 
El-Escorial criteria and its revisions were developed for the use in clinical trials 
and authors have questioned its clinical utility and its representation of the 
heterogeneity of ALS (Agosta et al., 2015; Rutter-Locher et al., 2016). Recently, 





Table 1.1. Criteria for diagnostic certainty for ALS 
Clinical Certainty Signs 
El-Escorial Criteria (1994) 
Definite ALS 
 









UMN and LMN signs in one region, UMN signs in two+ regions, 
LMN signs rostral to UMN signs 
 
Suspected ALS LMN signs is two+ regions 
Airlie House Revision (2000) 
Clinically Definite ALS UMN and LMN clinical signs in three regions  
 
Clinically Probable ALS UMN and LMN clinical signs in two regions with UMN signs 
rostral to LMN signs 
 
Clinically Probable ALS - 
Laboratory supported 
UMN and LMN clinical signs in one region, or UMN signs in 
one region with LMN signs by EMG in 2+ limbs (with proper 
exclusion of other causes)  
 
 
Clinically Possible ALS UMN and LMN clinical signs in one region, UMN clinical signs 
in 2+ regions, LMN signs rostral to UMN signs, where clinically 
probably ALS laboratory supported cannot be shown 
Awaji-Shima Revision (2008) 
Clinically Definite ALS UMN and LMN clinical or electrophysiological signs in the bulbar 
regions and at least two spinal regions, or UMN and LMN signs 
in three regions  
Clinically Probable ALS UMN and LMN clinical or electrophysiological signs in two 
regions with UMN signs rostral to LMN signs 
 
Clinically Possible ALS UMN and LMN clinical electrophysiological signs in one region, 
UMN signs in 2+ regions, LMN signs rostral to UMN signs 
 
 
possible ALS is sufficient for diagnosis. This is in part due to observations that 
clinical trials which included the category of possible ALS found a negligible 





recommended that the categories of probable and definite ALS be replaced with 
appropriate and validated disease staging systems, which includes appropriate 
imaging techniques, cognitive impairment, concomitant signs such as sensory 
and oculomotor disturbances, non-ALS phenotypes such as PLS, and genetics 
(Ludolph et al., 2015). However, these recommendations have yet to be validated 
(Strong et al., 2017). 
 
1.4. Disease progression and staging 
Understanding disease progression is important for both research and clinical 
practice. It aids description of the natural history of the disease and gain 
understanding of progression patterns, informs prognosis, and provides 
information as to the efficacy and effectiveness of clinical trials. Disease spread 
through the ALS nervous system has been suggested to occur contiguously and 
caudally, through adjacent areas in upper and lower motor neurons (Bak & 
Chandran, 2012). For example, individuals whose disease begins in the bulbar 
region are more likely to develop spinal involvement than vice versa. Spread may 
be due to motor neuron susceptibility, for example, motor neuron size, axon 
length, or microenvironment (Ravits & La Spada, 2009). As such, disease 
progression often presents as the worsening involvement within a region, and to 
other regions of the body. The resulting degeneration expresses as declining 
functional ability. Muscle strength tests, pulmonary function tests, and 
electrophysiological measures (including the recent Motor Unit Number Index) 
are methods of recording physical disease progression in ALS (Rutkove, 2015). 
However, clinically, the ALS Functional Rating Scale (ALSFRS) is commonly 






1.4.1. The ALSFRS and MITOS Disease staging systems 
The ALSFRS is a measurement of physical function in activities of daily living in 
ALS, covering bulbar functions, gross motor tasks, and fine motor tasks. The 
ALSFRS was revised (Cedarbaum et al., 1999) to incorporate respiratory function 
(ALSFRS-R). Disease progression on the ALSFRS-R has been shown to be 
curvilinear in that rate of functional decline is more rapid in early and late phases 
of the disease. The initial decline slows after 18 months of symptom onset and 
declines more quickly in patients with bulbar onset (Gordon & Cheung, 2006b; 
Gordon et al., 2010a). While the curvilinear form of ALSFRS-R progression is 
important, on a case-by-case basis, the ALSFRS-R may not be linear or 
curvilinear. Factors such as age and site of onset have modifying influences on 
the predictive ability of the ALSFRS-R and introduce large degrees of variability 
resulting in a heterogeneous profile of decline (Mandrioli et al., 2015; Swinnen & 
Robberecht, 2014). 
The prognostic value of the ALSFRS-R has been improved by the 
amalgamation of symptom duration making disease severity a function of time 
(Gordon & Cheung, 2006b; Kimura et al., 2006; Labra et al., 2015). The equation, 




48(𝑚𝑎𝑥 𝑠𝑐𝑜𝑟𝑒) − (𝐴𝐿𝑆𝐹𝑅𝑆 𝑠𝑐𝑜𝑟𝑒 𝑎𝑡 𝑣𝑖𝑠𝑖𝑡)







In a further attempt to improve prognostic value of the ALSFRS-R, this 
ALSFRS-R slope has been incorporated into a simple algorithm with site of onset 
and the presence or absence of executive dysfunction (Elamin et al., 2015). 
However, the unitary construct of the ALSFRS-R score may not be meaningful 
and rather, the ALSFRS-R has greater utility when viewed multidimensionally. In 
their factor analysis, Franchignoni, Mora, Giordano, Volanti, and Chiò (2013) 
report three dimensions of the ALSFRS-R: bulbar, fine and gross motor function, 
and respiratory function. This has been recently validated in an Irish cohort 
(Rooney, Burke, Vajda, Heverin, & Hardiman, 2016b).  
In addition to using the raw scores to measure disease progression, the 
ALSFRS-R has been adapted into a functional staging system. The ALS Milan 
Torino Staging (MITOS) system is based on the loss of independent functioning 
in domains present in the ALSFRS-R (Chiò, Hammond, Mora, Bonito, & Filippini, 
2015). The number of domains lost constitute the disease stage ranging from 0-
4, with Stage 5 constituting death. The domains are: self-care/walking, 
swallowing, communication, and breathing. As such, the MITOS system is a 
functional staging system reflecting the progressive disability associated with 
ALS, and advancing disease stages are shown to correlate with lower quality of 
life (Chiò et al., 2015). In a study to validate the utility of the MITOS in predicting 
long-term survival, Tramacere et al., (2015) found the MITOS to have good 
predictive sensitivity to death or respiratory failure longitudinally (82% and 71% 
at 12 and 18 months). However, the specificity of the MITOS was less accurate 
at 63% and 68% (respectively) suggesting the system overestimates progression 
in some individuals. Further issues exist with the MITOS system include its skew 





purportedly indicate no loss of function) until the disease has progressed quite 
significantly. The complete loss of independent function in a region is a milestone 
that people with ALS may never reach despite the presence of involvement in 
multiple bodily regions. For example, it is feasible for an individual to have 
physical involvement of the bulbar region, in addition upper and lower limb 
involvement but still be in MITOS Stage 0. 
 
1.4.2. The King’s Clinical Staging system 
An important advancement in developing measures of disease progression was 
the publication of the King’s Clinical Staging System (Roche et al., 2012). The 
stages of the King’s system are based on the number of bodily regions involved 
by clinical examination, and can be estimated from ALSFRS-R scores with an 
intra-class correlation coefficient of .92 (Balendra et al., 2014). Stage 1 is defined 
as the presence of one bodily regions (e.g., upper limbs), Stage 2 is defined by 
the presence of two bodily regions (e.g., upper limbs and lower limbs), Stage 3 is 
defined by the presence of three bodily regions (i.e., upper limbs, lower limbs, 
and bulbar region). Stage 4 of the King’s system is reached when the patient 
meets National Institute for Health and Care Excellence guidelines (NICE, 2016) 
for respiratory or nutritional intervention (i.e., loss of 10% body weight from 
baseline; FVC < 50% predicted or < 80% predicted when respiratory symptoms 
are present; SNIP < 50cmH2O or < 65cmH2O for men / < 55cmH2O for women 
when symptoms are present; persistent drop of > 10cmH2O per 3 months on 










As displayed in Figure 1.2, the stages of the King’s system are shown to 
have standardised median percentages of disease course with involvement of a 
second region at ~40%, a third region at ~60%, and Stage 4 at ~80% of the 
disease course. Diagnosis was found to occur at a similar point as Stage 2. In a 
large-scale validation study of the utility of the King’s system for clinical trials, 
Balendra et al. (2015) found that the majority of ALS patients progressed to 
consecutive stages, with the time spent in stages 2-4 (post diagnosis) ranging 
from 3-7 months. No participant progressed to an earlier stage of the disease, 
whereas a small number of patients did so using the MITOS system (Chiò et al., 
2015). As such, Balendra et al., (2015) suggest that the King’s Clinical Staging 
System may prove useful as predictable and shorter end-points in clinical trials. 
Imaging research has demonstrated bilateral atrophy of the homunculus which 
degenerates continuously with functional decline in respective bodily regions 
(Bede et al., 2013; Schuster et al., 2014) validating the use of clinical features to 
stage neurological disease progression. 
Two studies to date have compared the MITOS and the King’s Clinical 
Staging System. Ferraro et al. (2016) compared the system on 545 incident cases 















that 22% of people with ALS in Stage 1 died, 36% in Stage 2, 45% in Stage 3, 
and 61% in Stage 4. However, no such consistent pattern was observed for the 
MITOS system where death occurred in 33%, 46%, 68%, 63%, and 64% of 
patients in Stages 0-4 consecutively. Comparison of the prognostic abilities and 
linearity of the two systems showed that the King’s system had greater 
homogeneity within stages (differences in survival were smaller within a stage), 
discriminatory ability (differences in survival between stages), and linearity than 
the MITOS system. Standardised proportions found in Ferraro et al.’s study were 
similar to those by Roche et al. (2012). The MITOS, conversely, had standardised 
proportions of 35%, 67%, 79%, 100%, and 104% of the disease course 
demonstrating significant skew to late-stage disease. Recently, Fang et al. (2017) 
found a similar bias in the MITOS to end-stage disease compared to the King’s 
staging. For instance, the King’s Stage 3 linked most closely to the MITOS Stage 
0 and 1. For King’s Stage 4 (i.e., end-stage disease), more patients fell into 
MITOS Stage 1 and 2. Rather than specifying the King’s Clinical Staging System 
to be superior, Fang et al. suggest the two systems are complimentary with the 
MITOS system describing loss of function and the Clinical Staging System 
describing disease spread. As such, the two systems may be combined to 
describe detailed information, for example, K4M1 describes a patient in end-
stage disease (King’s Stage 4) but with relative intact functional abilities (MITOS 
Stage 1). Despite the evidence of clinical and prognostic efficacy of using clinical 
staging in ALS, disease staging in ALS is not used widely in practice (Rutter-






1.4.3. Post-Mortem Staging 
A final important staging system developed for ALS is that of TDP-43 
neuropathological disease stages. TDP-43 is an RNA-binding protein coded by 
the TARDBP gene, present in almost all ALS cases (Neumann et al., 2006). In a 
large study of pathological TDP-43 inclusions, Brettschneider et al. (2013) 
grouped ALS patients into disease stages based on the profile of TDP-43 
depositions in the brain. Stage 1 is defined by TDP-43 inclusions in the primary 
motor cortex, LMNs of the spinal cord (α-motor neurons), and cranial nerves V, 
VII, and XII (responsible for facial muscles). In Stage 2, the pathology of Stage 1 
was evident, with additional primary involvement of the reticular formation of the 
brainstem. Stage 3 includes the pathology of Stage 2 but with the prefrontal 
neocortex included. Finally, in Stage 4, TDP-43 pathology extends to the 
hippocampus. Imaging studies exploring diffusion tensor imaging tract correlates 
have supported these pathological changes (Kassubek et al., 2014; Schulthess 
et al., 2016). For example, in a large-scale multi-centre study of 253 ALS and 189 
healthy controls, fractional anisotropy using Diffusion Tensor Imaging (DTI) 
revealed significant changes in white matter tracts in the frontal lobes and the 
hippocampal regions. When segregated by ALSFRS-R as a proxy of disease 
progression, patterns of brain alterations followed post-mortem neuropathological 
TDP-43 deposition patterns (Müller et al., 2016). While these advances may 
elucidate the pathological progression of ALS in the brain, their clinical utility has 






1.5. The ALS-FTD Spectrum  
ALS has historically been viewed as a disease affecting the motor system solely, 
sparing non-motor functions. However, descriptions of non-motor symptoms 
have been described in ALS for almost as long as the disease itself. Since 1874 
when Charcot first described the clinical picture of ALS (Rowland, 2001), 
depictions of patients with cognitive and behavioural symptoms emerged from 
the 1880s onward (Bak, 2010). The neglected attention paid to cognitive and 
behaviour symptoms in ALS can be understood for several reasons, many of 
which pervade to this day. These include a) cognitive and behavioural 
assessment tools not suited to motor disability, b) small sample sizes reducing 
power to detect mild differences or changes, and c) learning effects from repeated 
assessment masking impairment. While many of these issues continue to 
complicate measurements of cognition and behaviour, advancements in recent 
years have allowed for greater precision.  
Frontotemporal dementia or frontotemporal lobar degeneration (FTD), are 
umbrella terms describing degenerative diseases marked by differential and 
heterogeneous involvement of the frontal and temporal lobes. The prevalence of 
FTD in the general population is approximately 15-22 per 100,000 (Onyike & 
Diehl-Schmid, 2013). The most common form of FTD is behavioural variant, the 
characteristic hallmarks of which include changes in personality, social conduct, 
and executive functions (Rascovsky et al., 2007; 2011). Semantic dementia is 
defined by the loss of word meaning and knowledge. Progressive non-fluent 
aphasia is a language variant of FTD characterised by the loss of words but 
maintenance of meaning, and speech apraxia (McMonagle & Kertesz, 2016). 





compared to behavioural variant FTD. While a relationship between ALS and 
FTD, has been suspected as early as 1922 (Nitrini, 2014), contemporary 
developments in clinical, imaging, genetic, and pathological findings have now 
established that ALS and FTD share considerable overlap (Goldstein & 
Abrahams, 2013).  
It is estimated that approximately 15% of patients diagnosed with ALS 
possess the cognitive and behavioural characteristics of FTD, with a further 35% 
of ALS patients experiencing milder cognitive and behavioural changes. 
Executive dysfunction and behaviour change (e.g., apathy, eating and stereotypic 
behaviours) are common in both diseases (e.g., Lillo et al., 2009; 2012a). A 
similar percentage of FTD patients develop the physical hallmarks of ALS 
(Lomen-Hoerth, Anderson, & Miller, 2002). A study by Burrell, (2011) found that 
while 12.5% of patients with FTD also met criteria for MND, an additional 27.3% 
presented with evidence of milder motor system involvement. A sample of studies 
examining the prevalence of neuropsychological impairment in ALS are 
summarized in Table 1.2. Thus, the prevalence of FTD in ALS is approximately 
15%, with a further 35% demonstrating milder cognitive and behavioural 
abnormalities, and the remaining patients presenting with motor-only symptoms.  
Structural and functional neuroimaging of ALS has suggested involvement 
beyond the primary motor cortex to extramotor areas including the frontal and 
temporal regions (see Chiò et al., 2014 for overview), which are in turn implicated 
in FTD. Several large studies have demonstrated that involvement of extramotor 
areas in ALS obeys an overlapping gradient with diagnosis, such that, patients 









Canosa et al., (2016) examined this gradient using F-FDG-PET. ALS 
patients with cognitive impairment (compared to ALS patients without cognitive 
impairment) demonstrated left-dominant clusters of hypometablism in the 
superior frontal gyrus, anterior cingulate, medial frontal gyrus, and the cingulate 
gyrus. The same pattern, but more widespread, was observed when ALS patients 
with cognitive impairment were compared to ALS-FTD patients. Here, ALS-FTD 
patients demonstrated greater hypometablism in the inferior, middle, and superior 
frontal gyri. Mioshi et al. (2013) similarly found that ALS with and without 
cognitive/behavioural impairment, and ALS-FTD showed similar patterns of 
cortical involvement using voxel-based morphometry. When compared to 
controls, ALS patients had grey matter atrophy in the temporal and frontal lobes, 
cerebellum, superior parietal lobes, and the putamen. ALS patients with 
Table 1.2. Prevalence of neuropsychological impairment and FTD in patients 
with ALS 





Massman et al. (1996) 146 35.6% - - 
Ringholz et al. (2005) 279 31.9% - 14.7% 
Witgert et al. (2010)* 225 60.3% 24% - 
Phukan et al. (2012) 160 34.1% - 13.8% 
Montusichi et al. (2015) 183 31.2% 6% 12.5% 
Murphy et al. (2016) 274 54.2% 14.1% 6.5 - 16.5% 
Note. * Did not differentiate FTD and non-FTD cognitive/behavioural impairment. 





cognitive/behavioural impairment demonstrated a similar patter, but with 
significantly greater grey matter involvement in the superior frontal and superior 
parietal regions. ALS-FTD patients and ALS with cognitive/behavioural 
impairment showed overlapping cortical involvement, but with ALS-FTD having 
more prefrontal and anterior temporal involvement. However, extra-motor atrophy 
may not be restricted to patients with observable cognitive and behavioural 
abnormalities. Bede et al. (2013) found that cognitively intact patients also 
possessed non-motor cortical involvement in the right occipital, left inferior 
temporal (para-hippocampal), right superior temporal gyrus, and right superior 
frontal gyrus. Rather, ‘neuropsychologically-intact’ patients may also have 
changes that are undetectable by current assessment methods, or have not 
progressed enough at the time of assessment to be detectable.  
Finally, genetically the presence of FTD in ALS (ALS-FTD) has been 
associated with the presence of the C9orf72 (chromosome 9 open reading frame 
72) repeat expansion, observed in approximately 12% of familial FTD cases and 
24% of familial ALS cases (Byrne et al., 2011; De Jesus-Hernandez et al., 2011). 
C9orf72 carriers are reported to have higher rates of cognitive and behavioural 
impairment, in addition to higher rates of dementia and neuropsychiatric features 
(Byrne et al., 2012; Hardiman et al., 2016; Snowden et al., 2012). Cortical 
changes may also be exacerbated by C9orf72 genetic phenotype (Westeneng et 
al., 2016) and TDP-43 pathology has also been found in almost all ALS cases 






1.6. Cognition in ALS  
Given the demonstrable overlap between ALS and FTD, neuropsychological 
research has often focused on cognitive abilities thought to be mediated by the 
frontal and temporal lobes. The prefrontal cortex is thought to contribute to higher-
order executive functions such attention, planning, organising, decision making, 
and social cognition. The temporal lobe, conversely, plays a role in language 
functions and the formation and retrieval of memory. A summary of the main 
cognitive research studies in ALS are summarised in Appendix I.  
 
1.6.1. Executive function  
Executive functioning describes a broad range of inter-related higher order 
cognitive abilities that allow individuals to determine goals, formulate ways of 
achieving those goals, and adapt to changing circumstances to achieve those 
goals (Burgess & Alderman, 2013). Assessment of executive functioning has 
been highly variable in ALS due to the use of tests dependent on intact motor 
functioning, but also due to the interconnectedness of different executive 
functions. Structures of executive functioning, namely attention, working memory, 
concept formation, and cognitive flexibility have been examined in ALS. 
Attention is perhaps one of the most fundamental aspects of executive 
functions, allowing an individual to focus, and sustain that focus, on relevant 
information. Ringholz et al. (2005) has suggested that ALS may be commonly 
typified by attentional impairments. Assessing attentional abilities can be 
complicated as tasks usually involve other cognitive processes. However, 
impairment of selective attention, or an inability to focus on one stimuli in the 





et al., 2008; Volpato et al., 2016; Witgert et al., 2010). Selective attention has 
been studied using the Stroop Colour-Word Test, which requires individuals to 
read as quickly as possible a list of words, each presented in a different colour 
(see Figure 1.3). In one condition, the congruent condition, the colour names are 
presented in the congruent colour (e.g., the word ‘RED’ is presented in the ink 
colour red). In the incongruent condition, the word is presented in a non-
complimentary colour (e.g., the word ‘RED’ is presented in the ink colour green). 
Successful completion of the task requires an individual to selectively attend to 
either the word or the colour, while inhibiting interference of competing stimuli. As 





While some researchers have found those with ALS make more 
interference inhibitory errors i.e., failure to inhibit the word name (Christidi, 
Zalonis, Smyrnis, & Evdokimidis, 2012; Pinkhardt et al., 2008; Zalonis et al., 
2012), in studies that controlled for motor speed, this impairment was not found 
(Abrahams et al., 1997; Stukovnik, Zidar, Podnar, & Repovs, 2010) suggesting 
potentially intact selective attention/inhibition.  
Figure 1.3. The Stroop task 
  
Congruent:   RED    GREEN    BLUE   
Congruent:   RED    GREEN    BLUE 






Cognitive inhibition has also been examined using the Hayling Sentence 
Completion Test. The Hayling test consists of two parts. In part A, participants 
are asked to complete a series of sentences with a logical response. In part B, 
participants must inhibit the logical response in favour of an incongruent and 
unrelated response. In ALS, inhibitory deficits have been observed using the 
Hayling test (e.g., Carluer et al., 2015; Lillo et al., 2012a), but not consistently 
(e.g., Girardi, Macpherson, & Abrahams, 2011; Taylor et al., 2013). 
In addition to selective attention and inhibition, Pettit et al. (2013) 
demonstrated deficits in divided attention in patients with ALS. In this study, 
participants were asked to hold a sequence of numbers in mind while attending 
to a simple visual discrimination task of geometric figures. While patients were 
comparable to controls on performance on each task separately, their 
performance declined greater than controls when asked to complete these tasks 
simultaneously. Using Diffusion Tensor Magnetic Resonance Imaging, this 
difficulty in divided attention was related to a reduction of white matter integrity in 
the middle frontal gyrus and anterior corona radiata.  
Working memory is a related facet of executive function, and allows people 
to store, process, and manipulate information on a short-term basis. Working 
memory is different from short term memory in that it allows you to store and 
‘work with’ information, rather than simply retain it. Reports are conflicting as to 
whether ALS is associated with deficits in working memory. A common task used 
to assess working memory is the backward digit span test in which participants 
are read a series of numbers of increasing length and instructed to recall them in 
reverse order. While some authors report deficient performance of the backward 





(Palmieri et al., 2013; Volpato et al., 2010). In a small but detailed examination of 
working memory abilities, Hammer, Vielhaber, Rodriguez-Fornells, Mohammadi, 
and Munte (2011) asked ALS patients to complete an N-Back test, in which they 
were presented with a sequence of shapes. Participants were asked to identify 
whether the current shape was in a) the same position (spatial working memory), 
or b) was the same shape (figural working memory) as that which appeared two 
images before (i.e., 2-back). Performance on standard neuropsychological 
measures of working memory showed no impairment compared to controls (i.e., 
digit span task). However, 35% of patients were unable to complete the N-back 
task due to an inability to understand the instructions. Of those patients who could 
complete the task, a demonstrable difficulty was observed in identifying the 
spatial position of items which previously appeared, whereas figural task 
performance did not differ from controls suggesting a specific deficit in spatial 
working memory. 
Executive functions also allow people to understand rules and concepts 
and to be flexible. Concept formation is the ability to mentally categorise, or 
classify, objects or events and is widely studied using the Wisconsin Card Sorting 
Test (Heaton, Chelune, Talley, Kay & Curtiss, 1981). In this test, participants are 
asked to classify features such as shape, colour, and number of items on each 
card. No instructions are given as to how cards should be categorised beyond 
being told ‘correct’ or ‘incorrect’ and the feature to be categorised changes 
periodically. Through trial and error, participants learn the categorisation system 
and adapt intermittently to changing rules, requiring both concept formation and 
cognitive flexibility. While not all studies have demonstrated impairment on the 





of performance in ALS demonstrated that patients complete fewer categorisation 
trials, made more errors (including perseverative errors), and took longer to learn 
new rules compared to control participants (Lange et al., 2016). The same 
authors, through their own experimental study, report that deficits in cognitive 
flexibility (i.e., shifting between categorisation rules) underlies the observed 
findings. When simply asked to describe how many ways cards can be sorted 
(using a similar card sorting test from the Delis-Kaplan Executive Function 
System), or to recognise categories when presented to them, those with ALS 
showed reduced performance on concept formation.  
Cognitive flexibility can also be understood in terms of task switching (i.e., 
the ability to shift attention). In addition to the card sorting tests, the Trail-Making 
Test is often used to assess task switching. However, given the reduction in motor 
speed present in ALS and its potential to interfere with interpretation, alterations 
to the scoring mechanism are frequently used. Commonly, a difference score 
(parts A-B) or a proportion (B/A) have been used with varying results. For 
instance, Carluer et al. (2015), Hartikainen et al. (1993), and Zalonis et al. (2012) 
found impaired ALS performance, relative to controls, in Trail-Making difference 
scores (B-A). Yet Machts et al. (2014) and Palmieri et al. (2009; 2010; 2013) 
found no impairment for the Trail-Making proportion score (B/A) or difference 
score (B-A). The independence of these scoring systems from motor speed has 
yet to be established, perhaps explaining the lack of agreement. Sánchez-Cubillo 
et al. (2009) found that part A, part B, B-A, and B/A all similarly correlated with a 
measure of motor speed (finger tapping) in healthy older adults. Indeed, 
Stukovnik et al. (2010) examined multiple scoring systems for the Trail-Making 





ALS whereas the difference score (B-A) was significant. After adjustment for 
motor speed (i.e., time need to produce correct sequence minus time taken to 
reproduce sequence), these authors note that part B, but not part A, of the Trail-
Making Test significantly differs from controls potentially suggesting a deficit in 
task switching but not processing speed. However, current methods of scoring 
the Trail-Making Test in the presence of motor impairment requires validation. 
As has been noted, executive functions are difficult to examine due to the 
overlapping functions and often non-specific tests. Kasper et al. (2015) attempted 
to rectify this limitation and explore which facets of executive dysfunction are most 
affected in ALS. By re-organising common neuropsychological tests into different 
aspects of executive function, these authors note that shifting and initiation were 
most often affected, while updating, inhibition, and problem solving were 
relatively intact. These findings perhaps make sense given the observations by 
some authors (e.g., Lange et al., 2016; Stukovnik et al., 2010) that task-switching 
impairments may underlie some of the profile of executive dysfunction seen in 
ALS. Furthermore, the preponderance for ALS patients to experience verbal 
fluency deficits (e.g., Abrahams et al., 1997; 2004) may relate to Kasper et al.’s 
(2015) cognitive initiation observation.  
 
1.6.2. Verbal fluency  
Verbal fluency deficits are one of the most widely recognised markers of cognitive 
impairment in ALS (Abrahams et al., 1997; Abrahams et al., 2004; Abrahams et 
al., 2000; Kew et al., 1993), over and above other measures of executive 
functioning (Stukovnik et al., 2010). For example, Phukan et al. (2012) found that 





fluency refers to a person’s ability to randomly generate a list of words beginning 
with a specified letter (letter/phonemic fluency), or a list of semantically related 
words (category fluency; e.g., names of animals). Successful performance on 
tests of verbal fluency requires cooperative involvement of language and 
executive abilities. Individuals must access their lexical store of words, under 
specified constraints, and continuously monitor their performance to avoid rule 
breaks and repetition (Shao, Janse, Visser, & Meyer, 2014). 
In 2000, Abrahams et al. conducted an extensive investigation of the 
verbal fluency abilities in ALS aimed at exploring the processes underlying verbal 
fluency deficits in ALS. Abrahams et al. examined whether intrinsic response 
generation, phonological loop functions (short term verbal memory), or simple 
word retrieval were responsible. People with ALS demonstrated general difficulty 
in letter, semantic, and design fluency tests (the ability to draw random abstract 
drawings) indicative of a deficit in non-specific intrinsic response generation. 
Auditory memory for words and sounds, in addition to simple word retrieval were 
relatively intact in patients. Abrahams et al. (2000) developed the verbal fluency 
index (VFI) as a measure of verbal fluency, independent of motor impairment. 
Participants are instructed to say or write as may words as they can that begin 
with a specified letter (generation condition). The participant is then instructed to 
re-read, or copy out the previously generated words (control condition). The VFI 
is calculated using the following equation:  
 
𝑉𝐹𝐼 =
𝑇𝑖𝑚𝑒 𝑔𝑖𝑣𝑒𝑛 𝑓𝑜𝑟 𝑔𝑒𝑛𝑒𝑟𝑎𝑡𝑖𝑜𝑛 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛 − 𝑡𝑖𝑚𝑒 𝑓𝑜𝑟 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛







Letter fluency may be a more specific marker of executive dysfunction and 
frontal lobe degeneration (Abrahams et al., 1995; Baldo, Schwartz, Wilkins, & 
Dronkers, 2006; Donaghy et al., 2009; Libon et al., 2009). Imaging studies of 
verbal fluency in ALS have observed involvement of extensive prefrontal regions, 
particularly the dorsolateral prefrontal cortex and anterior cingulate cortex using 
positron emission tomography (PET; Abrahams et al., 1995) and functional 
magnetic resonance imaging (fMRI; Abrahams et al., 2003; 2004; Sarro et al., 
2011; Quinn et al., 2012). Structural imaging studies have also demonstrated 
prefrontal involvement in fluency performance, such as fronto-temporal white 
matter association fibres. Pettit et al. (2013) demonstrated correlations between 
letter fluency performance and white matter integrity of the superior frontal gyrus, 
inferior frontal gyrus, corticospinal tract, and corpus callosum. In a meta-analysis 
of verbal fluency performance in patients with focal cortical lesions, Henry and 
Crawford (2004) demonstrated that letter and semantic fluency were sensitive to 
both frontal and temporal damage. However, semantic fluency was most strongly 
associated with temporal damage while letter fluency was most strongly linked to 
frontal damage (particularly left lateralised). 
In combining the evidence of initiation deficits (Abrahams et al., 2000; 
Kasper et al., 2015), imaging correlates of fluency (Abrahams et al., 1995; 
Abrahams et al., 2003; Abrahams et al., 2004; Pettit et al., 2013), and the profile 
of verbal fluency in ALS subgroups (Lepow et al., 2010), impairment in verbal 






1.6.3. Social cognition  
Social cognition is an umbrella term that describes the cognitive processes 
necessary for successful negotiation of social situations and interactions. Some 
authors have suggested that social cognitive deficits may “play a prominent role 
in clinical care of neurodegenerative conditions” (Elamin, Pender, Hardiman & 
Abrahams, 2012, pp. 1077). For instance, patients become increasingly 
depending on caregivers as the disease progresses and a breakdown in effective 
social interaction is likely to have a large impact (Abrahams, 2011). Similarly, a 
breakdown in the social interaction between clinicians and patients may impact 
the care provided.  
Social cognition encompasses both lower-order processes, such as a 
person’s response to, and recognition of basic emotions and emotionally-salient 
stimuli, and higher order processes, such as the ability to interpret the thoughts 
and actions of others. The recognition of social cognition deficits in ALS has only 
come about in recent years, despite being recognised as a key feature of FTD. 
In 2016, Beeldman and colleagues updated their 2008 meta-analysis of cognition 
in ALS. In the eight-year interval between these two reviews, the most significant 
change was the addition of social cognition deficits as an integral component of 
the cognitive profile of ALS. In ALS, social cognition has been studied under two 
broad components, namely, emotional processing and recognition, and theory of 
mind (ToM).  
Emotional processing and recognition are cognitive processes that 
describe a person’s response to emotional stimuli (e.g., a picture of a funeral) 
and the recognition of basic emotions in others (e.g., recognising a person’s 





emotionally charged stimuli, in that they rate emotionally charged pictures as 
being more positive and exciting than controls (Lulé et al., 2005). Furthermore, 
patients have been shown to rate the faces of strangers with a negative valence 
as being more approachable (Schmolck, Mosnik & Schulz, 2007) and show a 
reduced capacity to recognise emotional expressions (Burke et al., 2016a; Girardi 
et al., 2011; Savage et al., 2014; Zimmerman, Eslinger, Simmons, & Barrett, 
2007), particularly negative emotions (Crespi et al., 2014). The suggestion of a 
selective difficulty in processing negative emotions has be supported by fMRI 
research (Palmieri et al., 2010), and studies of patients with FTD (Snowden et 
al., 2008). However, this inability to recognise the emotions of others has not 
always been consistently found (Papps, Abrahams, Wicks, Leigh, & Goldstein, 
2005; Watermeyer et al., 2015), and may be more likely in ALS-FTD (Savage et 
al., 2014). In a recent meta-analysis, Bora (2017) found that recognition of 
disgust, surprise, and sadness was reduced in ALS but not anger, fear, or 
happiness.  
In addition to difficulty in the processing and recognition of emotions, 
patients with ALS have been shown to struggle with ToM in inferring and 
understanding the thoughts and actions of others. ToM can describe the ability to 
infer a person’s emotional state (Affective ToM) (Carluer et al., 2015). On the 
other hand, Cognitive ToM is the understanding that other people may have 
thoughts or beliefs that are different than one’s own (first-order ToM), or that one 
person might have thoughts and beliefs about a second person’s thoughts and 
beliefs (second-order ToM) (Elamin, Pender, Hardiman, & Abrahams, 2012). A 
common way of assessing ToM abilities in ALS has been the faux pas test. Here, 





characters says something they should not have, and asked to identify the ‘faux 
pas’. Successful completion of the task requires the participant to understand the 
thoughts and beliefs of story’s actor, for example:  
“Sally is a three-year-old girl with a round face and short blonde hair. She 
was at her Aunt Carol’s house. The doorbell rang and her Aunt Carol answered 
it. It was Mary, a neighbour. ‘Hi,’ Aunt Carol said, ‘Nice of you to stop by.’ Mary 
said, ‘Hello,’ then looked at Sally and said, ‘Oh, I don’t think I’ve met this little boy. 
What’s your name?” (Stone, Baron-Cohen & Knight, 1998) 
 Despite demonstrating intact story comprehension, one third of ALS 
patients were less able to detect the faux pas compared to controls (Meier, 
Charleston, & Tippett, 2010). Similarly, Cavallo et al. (2011) presented patients 
comic strips of social (e.g., a person preparing a romantic dinner) and non-social 
(e.g., a person changing a lightbulb) situations and asked them to interpret the 
intentions of the characters. Those with ALS performed worse than healthy 
controls in interpreting the social cartoons, but not the non-social cartoons 
indicating a specific difficulty in social understanding.  
Assessment of ToM has been extended to demonstrate a reduced ability 
to interpret eye gaze in ALS. For example, Girardi et al. (2011) and Van der Hulst 
et al. (2015) attempted to delineate affective and cognitive ToM using the 
Judgement of Preference Task. Participants were presented with a cartoon face 
called ‘Dina’, which looked at one of four items. Those with ALS were asked 
‘which picture does Dina love?’ (affective ToM), or ‘which picture is Dina thinking 
of?’ (cognitive ToM). Van der Hulst et al. found that 36% of patients displayed an 
affective ToM impairment and 27% displayed a cognitive ToM impairment. 





prefrontal, dorsolateral prefrontal, and supplementary motor cortices in ALS 
(Carluer et al., 2015). Conversely, affective ToM abilities have been associated 
with the anterior cingulate cortex and the right inferior frontal gyrus (Cerami et al., 
2014).  
Debate continues as to the source of social cognitive impairments in ALS. 
Cavallo et al. (2011) and Meier et al. (2010) found social cognitive deficits to be 
independent of executive function. Yet, many studies which have explored social 
cognition in ALS have suffered from small sample sizes, reducing their power and 
interpretability. Larger studies have suggested strong connections between the 
two (Burke et al., 2016b; Gibbons et al., 2007; Snowden et al., 2003; Watermeyer 
et al., 2015). Others suggest that social cognition relies on the brain’s ability to 
‘simulate’ the actions of others, thereby allowing for internal comprehension and 
inference (Gallese, Keysers, & Rizzolatti, 2004; Jelsone-Swain, Persad, Burkard, 
& Welsh, 2015), however this hypothesis requires further investigation. The meta-
analysis by Bora (2016) suggested that while executive dysfunction explains 
some of the variance in social cognitive abilities, a significant proportion of the 
variance remains unexplained.  
 
1.6.4. Language  
Psycholinguistics covers a broad range of cognitive skills necessary for the use, 
comprehension, and production of language. Language is recently recognised as 
an important cognitive domain affected in some ALS cases. Impaired 
performance has been observed in higher-order language, such as grammar 
(Ash et al., 2015; Tsermentseli et al., 2015). However, basic language functions, 





such as the Graded Naming Test or the Boston Naming Test, present participants 
with pictures of objects which are to be named. Some research has suggested 
that naming deficits are present in ALS (e.g., Cavallo et al., 2011; Hanagasi et 
al., 2002). Abrahams et al., (2004) demonstrated that ALS patients had reduced 
activation in regions involved in confrontation naming (Abrahams et al., 2003), 
including bilateral inferior frontal gyri (including Broca’s area) and right cingulate 
gyrus. As such, naming appears to be affected in patients with ALS. However, 
not all authors have consistently demonstrated a naming deficit in ALS (Gibbons 
et al, 2007; Pettit et al., 2015). This inconsistency may be due to the findings that 
people with ALS may have a particular difficulty in processing verbs or action-
words compared to nouns (Bak & Chandran, 2012). Many naming tests, including 
the Graded and Boston Naming Tests, rely on the processing of objects or nouns, 
whereas studies that have assessed the verb/action-word abilities of patients 
have more consistently found deficits (Grossman et al., 2008; Taylor et al., 2013).  
Some authors have suggested that this selective action-verb impairment 
may be due to a greater executive involvement in verb processing (e.g., Bak & 
Hodges, 2004), however, more recently this verb-noun dissociation has been 
attributed to the role of the motor cortex in language processing. Imaging studies 
have suggested that in addition to the prefrontal cortex, the motor cortex may 
play a role in action word processing (e.g., York et al., 2014). For example, in one 
study, participants were asked to move their tongue, feet, and fingers while 
undertaking fMRI. Participants were then asked to passively read words 
associated with these body parts (e.g., chew, lick, kick). Areas of the motor cortex 
that activated during the movement condition matched (either directly 





reading condition (Hauk, Johnsrude, & Pulvermüller, 2004). These findings 
suggest that the motor cortex is important for processing action words and that 
these correspond to areas of the brain responsible for the actual movement. 
However, other authors have argued strongly that this is not the case (For 
instance, see de Zubicaray, Arciuli, & McMahon, 2013). Watson, Cardillo, Ianni, 
and Chatterjee (2013) conducted a meta-analysis of patterns of cerebral 
activation associated with action words and images. The authors report that 
visual motor areas were consistently recruited but not motor or pre-motor areas. 
Rather, action words and images activated distinct but overlapping areas of the 
visual motor cortex (i.e., middle temporal visual area). Whereas action images 
related to the occipital cortex and visual motor area bilaterally, action words 
related to left middle and inferior temporal gyri and hippocampus.   
In addition to retrieving the correct word, an important aspect of language 
function concerns word meaning. Semantic memory is the aspect of language 
functions that describes a person’s understanding of word meaning. The Pyramid 
and Palm Trees Test was developed to assess semantic memory functions 
(Howard & Patterson, 1992). Here, participants are presenting with either a single 
word or a picture above two other words or pictures and asked to select which of 
the bottom items is most like the top item. However, the Pyramid and Palm Trees 
Test is noun/object based, and may not necessarily best reflect the previously 
noted profile of language deficits observed in ALS. To address this limitation, Bak 
and Hodges (2003) developed the Kissing and Dancing Test, which includes 
items from the Pyramid and Palm Trees Test, but also includes stimuli measuring 
action/verb knowledge. For example, participants are asked to select which of 





is given the option of a person typing or a person stirring a hot drink. The Kissing 
and Dancing Test has been shown to be impaired in ALS (Taylor et al., 2013, van 
der Hulst et al., 2015) to a greater degree than the Pyramid and Palm Trees Test 
(Bak & Hodges, 2003). 
It has been suggested that language impairment in ALS may be reflective 
of subclinical presentations of language-variants FTD (Abrahams, 2013a). Leslie 
et al., (2015) examined the semantic abilities of ALS, ALS-FTD, and semantic 
dementia patients. A gradation of impairment was observed (i.e., controls > ALS 
> ALS-FTD > SD) where 33.3% of ALS patients, 73.3% of ALS-FTD, and 100% 
of semantic dementia patients demonstrated deficits in semantic knowledge 
which was associated with degeneration of the temporal poles. However, pure 
semantic dementia is rarely seen in ALS suggesting a different relationship than 
that with behavioural variant FTD. A recent study by Taylor et al. (2013) showed 
that when tested using a battery of language and executive neuropsychological 
tests, 43% of ALS patients presented with language dysfunction and 31% with 
executive dysfunction. While 44% of the variance in language function was 
explained by executive functioning, suggesting a significant degree of overlap, 
the largest proportion of variance remained unexplained.  
 
1.6.5. Memory  
Memory functions are one of the most widely studies areas within psychology 
and one of the most common reported symptoms of brain injury and disease 
(Evans, 2013). Memory function describes our ability to encode, store, and 
retrieve information. In ALS, research has been focused on the type of 





consolidation (i.e., immediate memory compared to delayed memory); and 
whether the retrieval of information is by direct recall (e.g., being asked to recall 
a list of previously learned words) or recognition (e.g., being given a list of words 
and asked to identify which you were asked to learn).  
Impairments in memory have been found by some researchers (Christidi 
et al., 2012; Raaphorst et al., 2015), while others have found memory to be 
largely intact (Cuddy, Papps, Thambisetty, Leigh, & Goldstein, 2012). Most 
commonly however, researchers report mixed results, for example, intact 
immediate recall but impaired delayed recall (Mantovan et al., 2003), intact 
immediate recognition but impaired delayed recognition (Machts et al., 2014; 
Munte et al., 1998), or intact recall but impaired recognition (Machts et al., 2014). 
Some studies even found patients to be both impaired and intact depending on 
the type of test used, for example, list learning compared to story recall (Christidi 
et al., 2012). 
It has been suggested that problems with memory may be associated with 
emotional functioning. While healthy adults’ memory for information can be 
enhanced when information has an emotional component (e.g., “burn” compared 
to “bowl”), those with ALS did not show a similar benefit (Cuddy et al., 2012; 
Papps et al., 2005). Furthermore, observed deficits in memory may be partly 
explained by dysfunction of other cognitive domains, such as executive 
functioning (Christidi et al., 2012; Mantovan et al., 2003). However, Machts et al. 
(2014) found that executive functioning only explains 20.5% of the variability in 
memory performance in ALS, leaving a significant proportion of the variance 





which are related to executive functioning, may be the most prominent memory 
difficulties of patients with ALS and ALS-FTD (Kasper et al., 2015).  
A few neuroimaging studies have suggested that brain regions responsible 
for various facets of memory, particularly the hippocampus, may be affected in 
ALS (Takeda, Uchihara, Arai, Mizutani, & Iwata, 2009; Takeda, Uchihara, 
Mochizuki, Mizutani, & Iwata, 2007). It is suggested that pathological TDP-43 
deposition occurs in the hippocampus in late stage disease (Brettschneider et al., 
2013). Given that late-stage disease patients are often excluded from cognitive 
research (i.e., a forced vital capacity of less than 70% predicted), it may be that 
memory involvement is under-recognised in ALS, and that memory involvement 
is dependent on disease stage.  
 
1.6.6. Visuospatial functions  
Visuospatial functions describe skills necessary to identify, locate, and 
manipulate objects in a person’s visual environment. These abilities allow us to 
perform routine activities, such as driving, walking, recognising loved ones, and 
interpreting the motor actions of others. In the realms of FTD, visuospatial 
changes appear to be mediated by higher-order executive dysfunction, rather 
than due to simple perceptual difficulties (Possin, 2010; Possin et al., 2012). 
Thompson, Stopford, Snowden, and Neary (2005) compared the visuospatial 
abilities of patients with FTD and Alzheimer’s disease by asking patients to copy 
complex line drawings. While patients with Alzheimer’s disease made errors in 
the spatial location of the drawing’s various elements, FTD patients made errors 





Studies that have examined the visuospatial abilities in ALS have 
generally found that patients perform within normal ranges (Lillo & Hodges, 
2009), although some studies have found impairments (Hanagasi et al., 2002; 
Machts et al., 2014). However, the tasks used generally rely on processing line-
drawings, rotating blocks, or spatial location judgements. Fiori et al. (2013) found 
that while people with ALS could visualise and manipulate inanimate mental 
imagery (letters), they were less able to visualise and manipulate mental imagery 
concerning body parts (e.g., rotating hands). It is hypothesised that the ability to 
understand motor actions may rely on the ability to ‘simulate’ this in the motor 
cortex of the brain (Hesslow, 2002). Connections have been suggested between 
the motor cortex and other cognitive functions, such as social cognition (Jelsone-
Swain et al., 2015), action words and verb processing (Bak & Chandran, 2012; 
Hauk, Johnsrude, & Pulvermüller, 2004), and verbal fluency (Abrahams et al., 
1995; Grogan et al., 2009). However, as previously noted, this relationship is 
debated (e.g., Watson et al., 2013). It is likely that deficits in visuospatial ability in 
ALS may be accounted for by executive failures, rather than true visuospatial 
failures but this area remains under-studied.  
  
1.7. Behaviour in ALS 
Behaviour in ALS has received significantly less attention than cognition. Yet, as 
with FTD, behavioural features are common in ALS and are marked by changes 
in personality, social conduct, manners, and decorum. Behaviour change in ALS 
is often mild except in cases of ALS-FTD, and variable. For instance, Raaphorst, 
Beeldman, De Visser, De Haan, and Schmand (2012a) conducted a systematic 





symptoms were reported in included research. The subjective and contextual 
nature in what constitutes a ‘behaviour’ has limited the objectivity of 
measurement, and as such, research tends to focus on behaviour as a unitary 
symptom. Yet, Behaviours can appear as a single symptom, or constellation of 
symptoms. Common themes have emerged from the FTD literature 
operationalised in recent diagnostic criteria. Diagnostic criteria for behavioural 
variant FTD is based on the presence of behavioural features including 
disinhibition; apathy; loss of sympathy or empathy; perseverative, compulsive, or 
stereotypical behaviours; and altered eating behaviours (Rascovsky et al., 2011).  
Disinhibition describes a reduction in an individual’s ability to inhibit 
thoughts or desires that may be socially inappropriate. For example, making rude, 
offensive, or sexual comments or jokes; violating social norms, such as 
inappropriate physical contact with strangers; or making decisions that are 
careless or impulsive, such as new-onset gambling, stealing, or selling property 
without regard for the consequences. Caregivers have reported increases in 
disinhibited behaviour following the onset of ALS (Girardi et al., 2011; Grossman, 
Woolley-Levine, Bradley, & Miller, 2007; Terada et al., 2011; Van der Hulst et al., 
2015). However, Grossman et al. (2007) also noted that caregivers report 
features of behaviour dysfunction prior to disease onset, perhaps suggesting that 
behavioural features may precede motor dysfunction. Despite the noted 
increases in disinhibited behaviours from pre- to post-illness, studies tend to 
suggest that rates of disinhibition are lower than other behaviours. For example, 
Girardi et al. (2011) and van der Hulst et al. (2015) found that disinhibition 
significantly increased from pre- to post-illness, but that post-illness levels of 





that rates of disinhibition are relatively low (Lillo et al 2011; Raaphorst et al 2012a) 
with Abrahams et al. (2014) reporting it to be the least reported behaviour change. 
Hsieh et al., (2016) report that behavioural disinhibition may be uncommon until 
later in the disease course perhaps explaining the observed infrequency.  
Apathy, demotivation, or inertia is the most commonly reported 
behavioural feature of both ALS and FTD (Chiò et al., 2010; Grossman et al., 
2007; Kasper et al., 2015; Lillo et al., 2011; Meier et al., 2010; Watermeyer et al., 
2015; Witgert et al., 2010). A person may appear to lose drive, interest, or 
motivation to do things. Similarly, a person may require prompting to initiate or 
maintain common daily tasks such as self-care or cleaning. It is suggested that 
apathy is multidimensional in nature (Levy & Dubois, 2006). In reviewing and 
collating the available models of apathy subtypes, Radakovic and Abrahams 
(2018) proposed the Dimensional Apathy Framework consisting of initiation, 
emotional, and executive apathy. Initiation apathy describes a lack of motivation 
for the instigation of self-directed thinking or behaviour, executive apathy is a lack 
of motivation for attention, organisation, and planning, in that patients are 
demotivated to commit to goal directed behaviour, while emotional apathy is akin 
to emotional neutrality or indifference to oneself and one’s surroundings. In ALS, 
levels of executive apathy are similar to control samples, however, initiation 
apathy is a prominent feature (Radakovic et al., 2016). Conversely, executive 
apathy appears to profile apathy symptoms in Parkinson’s disease (Radakovic, 
Davenport, Starr, & Abrahams, 2017a), while Alzheimer’s disease possesses a 
heterogeneous apathy profile (Radakovic, Starr & Abrahams, 2017b). The 
presence of initiation apathy may share a common underlying mechanism to 





Radakovic et al., 2017c). The profile of multidimensional apathy in ALS has 
recently been validated in a large Italian cohort of ALS patients. Like Radakovic 
et al. (2016), Santangelo et al. (2017) found initiation apathy to be the most 
prominent form of apathy in ALS.  
Another behavioural symptom in ALS is a loss of sympathy and empathy. 
This behaviour can manifest in a diminished response to the needs and feelings 
of others, or demised interest in socialising and being close to others. For 
example, making hurtful or thoughtless comments without regard for other 
people’s feeling, or a lack of interest in being socially or emotionally close to 
others. Loss of sympathy/empathy has been relatively understudied due to its 
absence from common measures of behaviour (e.g., Frontal Systems Behaviour 
Scale, Neuropsychiatric Inventory, Cambridge Behaviour Inventory). However, 
Abrahams et al. (2014) found that rates of loss of sympathy/empathy was the 
second most common behavioural feature after apathy.  
People with ALS may also demonstrate perseverative, stereotyped, or 
compulsive behaviours. These behaviours can be analogous to obsessive-
compulsive behaviours and marked by simple repetitive movements (e.g., 
clapping, tapping, or rocking), more complex behaviours (e.g., such as hoarding, 
counting, cleaning rituals), or stereotyped speech (e.g., repeating single words or 
phrases). Unfortunately, research on perseverative behaviours in ALS are 
lacking.  
Changes in diet or eating behaviours can be perhaps the most objective 
behaviour to observe. Patients may develop cravings for particular types of food, 
especially sweet foods or carbohydrates, or continue to eat despite satiety. 





compulsively. In the only systematic study of eating behaviours across the ALS-
FTD spectrum, Ahmed et al. (2016a) demonstrated a range of behavioural 
changes. These changes were associated with disease duration and 
neuropsychological status, such that pure ALS patients experienced fewer eating 
behaviours, followed by ALS patients with cognitive or behavioural impairment, 
and finally patients with ALS-FTD/FTD. Ahmed et al. demonstrated changes in 
appetite, eating habits (i.e., stereotyped eating behaviours), food preferences and 
intake (e.g., sweet, carbohydrate, fat), and oral behaviours (e.g., cramming, 
smoking). It has been suggested that changes in eating behaviours may be 
protective of survival (Ahmed et al., 2016a; 2016b) 
A final behaviour common but non-specific to ALS and absent from the 
FTD diagnostic criteria is that of emotional lability. Described as pathological 
laughing, crying, and the recent addition of pathological smiling (Newsom-Davis, 
Abrahams, Goldstein, & Leigh, 1999), emotional lability can be highly variable 
and is estimated to affect 10-71% of patients (Gibbons, Richardson, Neary, & 
Snowden, 2008; Newsom-Davis, et al., 1999; Palmieri et al., 2009). Patients may 
laugh, cry, or grimace at an inappropriate time or place or when you would not 
expect it, for example laughing when angry. Emotional lability has been linked to 
the prefrontal cortex and executive functioning in ALS (Hübers et al., 2016; 
McCullagh, Moore, Gawel, & Feinstein, 1999). It can be present at early stages 
of the disease and is thought to be more common in patients with bulbar 







1.8. The profile of cognitive and behaviour change in ALS  
Cognitive impairment has been established as common non-motor features of 
ALS. Studies reporting the prevalence of impairment in ALS have suggested that 
cognitive deficits (see Table 1.2) are present in approximately 35% of patients 
(Grossman et al., 2008; Massman et al., 1996; Murphy et al., 2016; Phukan et 
al., 2012; Ringholz et al., 2005). Some authors have suggested classification 
systems, such as Phukan et al. (2012), in which patients are classified as being 
cognitively intact, having executive impairment (ALS-Ex), non-executive cognitive 
impairment (ALS-NECI), or ALS-FTD. In such cases, 21% were classified as 
ALS-Ex, 14% as ALS-NECI, and 14% ALS-FTD. Using the same categorisation 
system, Montuschi et al., 2015 categorised 20% as ALS-Ex, 5.5% as ALS-NECI, 
and 13% as ALS-FTD. Commonly however, Strong and Colleagues’ (2009) 
consensus criteria are used to direct classification of neuropsychological status 
in ALS (as described in Figure 1.4).  
 
Figure 1.4. ALS-FTD spectrum  
 
 
These criteria recommend the classification of patients based on their 
cognitive and behavioural profile. ALSci (cognitive impairment) and ALSbi 





cognitive or behavioural symptoms, but do not meet criteria for ALS-FTD. 
Patients classified at ALSci must demonstrate cognitive impairment in at least 
two distinct tests sensitive to executive functioning, whereas, patients classified 
as ALSbi must present with two non-overlapping behavioural features. To meet 
criteria for ALS-FTD, patients must possess signs of FTD as described in the 
Neary criteria (Neary et al., 1998). Rascovsky et al. (2007) notes that the Neary 
criteria contain significant limitations and proposed a revised diagnostic criteria 
for FTD (Rascovsky et al., 2011). The Rascovksy criteria specifies the need for a 
progressive deterioration of cognition and/or behaviour, marked by the presence 
of three symptoms from Table 1.3. Unfortunately, the Strong classification 
system, and the Rascovksy criteria is limited owing to the presence of cognitive 
deficits other than executive functioning in ALS. Additionally, substantial overlaps 
exist between ALSci and ALSbi, in a form of ALScbi (Murphy et al., 2016; Murphy 
et al., 2007).  
The Strong consensus criteria was updated in 2017 (Strong et al., 2017), 
modifying the criteria for ALSci, ALSbi, and ALS-FTD. ALSci is characterised by 
evidence of executive dysfunction (including social cognition), language 
dysfunction, or a combination of the two. Executive dysfunction is now defined as 
the presence of letter fluency impairment or impairment on two non-overlapping 
measure of executive functions. Language impairment is defined as impairment 
on two non-overlapping tests of language function. On the other hand, ALSbi is 
defined by the presence of apathy with or without other behavioural changes, or 
the presence of two or more behavioural features a) disinhibition, b) loss of 
sympathy and empathy, c) perseverative, stereotyped or compulsive behaviour, 





somatic delusions, hallucinations, irrational beliefs). While the updated guidelines 
(see Table 1.4) have incorporated the expanded understanding of the 
neuropsychological profile of ALS, these changes have not yet been validated or 
externally examined.  
 
 
Table 1.4. Revised Strong Consensus Guidelines for the characterisation of 
neuropsychological symptoms in ALS 
 
Heading Axis II. Neuropsychological characterisation 
ALSbi 
A diagnosis of ALSbi requires: 1) The identification of apathy with 
or without other behaviour change; OR 2) meeting at least two 
non-overlapping supportive diagnostic features from the Rascovsky 
criteria (Rascovsky et al., 2011). 
ALSci 
A diagnosis of ALSci depends on evidence of either executive 
dysfunction (including social cognition) or language dysfunction or 
a combination of the two. Executive impairment is defined as: 1) 
Impaired verbal fluency (letter); OR 2) Impairment on two other 
non-overlapping measures of executive functions (which may 
include social cognition). Language impairment is defined as: 1) 
Impairment on two non-overlapping tests and in which language 
impairment is not solely explained by verbal fluency deficits. 
ALScbi Patients who meet the criteria for both ALSci and ALSbi 
ALS-FTD 
A diagnosis of ALS-FTD requires: 1) Evidence of progressive 
deterioration of behaviour and/or cognition by observation or 
history; AND 2) The presence of at least 3 of the 
behavioural/cognitive symptoms outlined by Rascovsky et al. 
(2011); OR 3) The presence of at least 2 of those 
behavioural/cognitive symptoms, together with loss of insight 





1.9. Cognition and behaviour summary  
Most frequently, executive functions, fluency, and more recently, language and 
social cognitive functions appear to be affected in ALS, and may in part be 
Table 1.3. Rascovsky Criteria for the diagnosis of FTD 
Possible FTD 
1 Early behavioural disinhibition marked by one of the following: 
a. Socially inappropriate behaviour 
b. Loss of manners or decorum 
c. Impulsive, rash or careless actions 
2 Early apathy or inertia marked by one of the following: 
a. Apathy 
b. Inertia 
3 Early loss of sympathy or empathy marked by one of the following: 
a. Diminished response to other people’s needs and feelings 
b. Diminished social interest, interrelatedness or personal warmth 
4 Early perseverative, stereotyped or compulsive /ritualistic behaviour marked by one of the 
following: 
a. Simple repetitive movements 
b. Complex, compulsive, or ritualistic behaviours 
c. Stereotypy of speech  
5 Hyperorality and dietary changes marked by one of the following: 
a. Altered food preferences 
b. Binge eating, increased consumption of alcohol or cigarettes 
c. Oral exploration or consumption of inedible objects 
6 Neuropsychological profile: executive/generation deficits with relative sparing of memory and 
visuospatial functions marked by the presence of all of the following: 
a. Deficits in executive tasks 
b. Relative sparing of episodic memory 
c. Relative sparing of visuospatial skills  
Probable FTD 
 Meets criteria for possible FTD in addition to: 
a. Significant functional decline  
b. Imaging results demonstrating frontal and/or anterior temporal lobe atrophy, 
hypoperfusion, or hypometabolism  
Definite FTD 
 Meets criteria for possible or probably FTD in addition to: 
a. Histopathological evidence of FTD on biopsy or at post-mortem 
b. Presence of known pathogenic mutation 
impairment meeting criteria for semantic dementia/semantic variant 
PPA or non-fluent variant PPA. This may co-exist with 
behavioural/cognitive symptoms as outlined above. 
 





explained by degeneration of the prefrontal and temporal lobes. A summary of 
the main findings of cognitive research in ALS is displayed in Appendix I. 
Regarding behaviour, apathy is the most commonly reported behavioural feature, 
with loss of sympathy/empathy, perseverative, and eating behaviours also 
reported. The independence of cognitive and behavioural symptoms remains to 
be established, but previous research would suggest that there exists a 
considerable overlap. Higher-order executive functioning appears to moderate 
some of the findings in language, social cognition, and fluency deficits. For 
example, Taylor et al. (2013) found that executive functioning explained 44% of 
the variance in language functioning and Phukan et al. (2012) found that 94% of 
patients with executive dysfunction also demonstrated verbal fluency deficits. 
Similarly, Watermeyer et al. (2015) revealed that executive functioning 
significantly correlated with social cognition (r = .61), which, after controlling for 
relevant variables, significantly predicted social cognitive performance 
(standardized Beta = .49). Despite the potential overlap, a considerable amount 
of variance remains unexplained, suggesting that these domains work 
independently but also in conjunction. Deficits in memory and visuospatial 
functions have also been demonstrated, but these results are less consistent.  
Beeldman and colleagues’ (2016) meta-analysis suggests that all 
cognitive domains, bar visuospatial functioning, demonstrate significant effect 
sizes. Fluency, language, and social cognition possess the largest effect sizes, 
with visual and verbal memory, attention, and executive functioning 
demonstrating smaller effect sizes. With the frequency of cognitive symptoms in 
ALS, it is important to note that substantial heterogeneity continues to exist. 





the greatest heterogeneity, with language and social cognition possessing 
moderate heterogeneity. Fluency, immediate verbal memory, visual memory, and 
attention showed the least heterogeneity compared to other domains of cognition 
(Beeldman et al., 2016). Some of the heterogeneity may be explained in the 
continuing use of cognitive tasks that do not account for motor impairment. 
Alternatively, the variance may be explained by a relationship between disease 
severity and cognition (e.g., Elamin et al. 2013), or by undetected sub-clinical 
phenotypes of dementia (e.g., semantic dementia).  
Research concerning ALS has sought to explore how cognition and 
behaviour are affected separately, or in parallel. However, surprisingly little has 
been done to explicitly to explore how these sets of symptoms relate to one 
another. Relationships have been suggested between verbal fluency and 
behavioural symptoms (Gordon et al., 2007; Raaphorst, Beeldman, Schmand, et 
al., 2012b), in particular apathy (Grossman et al., 2007; Radakovic et al., 2017c), 
and between emotional lability and errors made on the Wisconsin Card Sorting 
Test (McCullagh et al., 1999). One study that did explore the relationship between 
behaviour and cognition in-depth was that of Witgert et al. (2010) who found 
apathy to significantly relate to verbal fluency, cognitive flexibility, attention, and 
visuospatial abilities.  
Stuss and colleagues have suggested a model for executive functions in 
which areas of the frontal lobes may be related to discrete, but overlapping, 
abilities (2007; 2011). The model forms a fractionated rethinking of the 
supervisory attention system (Norman & Shallice, 1986) and supposes that there 
exists no single organising function, but rather independent regulatory processes 





maintenance of response; monitoring/task-setting is the ability to monitor 
performance accuracy and adjust to changing circumstances; emotion/behaviour 
regulation integrates emotional, social, and reward-risk aspects of cognition; 
while metacognition is the ability to integrate other facets of frontal lobe functions 
to complete a task (Stuss et al., 2007; 2011). It is posited that energisation relates 
to dorsomedial prefrontal function; task-setting/monitoring relates to the left and 
right dorsolateral prefrontal cortex respectively; emotion/behaviour regulation to 
the lateral and medial orbitofrontal areas; and metacognition relates to the rostral 
prefrontal cortex. 
In their exploration of these component structures in patients with ALS, 
Gillingham and colleagues (2016) demonstrated specific deficits in energisation, 
and monitoring/task-setting despite normal performance on a battery of standard 
clinical tests. This finding may explain and connect some of the observed deficits 
in ALS. Verbal fluency impairment is commonly reported in ALS suggestive of a 
deficit in intrinsic response generation (Abrahams et al. 2004), which falls under 
the energization component of the Stuss model (Stuss et al. 2007). Verbal fluency 
has been related to apathy in ALS (Grossman et al. 2007; Radakovic et al., 
2017c). Additionally, the multicomponent view of apathy in ALS (Radakovic et al., 
2015) suggests a prominent involvement of initiation apathy (motivation for the 
instigation of self-directed thinking or behaviour). Taken together, this evidence 
suggests that verbal fluency deficits and apathy may share common underlying 
frontal-lobe pathology. Recently, Radakovic et al. (2017c) evaluated the 
relationship between cognition and apathy dimensions. ALS patients 
demonstrated a significant difference in tasks of intrinsic response generation 





that intrinsic response generation, or energizing, as measured with a task of 
verbal fluency significantly related to initiation apathy.  
Monitoring and task-setting are also affected in ALS (Stuss et al. 2007; 
2011), which is important for learning stimuli-response relationships, monitoring 
performance over time (e.g., detecting errors, timing), which may underlie deficits 
observed using the Wisconsin Card Sorting Task (Lange et al., 2016). Reported 
cognitive inhibition difficulties using the Stroop Colour-Word Test (Christidi et al., 
2012; Zalonis et al., 2012) and the Hayling Sentence Completion Task (Carluer 
et al., 2015; Lillo, et al., 2012a) may share common processes with behavioural 
disinhibition in that they both require inhibiting internal reactions to external 
stimuli. The relative infrequency of behavioural disinhibition (e.g., Abrahams et 
al., 2014) compared to other behavioural features may help to understand the 
inconsistency with which cognitive inhibition deficits are observed (e.g., Girardi et 
al., 2011; Taylor et al., 2013).  
Similarly, at face value, a behavioural loss of empathy may be related to 
the observed ToM deficits in ALS, emotional processing, and emotional 
recognition. While the relationship between behavioural symptoms and social 
cognition has been suggested previously in FTD (Adenzato, Cavallo, & Enrici, 
2010), to our knowledge, Radakovic et al. (2017c) is the only study to examine 
this. These authors report that emotional recognition significantly correlated with 
emotional apathy. However, evidence suggests that ALS results in reduced 
capacity to interpret the emotional expressions of others (Crespi et al., 2014; 
Girardi et al., 2011; Savage et al., 2014; Zimmerman et al., 2007), and that ToM 
deficits can be specific to interpreting others’ emotional state (van der Hulst, Bak 






1.10. Cognition, behaviour, and disease variables 
Some researchers have attempted to link neuropsychological status with physical 
disease symptoms. While many studies have found little to no relationship 
between cognitive, behavioural, and physical symptoms (Consonni et al., 2013; 
Elman & Grossman, 2007; Lillo, Garcin, Hornberger, Bak, & Hodges, 2010; Lillo 
et al., 2011; Ringholz et al., 2005; Terada et al., 2011; Witgert et al., 2010; 
Woolley, Zhang, Schuff, Weiner, & Katz, 2011), others have found a relationship. 
Associations between cognitive functioning and respiratory function in ALS has 
been suggested (Murphy et al., 2016; Newsom-Davis, Lyall, Leigh, Moxham, & 
Goldstein, 2001; Piepers et al., 2006) with memory and fluency performance 
significantly worse in patients in respiratory failure (Kim et al., 2007), but that 
performance may be partially corrected by non-invasive ventilation (Newsom-
Davis et al., 2001). Lomen-Hoerth et al. (2003) found that ALS-FTD patients were 
more likely to have a lower FVC reading and family history of dementia compared 
to non-demented group despite having similar ALSFRS-R scores.  
 
1.10.1. Neuropsychological function and bulbar involvement 
Site of onset (i.e., bulbar versus limb onset) is often studied with regards to 
cognitive and behavioural symptoms, with some suggesting that bulbar onset 
ALS patients are more likely to experience neuropsychological dysfunction 
(Burke et al., 2016a; Montusichi et al., 2015; Murphy et al., 2016). Yet, results of 
these studies are inconsistent with many researchers unable to find such a 
relationship (Cavallo et al., 2011; Lillo et al., 2012a; Lomen-Hoerth et al., 2003; 





way in which bulbar onset is conceptualised. Some researchers have explored 
whether bulbar involvement, and not onset, relates to neuropsychological 
functioning. By grouping patients by region of onset, those with limb-onset may 
have bulbar signs and vice versa distorting groupings. Abrahams et al. (1997) 
explored such a relationship and observed that executive impairment was more 
prominent in patients with pseudobulbar involvement (i.e., upper motor neuron). 
In a large-scale study, Ringholz et al. (2005) using a sample 279 patients reported 
no relationship between region of onset and cognition, but did report that patients 
with cognitive impairment are significantly more likely to have dysarthria. 
Similarly, in a sample of 175 patients, Sterling et al. (2010) reported that 
dysarthria significantly related to executive functioning, even after controlling for 
motor speed. With regards to behaviour, Santangelo et al. (2017) reported that 
apathetic and non-apathetic ALS cases differed on the ALSFRS-R with respect 
to bulbar functioning.  
 
1.10.2. Neuropsychological function and disease progression 
Whether cognition and behaviour change over the course of the disease is of 
clinical importance in ALS. Cross-sectional studies have used the ALSFRS-R as 
a proxy of disease progression. Associations have been observed between 
verbal fluency and functional status (Palmieri et al., 2009), and between symptom 
duration, functional status, rate of progression, and cognition (Gordon et al., 
2010b). More recently, a study by Murphy et al. (2016) including 286 patients 
demonstrated that behavioural symptoms, in particular apathy, and reduced 
language output, were significantly associated with functional status, respiratory 





heterogeneous trajectory for individuals and is curvilinear. As such, it may not be 
accurate as a measure of disease progression (see section 1.4.1).   
A recent cross-sectional study attempted to estimate disease progression 
using the King’s Clinical Staging System (Roche et al., 2012; see section 1.5.2). 
Executive and memory functioning significantly differed in line with advancing 
disease stage (Trojsi et al., 2016). Unfortunately, this study suffered from 
fundamental design limitations. The study is underpowered once groups were 
split into disease stages and no control group was included. Additionally, the 
authors did not control for motor speed in their cognitive evaluations, which is 
particularly pertinent given the lower ALSFRS-R scores corresponds to later 
disease stages. The Addenbrooke’s Cognitive Examination Revised used in this 
study, like other non-adapted screening instruments (e.g., the Montreal Cognitive 
Assessment or the Frontal Assessment Battery), can often not be administered 
to a significant proportion of people with ALS due to motor weakness and 
exaggerate performance deficits (Abrahams, 2013b; Burkhardt et al., 2017; Lulé 
et al., 2015; Xu et al., 2017).  
Several studies have attempted to trace the progression of behavioural 
and cognitive symptoms over time directly using longitudinal designs. 
Longitudinal studies of cognition are variable, suffering from small sample sizes, 
presence of practice effects, short test-retest intervals, and large rates of attrition 
(See Table 1.5 for summary). Kilani et al. (2004) found no difference in cognitive 
performance over time in their small study. Robinson et al. (2006) found no 
significant effect over six months when patients were viewed as a group. 
However, 36.84% of patients developed abnormal scores on tests of memory, 





Gordon et al. (2010b) and Schreiber et al. (2005) found mixed results where 
performance on some cognitive tasks got worse (e.g., word finding), some 
remained stable (e.g., verbal fluency), while others even improved (e.g., 
visuospatial). Kasper et al. (2016) explored longitudinal changes in executive 
functioning over time. No significant effect was observed, however, this study 
included non-ALS phenotypes, and split patients by cognitive status resulting in 
small group sample sizes. A recent large-scale study by Elamin et al. (2013) 
found that certain tasks of memory, language, and visuospatial functioning 
declined over time. Decline in memory functions were related to baseline 
performance in that patients with baseline memory impairment decline more 
quickly compared to patients with baseline executive impairment.   
The state of the literature regarding the relationship between cognition, 
behaviour, and physical factors is far from conclusive. As described in Table 1.5, 
these longitudinal studies suffer from design limitations which restricts their 
interpretability and generalisability. Previous studies have suffered small sample 
sizes and not controlled for practice effects, which may obscure any decline in 
cognition and behavioural functioning. Furthermore, high attrition will likely result 
in the retention of only the most cognitively, behaviourally, and physically healthy 
participants and research to date has not accounted for attrition in data analysis. 
Further research is needed to explore how, and if, cognitive, behavioural, and 
physical symptoms are related. Only one study to our knowledge has explored 
longitudinal changes in behaviour, and while it found no significant changes over 
time, its sample size was small and the majority of patients dropped out before 














Table 1.5. Summary of longitudinal cognitive studies in ALS 
Study Design Findings Critique 
Kilani et al. (2004) 19 ALS (n2 = 14, n3 = 13) 
and 19 controls (n2 = 19, 
n3 = 19) tested at 
baseline, 6 months, and 
12 months 
Significant decline in task switching (TMT B and B-A). No 
significant change over time observed in concept formation 
(WCST), memory (Rey Memory Test), visuospatial (BVRT), RPM, 
language (BNT) 
Small sample size. No control for 
motor speed in neuropsychological 
tests. Time used as proxy of 
progression.  No control for attrition.  
Abrahams et al. 
(2005a) 
20 ALS and 18 controls 
tested twice over 6 
months 
No significant deterioration in verbal fluency (spoken or written), 
language (GNT), visuospatial (JLO). Significantly slower 
computerised sentence completion task performance over time.  
Small sample size, time used as 
proxy of disease progression. 
Cognitive tests corrected for motor 
speed.  
Schreiber et al. 
(2005) 
52 ALS, four time points, 
four-month interval (n2 = 
32, n3 = 24, n4 = 19) 
Significant decline in perceptual interference (CWIT naming time), 
memory (AVLT learning achievement). Significant improvement in 
letter fluency (COWAT ratio words/errors), design fluency (5-PFT 
number of errors, ratio of number/errors), memory (AVLT loss by 
interference). No significant change in letter fluency (COWAT 
words and errors), design fluency (5-PFT number of designs), 
concept formation (WCST), perceptual interference (CWIT 
interference time, error score), memory (DS, RFT, AVLT words 
delayed recall and recognition), attention (TAP) 
No control group and no control for 
practice effects. Longitudinal 
analysis only conducted on patients 
who completed all time points. No 
control for motor speed. No 
adjustment for multiple 
comparisons.  Time used as proxy of 
progression.   
Robinson et al. 
(2006) 
19 ALS and 8 controls 
tested twice over 6 
months 
No significant decline in attention (DS forward), working memory 
(DS backward), verbal memory (RAVLT), language (PVLT), 
visuospatial (Object Decision test and Efron Shapes 
Discrimination test), executive functions (RPM, WCST). However, 
36.8% developed abnormal performance over follow-up, most 
commonly in verbal memory and WCST.  
Small sample size. Use of 1 
standard deviation for abnormality. 





Elamin et al. 
(2013) 
186 ALS (n2 = 98, n3 = 
46, n3 = 11) and 120 
controls (n2 = 58, n3 = 
31, n4 = 10) tested at 
baseline, 6 months, and 
12 months 
Significant decline in visuospatial functioning (ROCF). For 
patients impaired at baseline, a significant decline relative to 
controls observed for language (BNT, delayed recall of VPA) 
High attrition and no control for drop-
out in analysis. Time used as proxy 
of progression. No statement about 
controlling for motor speed in 
testing.  
Kasper et al. 
(2016) 
93 ALS and 73 controls, 
one follow up at six 
months and another at 3-
6 months 
No significant change, relative to controls, for task switching 
(TMT), short term memory (DS), cognitive inhibition (Stroop). 
Letter fluency showed a significant Time*Group effect but was not 
significant when age was added to model.  
Sample size at each follow-up not 
reported. Adjustment for motor 
speed in assessment. Patient 
groups split into small groups which 
may affect statistical models. Time 
used as proxy of progression. 
Burkhardt et al. 
(2017) 
40 ALS (n2 = 24, n3 = 10) 
and 49 controls (n2 = 21, 
n3 = 0) three times at six 
month intervals 
Practice effects in ECAS observed in control group. No change in 
ECAS cognition or Behaviour observed over time.  
High attrition and lack of control 
group at time 3.  Time used as proxy 
of progression. Practice effects in 
control group not controlled for in 
ALS.  
Note. 5-PFT = 5-Point Fluency Test, AVLT = Auditory Verbal Learning Test, BVRT = Benton Visual recognition Test, COWAT = Controlled Oral Word 
Association Test, CWIT = Controlled Word Interference Test, DS = Digit Span, GNT = Graded Naming Test, JLO = Judgement of Line Orientation, 
PVLT = Peabody Verbal Learning Test, RAVLT = Rey Auditory Verbal Learning Task, RFT = Recurring Figures Test, ROCF = Rey-Osterrieth Complex 
Figure, ,RPM = Raven’s Progressive Matrices, TAP = Test batterie zur Aufmerksamkeitsprüfung,  VPA = Verbal Paired Associates, WCST = Wisconsin 
Card Sorting Test. n2 = sample size at Time 2, n3 =  sample size at Time 3, n4 =  sample size at Time 4 
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1.11. Impact of cognitive and behaviour change 
It is difficult to overstate the importance of understanding cognitive and 
behavioural status in ALS. Some clinicians may be reticent to subject patients to 
cognitive and behavioural assessments, however the potential benefits outweigh 
the perceived cost. The impact of physical symptoms associated with ALS has 
been widely demonstrated (Abdulla et al., 2014; Goldstein et al., 1998; Pagnini 
et al., 2010), yet, cognitive and behavioural symptoms appear to contribute 
uniquely to patients’ and caregivers’ quality of life, mood, and burden. Patients’ 
quality of life has been associated with subjective cognitive lapses (Goldstein, 
Atkins, & Leigh, 2002). However, it may be behavioural symptoms that most 
impacts caregiver burden (Andrews, Pavlis, Staios, & Fisher, 2017; Chiò et al., 
2010; Tremolizzo et al., 2016), quality of life and depression (Chiò, 2010), 
activities of daily living (Mioshi, Lillo, Kiernan, & Hodges, 2012), and relationship 
intimacy (Goldstein et al., 1998). In a survey of ALS caregivers, Lillo, Mioshi, and 
Hodges (2012b) found that 48% of carers experienced high levels of burden, and 
that abnormal behaviour and caregiver stress, not physical symptoms, 
significantly predicted this. Recently, in a relatively large cohort of 84 patients and 
caregiver dyads, the impact of cognition and behaviour on caregiver burden was 
explored. In this study, caregiver burden was significantly associated with 
patients’ behaviour, even after controlling for severity of functional disability 
(Tremolizzo et al., 2016).  
While the psychological impact on caregivers and people with ALS is 
sufficiently meaningful to justify knowing a patients’ cognitive and behavioural 
status, the impact of such symptoms on disease course has recently been 
elucidated. In 2005, Olney et al. found that those with ALS and comorbid FTD 
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were less compliant with respiratory and nutritional interventions. Rates of non-
compliance in ALS-FTD patients were twice that of ALS without comorbid 
dementia. Additionally, Chiò et al. (2012) found that while ALS cases with and 
without behavioural symptoms showed similar rates of nutritional and respiratory 
intervention uptake, patients with behavioural symptoms survived for shorter 
periods suggestive of poor treatment compliance. Martin et al. (2014) report that 
patients with a higher level of intellectual functioning were significantly more likely 
to accept respiratory and nutritional interventions.  
Futhermore, Stukovnik et al. (2010) found that people with ALS were 
significantly less able than a control group in medication scheduling task. When 
asked to correctly and safely schedule a day’s medication use, patients were less 
able to schedule pills at the correct time, and made more errors and omissions. 
This was despite spending a similar amount of time completing the task, making 
similar number of steps to completion, and viewing the instructions a similar 
amount of times as the control group. While these results are by no means 
conclusive, they highlight the potential impact that cognitive impairment can have 
on intervention compliance. Yet, some of the most notable findings regarding the 
impact of cognition and behaviour in ALS concerns survival. Behavioural change, 
particularly apathy (Caga et al., 2016), and cognitive change, particularly 
executive dysfunction (Elamin et al., 2011), have shown to be negative prognostic 
indicators in ALS, with significant survival time reduction of approximately one 
year (Chiò et al., 2012; Elamin et al., 2011; Gordon et al., 2010b; Gordon et al., 




1.12. Assessment of cognition in ALS 
As has been demonstrated, cognitive and behavioural symptoms are common in 
ALS. These symptoms can impact caregiver and patients’ psychological 
wellbeing, medical decision making, patients’ ability to engage with interventions, 
and have a negative prognostic effect on survival. Recently published guidelines 
on the assessment and management of patients with MND have emphasised the 
need for timely assessment of cognitive and behavioural symptoms as part of a 
multidisciplinary team (NICE, 2016). These guidelines highlight the impact that 
cognitive and behavioural status can have on issues of capacity, patient 
management, and care planning. Important factors should be considered in the 
assessment of neuropsychological status in ALS, namely, assessment factors 
and disease factors.  
 
Assessment factors (practice effects): An important factor to consider is that of 
learning/practice effects that pervade neuropsychological testing. This occurs 
when a person is administered the same or very similar tests more than once. 
Performance can improve, not due to an increase in cognitive ability, but because 
the individual has become familiar with the test or the testing environment. 
Practice effects are worse for younger and more educated individuals (Calamia, 
Markon, & Tranel, 2012), for shorter durations between testing (Bartels, Wegrzyn, 
Wiedl, Ackermann, & Ehrenreich, 2010; Benedict, 2005), and are worse for tests 
that have a novel learning component. For example, some research has 
suggested that practice effects can persist in the Wisconsin Card Sorting Test for 
up to 7 years (Calamia et al., 2012). Not accounting for this improvement may 
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lead to the false belief that the patient is improving, or it may mask a decline if 
present.  
Practice effects can, in some situations, be accounted for statistically, for 
instance, in the inclusion of control groups in statistical models. Other methods 
to control for practice effects are in using reliable change indices (Jacobson & 
Truax, 1991). These indices determine whether an observed change between 
testing sessions is statistically meaningful. Regression models (both univariate 
and multivariate) can also be used to generate predicted scores, which can then 
be compared to an individual’s actual score (Temkin et al., 1999). However, 
statistical approaches may not always be appropriate, or the best method 
available. A common alternate method of accounting for practice effects is in the 
use of alternate forms. Alternate forms of a test are those in which multiple 
versions of the same test exist which measure the same outcome, in the same 
way, with similar levels of difficulty. For example, alternate forms of the Trail 
Making Test have been developed in which the placement of number and letters 
differ between forms such that the quantity of items to connect and their distances 
are the same (Wagner, Helmreich, Dahmen, Lieb, & Tadíc, 2011). Other common 
neuropsychological tests with alternate forms include the Rivermead Behavioural 
Memory Test (Wilson et al., 2008), Repeatable Battery for the Assessment of 
Neuropsychological Status (Randolph, 1998), and Montreal Cognitive 
Assessment (see Costa et al., 2012b). 
 
Disease factors: Many neuropsychological assessment tools and experimental 
tasks rely on intact motor functioning, for instance, through timed or time-limited 
tests, or reaction speeds. Given that ALS is predominantly a disease of the brain’s 
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motor system, it is surprising that research continues to be conducted without 
fully accounting for physical disability (e.g., Lepow et al., 2010; Machts et al., 
2014; Pinkhardt et al., 2008; Rusina et al., 2010; Savage et al., 2014; Schreiber 
et al., 2005). Stukovnik et al. (2010) compared the test performance of ALS cases 
before and after correcting for motor disability. Before correcting, patients 
displayed high levels of impairment on numerous executive tasks (e.g., category 
fluency, Stroop Colour-Word Interference, Trail-Making), however, after 
correcting for motor speed, many tasks become non-significant. Not correcting 
for motor speed can lead to over-estimation of the cognitive difficulties of 
individuals.  
As previously noted, respiratory status may be an important factor to 
consider when assessing cognitive abilities in ALS. Respiratory insufficiency has 
been shown to affect cognitive functioning, for example, in sleep apnoea (Findley 
et al., 1986; Lal, Strange, & Bachman, 2012), chronic obstructive pulmonary 
disease (Crews et al., 2001; Dodd, Getov, & Jones, 2010), and a relationship has 
similarly been suggested in ALS (Kim et al., 2007; Murphy et al., 2016; Newsom-
Davis et al., 2001; Piepers et al., 2006). Therefore, careful consideration should 
be made as to how a patient’s respiratory function may affect performance.  
 
1.12.1 Cognitive Assessment tools 
While extensive neuropsychological evaluations are considered the gold 
standard for assessment, they are burdensome to patients and require qualified 
clinical neuropsychologists. Brief assessments exist that can be administered by 
non-specialist healthcare professionals. Yet, these tools often assume intact 
motor functioning, and are not designed to measure the heterogeneous profile of 
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cognitive change in ALS. In recent years, several ALS-specific tools have been 
created to assess the cognitive and behavioural status of patients with MND. 
These tools can be informative for clinical practice, for research, and to determine 
whether a more extensive neuropsychological investigation is warranted. While 
several screening batteries have been suggested (see Table 1.6 for summary), 
the most relevant general screening instruments are the Edinburgh Cognitive and 
Behaviours ALS Screen (ECAS) and the ALS Cognitive Behavioural Screen 
(ALS-CBS), both of which include measures of cognition and behaviour. Both 
tools were designed specifically for ALS and can be used by any suitable 
healthcare professional. Recently updated ALS consensus guidelines suggest 







Table 1.6. Cognitive Screening instruments 
 
Name Time Taken Description Strengths Weaknesses 
Penn State Screen 
Exam (Flaherty-Craig 
et al., 2006; 2009) 
20 mins 
A cognitive screen including 
measures of executive 
functions, language, 
visuospatial, fluency, and 
memory.  
Revised adjusted for motor 
disability (Flaherty-Craig et al., 
2009). Measures multiple areas 
of cognition. May be useful in 
detecting language variants of 
FTD.  
Not formally validated. 
Expensive to use. Originally 
designed for other neurological 
disorders. Includes behaviour 




(Nasreddine et al., 
2005) 
15 min 
A cognitive screen measuring 
visuospatial, executive, 
attention, language, memory, 
orientation.  
Freely available. Alternate 
versions allow for repeat testing, 
and additionally has a ‘mini form’. 
Measures multiple areas of 
cognition. Has been validated in 
numerous diseases and 
available in dozens of languages 
(see www.mocatest.org).  
Not designed for ALS and relies 
on intact motor function, 
adaptations may be possible 
however (Osborne, Sekhon, 




Battery (Dubois, et al., 
2000) 
5-10 mins 
A cognitive screen measuring 
executive functions, fluency, 
and motor programming. 
Well validated for measuring 
frontal-executive functions.  
Only measures executive 
functions. Not suitable for 
patients with motor disability 
(Raaphorst et al., 2013). No 







(Woolley, et al., 2010) 
10 minutes 
A cognitive and behavioural 
screen measuring executive 
functions, fluency, and attention  
Very brief and most tasks 
independent of motor speed. 
Spanish version available 
(Turon-Sans et al., 2016). Good 
accuracy in detecting FTD 
(Woolley et al., 2010). Available 
freely. Formally validated in ALS 
(Woolley et al., 2010). Includes 
behaviour screen (See Table 
1.7). 
Primarily measures executive 
functions and does not address 
the heterogeneity of cognitive 
impairment. Fluency task does 
not adjust for motor speed. 
Limited ability to detect mild 
cognitive impairments (Woolley 
et al., 2010). Limited range of 
scores and presence of ceiling 
effects (Woolley et al., 2010) 
ALS Brief Cognitive 
Assessment (Hu et 
al., 2013) 
~5 mins 
A 5-item cognitive and 
behavioural tool measuring 
executive functioning, fluency, 
and FTD behaviours.  
Good accuracy for detecting 
FTD. Extremely brief.  
Designed for other neurological 
populations. Not good at 
detecting mild cognitive 
impairment. Only measures 
executive functions. Does not 
control for motor speed.  
Edinburgh Cognitive 
and Behavioural ALS 
Screen (Cognitive 
Section) (Abrahams et 
al., 2014) 
15-20 mins 
A cognitive and behavioural 
screen measuring executive 
functions, social cognition, 
language, visuospatial, and 
memory. 
Measures multiple domains of 
cognition. Only tool to include 
social cognition. Available in 22 
languages. All tasks adjusted for, 
or independent of motor speed. 
Available freely. Formally 
validated in ALS (Niven et al., 
2015). Includes behaviour screen 
Ceiling effects present in 





(See Table 1.7). Available from 
ecas.psy.ed.ac.uk. 
UCSF Brief Screening 
Battery (Murphy et al., 
2015) 
40 mins 
A combination of the ALS-CBS 
(Woolley et al., 2010), 
Abrahams’ verbal fluency test 
(Abrahams, 2000), and an ALS 
version of the FBI administered 
to caregiver. 
Same strengths as the ALS-CBS 
but combines a motor-
independent measure of fluency 
with the ALS-CBS. Includes 
behaviour measure (ALS-FBI; 
Table 1.7). Improves predictive 
ability of ALS-CBS (Murphy et 
al., 2015). Includes a behaviour 
screen.  
Does not account for cognitive 
heterogeneity. Considerably 
longer than the ALS-CBS.  
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1.12.1.1 ECAS  
The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) is a multi-domain 
cognitive and behavioural measure specifically designed for ALS (Abrahams et 
al., 2014; ecas.psy.ed.ac.uk). It contains 15 subtests divided into those functions 
most commonly impaired in ALS (ALS-Specific functions), and those less 
commonly associated with ALS (ALS Non-Specific functions). ALS-Specific 
functions include measures of executive ability, including working memory 
(reverse digit span), task switching (oral trail-making), inhibitory control (sentence 
completion), and social cognition (judgement of preference). Due to its sensitivity 
to detecting impairment in ALS, verbal fluency is measured as its own domain. 
Adapted for motor impairment by calculation of the verbal fluency index 
(Abrahams et al., 2000), the ECAS fluency task requires the free generation of 
‘S’ words, and the restricted generation of 4-letter ‘T’ words (see section 1.6.2). 
Language functions are measured using tasks of confrontation naming, 
comprehension, and spelling. All tasks are designed to tap both noun and verb 
knowledge thereby accounting for the specific verb-deficit suggested in ALS. ALS 
Non-Specific tasks are those of memory (involving the immediate and delayed 
recall and recognition of a prose story), and visuospatial functions (including dot 
counting, cube counting, and number location).  
All subtests of the ECAS can be adapted to the motor ability of the patient, 
in that responses can be given orally, verbally, or using assistive technology. The 
ECAS has been validated against a full neuropsychological battery and shows 
good sensitivity and specificity to cognitive impairment in Scottish (Niven et al., 
2015), German and German-Swiss (Loose et al., 2016; Lulé et al., 2015), Italian 
(Poletti et al., 2016), Irish (Pinto-Grau et al., 2017), Chinese (Ye et al., 2016) 
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populations, and is available in Spanish (Mora et al., 2018). The ECAS possesses 
good convergent validity with other screening tools, for example, the Montreal 
Cognitive Assessment (Lulé et al., 2015; Poletti et al., 2016) and Frontal 
Assessment Battery (Poletti et al., 2016). In addition to its motor-free design, 
administration of the ECAS is possible in cases of severe motor disability where, 
by comparison, not all patients could complete the Montreal Cognitive 
Assessment and the Frontal Assessment Battery (Burkhardt, Neuwirth, & 
Webber, 2017; Lulé et al., 2015). The ECAS has additionally been adapted for 
eye-tracking and early results suggest it may be useful in the assessment of end-
stage disease (Keller et al., 2017).  
 
1.12.1.2. ALS-CBS 
The ALS Cognitive Behavioural Screen (ALS-CBS; Woolley et al., 2010) is a short 
cognitive and behavioural screen specifically designed for ALS. It includes brief 
measures of attention (following commands, mental addition, eye movements), 
concentration/working memory (backward digit span test), tracking/monitoring 
(saying the months backward, reciting the alphabet, oral trail-making test), word 
initiation and fluency (letter fluency for letter ‘F’). The ALS-CBS additionally 
includes a behaviour questionnaire addressing an extensive list of behaviours, 
including apathy, inhibition, empathy, emotional control, frustration tolerance, 
cognitive flexibility, insight, judgement, food preferences, decision making, and 
language. It has been validated against a full neuropsychological battery, with 
good sensitivity and specificity for detecting FTD; however, it is unable to 
distinguish mild cognitive impairment from FTD (Woolley et al., 2010). It has been 
validated in Brazilian Portuguese (Branco et al., 2017) and is available in Spanish 
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(Turon-Sans et al., 2016). The ALS-CBS benefits from being brief and can be 
utilised by any health care professional, as with the ECAS. While the ALS-CBS 
benefits from being largely independent of motor functioning, its most sensitive 
subtest, the verbal fluency test, is not adjusted for motor speed. While participants 
are able to speak, write, or use assistive communication devises, it does not 
adjust for the different lengths of time these methods take, nor for slowed motor 
speed.  
The ALS-CBS has recently been incorporated into the UCSF Screening 
Exam (Murphy, Ahmed, & Lomen-Hoerth, 2015) which includes a separate 
measure of the Abrahams et al. (2000) fluency test adjusted for motor speed. 
While the ALS-CBS primarily measures executive functioning, and does not 
directly measure language, memory, or visuospatial functioning, the expanded 
UCSF Screening Exam includes an expanded ALS-specific behavioural 
measurement (ALS-FBI). A modified version of the UCSF Screening exam was 
proposed for utility in telephone administration. The ALS-CBS portion of the 
UCSF showed similarities between telephone and in-person testing. However, 
results suggest that the telephone-administered fluency components and the 
ALS-FBI screen are not equivalent to in-person testing (Christodoulou et al., 
2016). 
 
1.13. Assessment of behaviour in ALS 
While ALS and FTD are now understood to be overlapping conditions, 
behavioural symptoms are largely mild in non-demented ALS (Raaphhorst et al., 
2012a). As such, symptoms may go unnoticed, in part due to the lack of objective 
specificity in behavioural assessments. The culture and background of the 
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individual may mediate whether behaviours are considered abnormal. Moreover, 
the prevalence of mild ALS-FTD type behaviours in the general population has 
not been established. Common behaviours in FTD, such as apathy, hoarding, 
and disinhibition have been found in healthy ageing (Brodaty, Altendorf, Withall, 
& Sachdev, 2010; Esposito et al., 2014; Marx & Cohen-Mansfield, 2003; Morales-
Vives & Vigil-Colet, 2012). This means that true prevalence of pathological 
behaviours is not fully known. Caregivers in Grossman et al. (2007) study 
reported that 11% and 20% of patients exhibited apathy and disinhibition prior to 
the onset of ALS, and as such, behavioural symptoms may manifest before 
physical symptoms (Mioshi, et al., 2014a).  
Methods of behavioural assessment are inherently less specific and 
objective than those of cognition. Behaviours may be symptomatic or reactionary 
to the disease, for example, a person with ALS may exhibit apathy which may be 
a symptom of ALS, or a psychological reaction to the burden of the disease. Most 
behavioural assessments rely on information provided by a third party, a so-called 
informant. While this will often be the patient’s spouse, this is not always possible. 
Assessment tools of behaviour that are currently available usually aim to 
diagnose overall dementia-related behaviour, rather than profiling specific 
behaviours such as apathy, disinhibition, or stereotypic behaviours. As such, their 
clinical utility can be limited. Moreover, many measures of behaviour used with 
ALS were not originally designed for a patient population with physical disability. 
As such, questions that seemingly measure a behaviour may be affected more 




1.13.1. Behavioural Assessment Tools 
Behavioural assessment can be subjective, and it can be difficult to determine 
what constitutes abnormality. Generally, abnormal behaviours are those which 
represent a change from the individuals previous functioning or are considered 
out of place within the individual’s unique context. Both questionnaires and 
interviews have been utilised as methods of assessment behaviour change in 
ALS. Additionally, many behaviour screens only provide information on overall 
behavioural dysfunction, and do not allow for the detection of specific behaviour 
manifestations. Questionnaire-based assessments reduce subjectivity to a 
degree but also result in a loss of the nuanced and variable presentations that 
behavioural symptoms can have. Common behaviour measurements used in 
ALS research are summarised in Table 1.7. Disease-specific tools have been 
published in recent years that attempt to overcome the possible confound of 
physical disability. The MiND-B, the ALS-FTD-Questionnaire, the Frontal 
Behavioural Inventory (ALS), ALS-CBS (behaviour screen), and the Beaumont 
Behaviour Inventory (BBI) are questionnaire-based measures of overall 
behavioural symptomatology, while the ECAS (behaviour screen) is interview 
based and designed to detect specific behavioural features.  
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Table 1.7. Behavioural screening instruments 
 




Schmand, et al., 
2012b) 
5-10 mins 25 item behaviour questionnaire 
including questions of emotional 
lability and subjective cognitive 
functioning.  
Based on systematic review and 
therefore likely to capture many of 
the common behaviours. Initial 
results of validation are promising. 
Takes frequency and severity of 
behaviours into account. Provides 
clinical cut-offs. Free to use. 
Independent of motor function. 
Only validated in Dutch population. 
Does not provide information on 
individual behaviours. Is restricted 
to behaviours observed currently or 
over past month.  
MiND-B (Mioshi, 
et al., 2014b) 
5 mins 9 item caregiver questionnaire 
measuring apathy, disinhibition, 
and stereotypic behaviours.  
Very brief and available freely. Data 
driven. Independent of motor 
function. Provides clinical cut-offs 
for presence of behaviour and 
subdomains.  
Unable to differentiate severity of 
symptoms i.e., ALSbi to ALS-FTD 
(Hsieh et al., 2016; Mioshi, et al., 
2014b). Only measures behaviour 
over previous month. Limited to 









(Murphy et al., 
2015) 
10 mins The 24-item FBI was originally 
designed to measure behaviours 
associated with frontal lobe 
dysfunction (Kertesz et al., 
1997). It has been adapted for 
motor disability in ALS. 
Information is provided by 
caregiver.  
Instructions explicitly specify 
changes in behaviour not due to 
physical symptoms. Accounts for 
frequency of behaviour. Freely 
available.  
No direct measure of symptom 
severity. Inconclusive results on its 
predictive ability. No cut-offs for 






(Abrahams et al., 
2014) 
5-10 mins Assesses 10 behaviour 
symptoms across 5 behaviour 
domains. Based on diagnostic 
criteria for FTD, including. 
Information is provided by 
caregiver. 
Specifically designed for ALS. 
Provides opportunity to gather 
qualitative information about 
behaviours including frequency, 
severity, and time course. Based 
on FTD diagnostic criteria. 
Available freely. Includes cognitive 
screen.  
Reliant on subjective judgement of 
clinician/researcher. Restricted to 
diagnostic criteria and may not fully 
reflect research findings of common 




York, et al., 2010) 
5 mins Assesses overall behavioural 
involvement with 15 questions 
measuring multiple areas of 
behaviour. Four additional 
questions address depression, 
anxiety, emotional lability, and 
fatigue. Information is provided 
by caregiver. 
Specifically designed for ALS and 
research driven. Behaviour screen 
is objective and accounts for 
symptom severity. Available freely. 
Includes cognitive screen. 
Not detailed enough to measure 
specific behaviour domains. Does 
not cover behaviour domains 
included in FTD diagnostic criteria. 
Does not account for frequency of 
behaviours, and may be unreliable 
for behaviours that presented prior 







(Cummings et al., 
1994) 
10 mins Developed for Alzheimer’s 
disease, the NPI 10 or 12 
(depending on version) 
measures aspects of behaviour 
and psychiatric symptoms.  
Measures frequency, severity, and 
impact of symptoms. Quite 
detailed. Available in numerous 
languages. Short form version 
available (NPI-Q) (Kaufer et al., 
2000). 
Not specific to ALS and not 
independent of motor disability.  
Frontal Systems 
Behaviour Scale 
(FrSBe) (Grace & 
Malloy, 2001) 
10 mins Originally developed for stroke 
patients (Grace & Malloy, 2001), 
the FrSBe is a 46-item scale 
assessing frontally-associated 
behaviours of apathy, executive 
dysfunction (functional aspects), 
and disinhibition.  
Includes both carer and patient 
report forms. Can be used to 
estimate behaviour change from 
premorbid rates. Validated for use 
in FTD (Carvalho, Ready, Malloy, & 
Grace, 2013; Malloy, Tremont, 
Grace, & Frakey, 2007).  
Not independent of motor functions. 
The FrSBe is costly to use. Limited 
to three behaviour domains. Too 
much focus of psychiatric 





et al., 2017) 
5-10 mins 41 item proxy-report 
questionnaire assessing 
behaviours noted in FTD 
diagnostic criteria, in addition to 
emotional lability, psychosis, and 
altered response to sensory 
stimuli.  
Developed specifically for ALS 
incorporating multiple diagnostic 
criteria. Covers broad range of 
behaviours. Accounts for time and 
severity in ratings. Validated with 
large cohort.  
Non-specific factor structure. No 
clear guidelines on measuring 
individual behavioural symptoms. 
Some question items are overly 
vague and the weightings of 
questions are unclear i.e., many 
more questions relating to 




1.13.1.1. ECAS Behaviour Screen 
The ECAS includes a caregiver-interview behaviour screen measuring 10 
symptoms of behaviour that combine into five dimensions, namely: disinhibition; 
apathy or inertia; loss of sympathy or empathy; perseverative; stereotyped; 
compulsive; or ritualistic behaviours; and hyperorality and altered food 
preferences. These domains are based on the revised diagnostic criteria for FTD 
(Rascovsky et al., 2011), which have shown good sensitivity and specificity to 
detecting FTD (Costa et al., 2013; Harris et al., 2013; Lamarre et al., 2013). The 
ECAS behaviour screen also measures psychotic symptoms less commonly 
seen in ALS cases (Strong et al., 2017). The ECAS behaviour screen benefits 
from its semi-structured interview design. It allows the freedom to probe the carer 
as to the frequency, severity, time-line, and qualitative nature of observed 
behaviours. Conversely, this adds variability in measurement due to interviewers’ 
individual techniques.  
 
1.13.1.2. ALS-Cognitive Behavioural Screen (ALS-CBS) 
The behavioural section of the ALS-CBS is a brief 15-item carer questionnaire. 
Usefully, four additional questions address depression, anxiety, emotional lability, 
and fatigue. The ALS-CBS was specifically designed for ALS and as such, the 
behaviour screen is not dependent on motor function. However, as with other 
questionnaire-style tools, it cannot provide information on specific behaviours, 
does not account for frequency of behaviours, and specifies that behaviours 
should develop after motor symptom onset. Currently the ALS-CBS has 
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demonstrable ability to detect FTD, however, is has poor discriminant ability to 
differentiate mild behaviour change from FTD (Woolley et al., 2010).  
 
1.13.1.3. Frontal Behavioural Inventory ALS Version (FBI-ALS) 
The Frontal Behavioural Assessment was designed to measure frontally-
mediated behavioural symptoms (Kertesz, Davidson, & Fox, 1997). It has been 
shown to have good predictive ability from differentiating FTD from other forms 
of dementia (Kertesz, Nadkarni, Davidson, & Thomas, 2000; Milan et al., 2008; 
Slachevsky et al., 2004). While it has been previously used to measure behaviour 
in ALS (Flaherty-Craig et al., 2009; Gordon et al., 2007; Hu et al., 2013), the 
original FBI contains questions that may be exaggerated by motor disability e.g., 
“Does s/he take as much care of his/her personal hygiene and appearance as 
usual”, or “does s/he neglect to wash or change his/her underwear?”. Murphy et 
al. (2015) has recently adapted the FBI to measure changes in behaviour, 
frequency of behaviour, and account for motor disability e.g., “When you think 
about those personal hygiene activities that they can complete on their own, does 
s/he neglect to initiate grooming or personal care activities as compared with their 
behaviour in the past?”. While the FBI-ALS is promising, and has recently been 
used in a large multi-centre research study (Murphy et al., 2016), its validity has 
not been fully established. The validity of the FBI-ALS has only been measured 
in a small sample of 24 patients, and was related to other measures of behaviour 
(the ALS-CBS behaviour scale, and the FrSBe) inconsistently. Additionally, cut-
offs are not provided for determining behavioural impairment (Murphy et al., 
2015). Further validation research is required to determine its research and 




1.13.1.4. The Motor Neuron Disease Behaviour Scale (MiND-B) 
The MiND-B is a brief data-driven tool derived from the Cambridge Behavioural 
Inventory (Mioshi, et al., 2014b; Wear et al., 2008). The MiND-B consists of 9 
questions measuring levels of apathy, disinhibition, and stereotyped behaviour. 
The MiND-B was designed to detect behavioural impairment and benefits from 
providing individual domain-specific clinical cut-offs. In a recent study of 70 ALS 
patients, the MiND-B demonstrated good discriminant validity in detecting 
behavioural change. However, due to the variability present in behaviour scores 
of patients with ALS-FTD, the MiND-B was not able to discriminate between ALS-
FTD and ALS with mild behaviour changes (Hsieh et al., 2016). 
 
1.13.1.5. The ALS-Frontotemporal Dementia-Questionnaire (ALS-FTD-Q) 
The ALS-FTD-Q is a 25-item caregiver questionnaire providing an overall 
behavioural symptomatology score, in addition to the frequency or severity of the 
symptoms. Questions include the domains of apathy, irritability, disinhibition, 
emotional lability, and altered food preferences. This scale was developed 
following a systematic search of behaviour symptoms in ALS (Raaphorst et al., 
2012b). It has good validity and reliability and correlates well to the FrSBe 
(Raaphorst et al., 2012b). The ALS-FTD-Q is available in 9 languages, but has 
currently only been validated in Dutch, and recently Japanese (Watanabe et al., 
2016). The cut-offs for this scale provide distinctions between mild behavioural 
symptoms and more severe symptoms (ALS-FTD), however, it does not provide 
clinically relevant measures of any individual behaviour. Further research is 




1.13.1.6. The Beaumont Behavioural Inventory (BBI) 
The Beaumont Behaviour Inventory (BBI) is the most recently published 
behavioural assessment (Elamin et al., 2017). The questionnaire is based on 
multiple diagnostic criteria for FTD including the Neary and Rascovsky criteria. 
Questions cover the domains of apathy, disinhibition, loss of empathy and 
sympathy, perseveration, altered food behaviour, utilisation behaviour, and 
psychosis. Ratings of the BBI incorporate gross timelines (last 10 years and since 
onset of MND) and severity. The BBI possesses good sensitivity and specificity 
against the FrSBe for both mild behavioural impairment and FTD (Elamin et al., 
2017). Burke et al., (2017) suggests that individual behaviour domains can be 
extracted from the BBI, however, no guidelines are provided which explain how 
this is achieved. Additionally, factor analysis of the BBI revealed non-specific 
groupings such that multiple behaviours types fall into one factor. As such, the 
structure and clinical utility of the BBI remain to be established.  
 
 
1.14. Cognitive and behaviour screening summary  
While classification systems describing patients as ALSci, ALSbi, or ALS-FTD 
may be useful for research purposes, the translation into clinical practice has not 
been evaluated. Providing indication that a patient may have a general cognitive 
or behavioural impairment may not provide the necessary detail to formulate 
additional support, or adjust care management. Additionally, focusing on 
cognition and behaviour as a unitary concept runs the risk of missing out patients 
whose impairment may be limited to one domain. An understanding as to the 
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individual cognitive and behavioural profile which is domain specific is more 
informative. Brevity may be important in a busy clinic environment, but the impact 
that non-motor symptoms can have warrants a review of how important such 
symptoms are viewed. To truly provide holistic and individualised care, time must 
be spent establishing the current cognitive and behavioural status of a patient so 
that the necessary support systems can be put in place.  
 In terms of cognitive assessment, full neuropsychological batteries are the 
gold standard. However, such an exercise is time consuming and burdensome 
for patients, and is therefore inappropriate for all cases of ALS. Fortunately, 
validated tools specific to ALS are available which provide the opportunity to 
provide cognitive assessment as standard practice. The ECAS and the ALS-CBS 
are the most widely recognised screening tools in ALS, providing measures of 
both cognition and behaviour. While the ALS-CBS benefits from a greater brevity 
compared to the ECAS, it is limited to assessing executive functioning. Given the 
growing evidence of language impairment and, to a lesser degree, memory 
involvement, broad screening tools such as the ECAS provide more 
comprehensive and clinically useful information. The ECAS, while longer than the 
ALS-CBS, takes only 20 minutes to administer and covers a broader range of 
cognitive functions. The ECAS is also available and validated in considerably 
more populations compared to the ALS-CBS and can detect mild cognitive 
impairment, whereas the ALS-CBS currently cannot. Additionally, the ALS-CBS 
is not entirely motor independent in that the verbal fluency task relies on motor 
speed. Though the ALS-CBS has been incorporated into the UCSF Brief 
Screening Battery, this battery takes approximately 40 minutes to administer 
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undermining the goal of clinical screening tools. As such, the ECAS is currently 
the best option for cognitive screening in ALS.  
Assessment of behaviour in ALS benefits from a broader range of tools 
available. However, the quality of these tools remains to be established fully. 
Questionnaire based-tools attempt to reduce behavioural features, which are 
qualitative, to quantitative scores. Additionally, most do not address important 
factors, such as behavioural frequency, severity, whether the behaviour 
represents a change from premorbid functioning, or confounding variables such 
as motor disability. Unfortunately, behaviour screening tools have also lacked 
appropriate validation against clinical diagnosis or other standardised measures. 
The ECAS can detect mild behaviour change in addition to possible FTD when 
the consensus guidelines are applied (Strong et al., 2017). As with the cognitive 
screen, the ALS-CBS cannot differentially detect milder forms of behavioural 
impairment which are more common than full-blown FTD in ALS. The MiND-B 
was an important step forward in adapting a comprehensive behaviour tool for 
ALS. The MiND-B demonstrated good discriminant ability in detected FTD, 
however, as with the ALS-CBS it could not detect milder behavioural changes. 
Additionally, the MiND-B does not include measures of altered eating behaviours 
or loss of sympathy or empathy which are relatively common in ALS. The ALS-
FTD-Q is the only questionnaire-based behaviour screen that allows for the 
detection of mild behaviour changes. However, an English language version has 
yet to be validated. Finally, the BBI while promising, is inconsistent as to the 
constructs being measured and whether it has the power to detect specific 
behaviour domains.  
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As such, the ECAS is the only behaviour measure which allows for the 
detailed exploration of behaviours common in FTD. Benefiting from its interview 
basis, the ECAS behaviour interview allows for the examination of specific 
behaviours in terms of frequency, severity, whether the behaviour represents a 
decline, and to tease apart the confounding effects of motor impairment. While a 
limitation may be that the ECAS requires clinical interpretation to determine the 





1.15. General Aims 
It is now established that cognitive and behavioural impairment are common 
features of ALS, with ALS and FTD demonstrating considerable overlap. 
Specifically, executive functioning, language, fluency, and social cognition are 
commonly affected in ALS, while apathy is the most frequently reported 
behavioural feature. However, despite these advances, questions remain.  
Associations between neuropsychological impairment and clinical disease 
variables have been proposed, but results are inconsistent. Additionally, whether 
neuropsychological impairment worsens over the course of the disease in ALS 
has yet to be established. Cross-sectional and longitudinal research examining 
the relationship between disease severity, spread, and cognition are highly 
variable. Cross-sectional research has been limited using imprecise measures of 
disease severity (i.e., the ALSFRS). Longitudinal studies have similarly been 
limited by the use of time or the ALSFRS-R as a proxy of disease progression, 
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by poor statistical methods which do not account for attrition, and small sample 
sizes. Furthermore, the assessment of cognition and behaviour continues to be 
confounded by tools not suited for patients with motor disability, or the presence 
of practice effects in repeated assessment. Fortunately, ALS-Specific tools for 
measuring cognition (i.e., the ECAS, see section 1.12) and standardised 
measures of disease progression (the King’s Clinical Staging System, see 
section 1.4.2) are now available. As such, the general aims of this study are to 
amalgamate advances in the assessment of cognition, behaviour, and disease 
progression to elucidate the evolution of neuropsychological symptoms over the 
course of ALS.  
 
 
Aim 1: Develop, and validate, alternate forms of the Edinburgh Cognitive and 
Behavioural ALS Screen (ECAS) to accommodate repeated longitudinal 
assessment in ALS (Chapters 2 and 3).  
To explore cognition and behaviour longitudinally, alternate forms of the ECAS 
will first be developed. The newly developed forms will be equivalent to the 
original ECAS in terms of the content, difficulty, administration, length, and 
semantic characteristics. The new forms will allow for the repeated assessment 
of cognition in ALS while controlling for practice effects common in cognitive 
assessment. Cut-off scores will be derived from healthy control data, in addition 
to metrics of reliable change. As such, these tools will useful to both researchers 
and clinicians in tracking changes over the course of the disease. These new 




Aim 2: Explore how cognition and behaviour relate to clinical disease stage in 
ALS (Chapter 4). 
Cross-sectionally, a cohort of ALS patients will be recruited from three research 
sites: Edinburgh, Dublin, and London. Assessment of cognition and behaviour 
will be conducted using the original ECAS form and compared against each 
patients’ disease stage using the King’s Clinical Staging System. This study will 
allow us to explore whether a patients’ neuropsychological functioning is related 
to how advanced their disease is, and whether other clinical variables relate to 
neuropsychological symptoms.  
 
Aim 3: Explore how cognitive and behavioural symptoms evolve over the course 
of the disease in ALS (Chapter 5).  
Patients recruited from the three research sites will be followed up at clinical 
meaningful intervals. Patients’ cognitive and behavioural functioning will be 
monitored longitudinally and as they transition through disease stages using the 
alternate forms of the ECAS. This will allow for the examination of longitudinal 
trajectories over time, how changes relate to one another and to clinical disease 
stage, and evaluate the presence of patient subgroups. Additionally, this study 
will also allow for the longitudinal validation of Aim 2. 
 
Aim 4: Explore clinicians’ attitudes and practices around cognitive and 
behavioural screening in ALS (Chapter 6).  
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It is currently unknown how clinicians think about cognitive and behavioural 
screening in ALS. This study will qualitatively explore clinicians’ attitudes toward 
cognitive and behavioural assessment, their practices, and whether barriers exist 







CHAPTER 2: ECAS A-B-C: Alternate forms of 
the Edinburgh Cognitive and Behavioural ALS 
Screen 
 
Previous research of cognition in ALS has been limited owing to the use of 
assessment tools which are not appropriate for participants with motor weakness. 
This is of particular importance when examining how cognition evolves of the 
course of the disease due to the progressive nature of physical disability in ALS. 
The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) was developed 
to overcome the limitations imposed by physical disability and provide a 
comprehensive and ALS Specific measure of neuropsychological functioning.  
However, as with many cognitive assessment tools, the utility of the ECAS 
in monitoring cognition longitudinally is potentially limited by practice effects.  To 
overcome the limitations imposed by practice effects, Chapter 2 describes the 
development of the ECAS alternate forms (ECAS-B and ECAS-C). The following 
chapter was published open access (CC-BY) in Amyotrophic Lateral Sclerosis 
and Frontotemporal Degeneration (DOI: 10.1080/21678421.2017.1407793). 
Supplementary materials published with this article are available in Appendix II. 




































In Chapter 2, the alternate forms of the ECAS (B and C) were found to be 
equivalent to the original ECAS-A. Not only were alternate forms shown to be 
equivalent, cut-off scores for impairment demonstrated substantial parity across 
versions. It was demonstrated that the repeated assessment of cognition over 
short test-retest intervals using version A resulted in practice effects, whereas no 
such result was observed when the alternate versions were used. Finally, inter-
rater reliability of the three forms (A-B-C) were excellent. As such, the newly 
developed ECAS-B and ECAS-C are valuable for measuring the evolution of 
cognition longitudinally in ALS.  
 However, further investigations are required to validate their reliability over 
clinically meaningful time periods. Additionally, the interpretation of individual 





CHAPTER 3: Measuring reliable change in 
cognition using the Edinburgh Cognitive and 
Behavioural ALS Screen (ECAS) 
 
In the previous chapter, it was shown that the ECAS-B and C overcame practice 
effects when administered in an experimental setting. However, ALS patients 
attending clinics will often return at approximately 3-6 month intervals. As such, 
it is important to validate the properties of the alternate forms across clinically 
meaningful times periods. Additionally, to improve the clinical utility of the ECAS-
B and C, further investigation is required to accommodate the case-by-case 
interpretation of change over time. 
 Chapter 3 describes the establishment of reliable change scores for the 
ECAS alternate forms, and test-retest reliability across clinically relevant 
intervals. The following chapter was published open access (CC-BY) in 
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (DOI: 
10.1080/21678421.2017.1407794). Supplementary materials published with this 






























In Chapter 3, it was demonstrated that the ECAS-A-B-C possess no significant 
practice effects and high test-retest reliability over clinically meaningful time 
periods. Metrics of reliable change were provided using four approaches with 
clinically recommended cut-offs. The evidence provided in Chapters 2 and 3 
provide strong evidence for the equivalence and utility of the ECAS alternate 
forms in the longitudinal monitoring of cognition in ALS. As such, Chapters 2 and 
3 were successful in meeting Aim 1; namely, to develop, and validate, alternate 
forms of the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) to 
accommodate repeated longitudinal assessment in ALS. These findings provide 
the foundation for the use of the ECAS alternate forms within the clinic. 
 Thus, it is now possible to explore the evolution of neuropsychology health 
over the course of ALS while overcoming limitations imposed by the disease (e.g., 








CHAPTER 4: ALS specific cognitive and 
behavioural changes associated with 
advancing disease stage in ALS  
 
In Chapters 2 and 3, a means of observing cognitive functioning over time was 
demonstrated using the ECAS-A-B-C. This, taken with the King’s Clinical Disease 
Staging provide the opportunity to explore how cognition and behaviour evolves 
over the course of the disease. The King’s Clinical Disease Staging system 
provides a standardised metric of disease progress, which is superior to time or 
the functional rating scales (see Chapter 1 for discussion). As such, Chapter 4 
explores how the ECAS relates to clinical disease stage cross-sectionally.  
Cross-sectionally, a cohort of ALS patients were recruited from three 
research sites: Edinburgh, Dublin, and London. Assessment of cognition and 
behaviour were conducted using the original ECAS form and compared against 
each patients’ disease stage using the King’s Clinical Staging System. This study 
allows for the examination of whether a patients’ neuropsychological functioning 
is related to disease stage. Specifically, this chapter will examine whether 
neuropsychological symptoms are more severe or widespread in advanced 
disease stages.  
The following chapter was accepted for publication by open access (CC-
BY) in Neurology. Supplementary materials published with this article are 
available in Appendix IV. 
 
 107 
Title: ALS Specific cognitive and behaviour changes associated with advancing 
disease stage in ALS. 
 
Authors: 
Christopher Crockford MSc1,2, Judith Newton MSc1,3, Katie Lonergan BSc5,6, 
Theresa Chiwera MSc7,Tom Booth PhD1, Sidharthan Chandran Prof MD3, Shuna 
Colville MPH3, Mark Heverin MSc5, Iain Mays BSc5,6, Suvankar Pal PhD,3, Niall 
Pender PhD6, Marta Pinto-Grau MSc5,6, Ratko Radakovic PhD1,3,4, Christopher E 
Shaw Prof MD7, Laura Stephenson MSc3, Robert Swingler MD3, Alice Vajda 
PhD5, Ammar Al-Chalabi Prof PhD7, Orla Hardiman Prof MD5,8, and Sharon 
Abrahams Prof PhD1,2,3. 
 
Affiliations: 
1. Human Cognitive Neuroscience, Psychology, PPLS University of Edinburgh, 
Edinburgh, UK 
2. The Euan MacDonald Centre for Motor Neurone Disease Research, University 
of Edinburgh, Edinburgh, UK 
3. Anne Rowling Regenerative Neurology Clinic, Royal Infirmary of Edinburgh, 
Edinburgh, UK  
4. Alzheimer Scotland Dementia Research Centre, University of Edinburgh, 
Edinburgh, UK 
5. Academic Unit of Neurology, Trinity College Dublin, Dublin, Ireland 
6. Department of Psychology, Beaumont Hospital, Dublin, Ireland 
7. Maurice Wohl Clinical Neuroscience Institute, King’s College London, 
Department of Basic and Clinical Neuroscience, London, UK 
8. Department of Neurology, Beaumont Hospital, Dublin, Ireland 
 
Supplementary materials: comparison of patient and control cognition; 
correlations between cognition, behaviour and disease variables; and cognitive 




Acknowledgement: The authors would like to thank the patients and 
caregivers who took part in this study, in addition to the MND Scotland Clinical 
Specialists.  
 
Funding: The authors thank ALSA (the ALS Association) for funding this study 
(ALSA Grant ID: 179), in addition, further support was gained from University of 
Edinburgh’s Development and Alumni Innovative Initiative Grant. CC was funded 
by a scholarship from the Euan MacDonald Centre for Motor Neurone Disease 
Research. Clinical and genetic data were collected with thanks to the MND 
Register, hosted by the Euan Macdonald Centre for MND Research and funded 
by MND Scotland. The project is supported through the following funding 
organisations under the aegis of JPND (EU Joint Programme - 
Neurodegenerative Disease Research) United Kingdom, Medical Research 
Council (MR/L501529/1), Economic and Social Research Council 
(ES/L008238/1), and Irish Health Research Board (HRB-JPND/2013/1)). CES 
and AAC receive salary support from the National Institute for Health Research 
(NIHR) Biomedical Research Centre at South London and Maudsley NHS 
Foundation Trust and King’s College London. The work leading up to this 
publication was funded by the European Community’s Health Seventh 
Framework Programme (FP7/2007–2013; grant agreement number 259867) and 
Horizon 2020 Programme (H2020-PHC-2014-two-stage; grant agreement 






Christopher Crockford reports no disclosures. Judith Newton reports no 
disclosures. Katie Lonergan reports no disclosures. Theresa Chiwera reports no 
disclosures. Tom Booth reports no disclosures. Sidharthan Chandran reports no 
disclosures. Shuna Colville reports no disclosures. Mark Heverin reports no 
disclosures. Iain Mays reports no disclosures. Suvankar Pal reports no 
disclosures. Niall Pender reports no disclosures. Marta Pinto-Grau reports no 
disclosures. Ratko Radakovic reports no disclosures. Christopher E Shaw reports 
no disclosures. Laura Stephenson reports no disclosures. Robert Swingler 
reports no disclosures. Alice Vajda reports no disclosures. Orla Hardiman has 
received fees for consultation work from Biogen Idec, Cytokinetics and Novartis. 
She serves as Editor-in-Chief of Amyotrophic Lateral Sclerosis. Ammar Al-
Chalabi has consulted for Biogen Idec, Cytokinetics Inc, OrionPharma, 
Mistubishi-Tanabe Pharma and Chronos Therapeutics. Sharon Abrahams 





4.1. Abstract  
Objective: The purpose of this study is to elucidate the relationship between 
disease stage in ALS, as measured using the King’s Clinical Staging System, and 
cognitive and behavioural change using the Edinburgh Cognitive and Behavioural 
ALS Screen (ECAS).   
Methods: A large multicentre observational cohort of 161 cross-sectional patients 
with ALS and 80 healthy matched controls were recruited across three research 
sites (Dublin, Edinburgh, London). Participants were administered the ECAS and 
categorised into independent groups based on their King’s Clinical Disease Stage 
at time of testing.  
Results: Significant differences were observed between patients and controls on 
all subtests of the ECAS, except for visuospatial functioning. A significant cross-
sectional effect was observed across disease stages for ALS Specific functions 
(executive, language, letter fluency), and ECAS total score, but not for ALS Non-
Specific functions (memory, visuospatial). Rates of ALS-Specific impairment and 
behavioural change also related to disease stage. The relationship between 
cognitive function and disease stage may be due to letter fluency impairment, 
whereas higher rates of all behavioural domains were seen in later King’s stage. 
The presence of bulbar signs, but not site of onset, significantly related to ALS 
Specific, ECAS Total, and behavioural scores.  
Conclusions: ALS specific cognitive deficits and behavioural impairment are more 
frequent with more severe disease stage. By end-stage disease only a small 
percentage of patients are free of neuropsychological impairment. The presence 
of bulbar symptoms exaggerates the differences observed between disease 
stages. These findings suggest that cognitive and behavioural change should be 
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incorporated into ALS diagnostic criteria, and should be included in future staging 
systems.  
  
4.2. Introduction  
Amyotrophic Lateral Sclerosis (ALS) is marked by progressive degeneration of 
motor neurons, with death usually occurring 2-3 years from onset (Al-Chalabi & 
Hardiman, 2013). Approximately 35% of ALS patients experience cognitive or 
behavioural impairment, with an additional 15% having frontotemporal dementia 
(FTD) (Goldstein & Abrahams, 2013; Phukan et al., 2012).   
Executive dysfunction is commonly reported in ALS in addition to 
impairment in language and social cognition (Abrahams et al., 2000; Abrahams 
et al., 2004; Phukan et al., 2012; Taylor et al., 2013; Van der Hulst, Bak, & 
Abrahams et al., 2015), whereas apathy is the most frequently reported 
behavioural feature (Radakovic et al., 2016, Grossman et al., 2007). Longitudinal 
studies of cognition in ALS have been confounded by small numbers, the use of 
clinic based populations, and attrition (Abrahams, Leigh, & Goldstein, 2005a; 
Schreiber et al., 2005; Gordon et al., 2010). However, existing data (Elamin et 
al., 2013) indicates that cognitive change may relate to indirect measures of 
disease progression (for example, total score on the ALS Functional Rating 
Scale-Revised (ALSFRS-R), suggesting that this third domain should be included 
in diagnostic criteria and staging systems, such as the King’s Clinical Staging 
System (Roche et al., 2012).  
The objective of this study was to examine the clinical presentation of 
cognitive and behavioural symptoms across different disease stages of ALS as 
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defined by the King’s Clinical Staging System. Specifically, the aim was to 
examine a) whether cognition and behaviour is related to advancing disease 
stage in a clinically representative sample of ALS patients, b) which domains of 
cognition and behaviour are particularly related to disease stage, and c) which, if 
any, clinical variables relate to cognition and behaviour in ALS.  
 
4.3. Materials and Methods 
4.3.1. Standard Protocol Approvals, Registrations, and Patient Consents 
This study is a multicentre cross-sectional observational study. All participants 
provided informed written consent and this research was approved by the South-
East Scotland Research Ethics Committee, and the Medical Research Ethics 





One hundred sixty-one patients meeting revised El Escorial diagnostic criteria for 
possible, probable, or definite ALS (Brooks et al., 2000) were included. Patients 
were prospectively recruited across three research centres in Edinburgh, Dublin, 
and London between July 2014 and July 2016. Of the patients recruited, 88.8% 
were incident cases (n = 143) being assessed within 12 months of diagnosis. 
Recruitment was population-based in Dublin, and through ALS clinics in 
Edinburgh and London. Exclusion criteria included: a history of dyslexia, marked 
premorbid reading or writing difficulties, or a learning disability; non-fluent 
premorbid English reading and writing abilities; history of other neurological 
conditions that could affect cognition such as major hemispheric stroke, traumatic 
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brain injury, and severe active epilepsy; alcohol and drug dependencies; and 
severe physical disability or weakness at time of assessment prohibiting 
participation. Of the 161 participants with ALS, 149 primary caregivers consented 
to provide behavioural data. Eighty demographically matched healthy adults were 
additionally recruited as a control group. Healthy controls met the same inclusion 
criteria as the patient group and were not a blood relative of a person with ALS. 
The control group were recruited through research volunteer panels held by the 
University of Edinburgh and Trinity College Dublin, non-blood relatives of ALS 
patients, and local community noticeboards.  
 
4.3.3. Procedure and Materials 
Clinic- and home-based semi-structured interviews were conducted to collect 
demographic and clinical data. Socioeconomic Status (SES) was measured 
using the National Statistics Socio-Economic Classification (NS-SEC) Self-
Coded Scale (Standard Occupational Classification, 2010) modified to include 
the category of long-term unemployed. Functional status was assessed using the 
revised ALS Functional Rating Scale (ALSFRS-R) (Cedarbaum et al., 1999). 
Mood was measured using a modified version of the Hospital Anxiety and 
Depression Scale (HADS), which excludes items confounded by motor disability 
(Abrahams et al., 1997; Gibbons et al., 2011).  
Clinical staging was measured using the King’s Clinical Staging System 
(Roche et al., 2012, Fang et al., 2017). Each stage of the disease is based on 
regions of involvement where regions are bulbar, upper limbs, lower limbs, and 
respiratory or nutritional domains. Stage 1 is defined as the involvement of one 
bodily region (e.g., an upper limb); Stage 2 is defined as the involvement of two 
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bodily regions (e.g., upper limb and lower limb); Stage 3 is defined as involvement 
of three bodily regions (i.e., upper limb, lower limb, and bulbar); and Stage 4 is 
defined as respiratory or nutritional insufficiency requiring intervention. Regional 
involvement was determined by the presence of functional signs (e.g., changes 
in speech) or clinical examination (e.g., fasciculations, wasting of first dorsal 
interosseous). Respiratory and nutritional insufficiency was determined as per the 
NICE guidelines for Motor Neuron Disease Assessment and Management (NICE, 
2016), including arterialised capillary blood gas tensions, nocturnal arterial 
oxygen saturation, forced vital capacity, or sniff nasal inspiratory pressure. The 
King’s system has demonstrated good prognostic utility, providing a linear and 
standardised metric of disease progression (Roche et al., 2012; Fang et al., 2017; 
Balendra et al., 2015) 
Neuropsychological status was measured using the Edinburgh Cognitive 
and Behavioural ALS Screen (ECAS)(Abrahams et al., 2014). The ECAS is 
independent of motor disability and consists of 16 subtests across five cognitive 
domains: language functions, executive functions, and letter fluency combine to 
generate a composite ALS Specific score, while memory and visuospatial 
functioning combine to form an ALS Non-Specific score. The ECAS also consists 
of a carer behavioural interview based on the Rascovsky criteria for behavioural 
variant Frontotemporal Dementia (Rascovsky et al., 2011). The behaviour 
interview is a structured clinical interview conducted in private with patients’ 
caregivers. The interview measures five domains of behaviour: behavioural 
disinhibition; loss of sympathy/empathy; apathy or inertia; perseverative, 
stereotyped, or compulsive/ritualistic behaviours; or hyperorality and dietary 
changes. The behaviour interview additionally includes three questions 
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measuring the presence of psychotic features. Behavioural data gathered at the 
Dublin site, and the presence/absence of behaviour features was supported by 
the Beaumont Behaviour Inventory (Elamin et al., 2017). The ECAS was selected 
as the primary outcome measure to reduce the burden of participation due to its 
brevity and independence on motor speed, thereby reducing bias in participation.   
 
4.3.4. Statistical Analyses  
Demographic, clinical, and neuropsychological data for the patient and control 
groups were compared using a χ2 test for categorical data (or Fisher’s exact test 
when expected cell frequencies fell below 5) or Welch t-tests and one-way 
analyses of variance for continuous data. Effect sizes for group comparisons 
were calculated using η2, Cramer’s V, and r for Mann Whitney U tests. The 
relationship among ECAS subdomains were explored using tetrachoric 
correlation analysis. To examine whether cognition or behaviour is related to 
disease stage, patients with ALS were divided into independent groups based on 
their King’s clinical disease stage at time of testing. Jonckheere-Terpstra Tests 
were employed on raw ECAS scores specifying a decreasing trend for cognition 
and an increasing trend for behaviour with p-values approximated under the 
central limit theorem for 10,000 permutations. The ALS Specific, ALS Non-
Specific, and ECAS Total scores were the primary cognitive outcome measures 
due to their high sensitivity to cognitive impairment against a full 
neuropsychological battery (Niven et al., 2015, Pinto-Grau et al., 2017). The 
number of reported behaviour domains (max 5) of the ECAS behaviour interview 
was the primary behavioural outcome measure. When significant relationships 
were observed, the respective ALS Specific (Language, Executive, and Fluency), 
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ALS Non-Specific (memory and visuospatial), and behaviour (apathy, 
disinhibition, loss of sympathy/empathy, perseverative, and eating behaviours) 
subdomains were analysed to explore the nature of this relationship. 
Cognitive impairment was determined using local validated abnormality 
cut-off scores from UK and Irish populations (Niven et al., 2015, Pinto-Grau et al., 
2017). Behavioural impairment was defined as the presence of two or more 
behavioural features or the presence of apathy, as described by the recent 
consensus guidelines for diagnosing frontotemporal spectrum disorder (Strong et 
al., 2017). Rates of impairment between disease stages was analysed with the 
Cochran-Armitage Test, which evaluates the significance of an increasing 
binomial proportions trend across an ordinal grouping variable.  
The relationship between neuropsychological performance and clinical 
variables was also explored using one-way analyses of variance (ANOVA), 
Wilcoxon Mann-Whitney, and Spearman correlation tests. For all analyses, when 
data violated statistical assumptions, log or power transformation were applied. 
When transformation failed to correct violations, non-parametric alternatives were 
used. Multiple comparisons were corrected for using the Holm-Bonferroni 
method. Missing values were excluded pairwise, unless otherwise stated. 
Analyses were conducted using R 3.3.2 with alpha set to .05. 
 
Data availability 
Anonymised data presented in this article will be made available at the request 
of a qualified investigator. Requests should be made to Sharon Abrahams 





ALS patients and control demographic data are presented in Table 4.1. No 
significant differences were observed between the patient and control group for 
background variables or levels of depression and anxiety. 64% (n = 103) of 
patients had classical ALS, with symptom onset in the upper or lower limbs, 26% 
(n = 41) had bulbar onset, 9% (n = 15) had mixed onset, and 1% (n = 2) had 
respiratory onset.  
ALS patients’ cognitive performance was compared to that of the control 
group for each domain of the ECAS. Significant differences were observed for 
language, executive functions, letter fluency, and memory, while no significant 
difference was observed for visuospatial functioning. The composite ALS 
Specific, ALS Non-Specific and ECAS total score all demonstrated significant 
between-group differences (see supplementary tables). 28.5% of patients were 
found to have cognitive impairment on the ECAS Total, 27% on ALS Specific, 
and 19.4% on ALS Non-Specific Scores. Letter fluency impairment was most 
commonly observed (30.4%), followed by executive (22.5%) and language 
(21.3%) dysfunction. Memory (16.8%) and visuospatial (9.4%) impairment were 




Of the 149 patients for whom behavioural data were available, 45% had 
no behavioural features, 21.5% with one feature, 14.1% with two features, and 
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19.5% with three or more features. Behavioural impairment as described by the 
revised consensus guidelines (Strong et al., 2017) was found in 39.6% of 
patients. Apathy was the most commonly reported behavioural feature (30.9%), 
followed by a loss of sympathy/empathy (27.5%), changes in eating behaviours 
(24.8%), perseveration (24.8%), and disinhibition (15.4%). 
Impairment in cognitive domains was most strongly associated with other 
cognitive domains, rather than behavioural features, and vice versa (see 
supplementary see supplementary tables and figures). Language, fluency, 
executive, and memory impairment co-occurred (rtet = .27 - .49). Similarly, the co-
occurrence of behavioural features was strong ranging from .37 - .79. The 
Table 4.1. Demographic data for patients with ALS and control participants 
(ALS = 161; Controls  = 80) 
 ALS Control t or W or χ2 P-value 
Dublin n 86 43   
Edinburgh n 53 37   
London n 22 -   
Sex (% male)a 67.1 60 0.884 0.347 
Education (years) 13.93 ± 3.52 14.49 ± 3.31 1.22 0.224 
Age at testing (years) 61.39 ± 11.58 60.83 ± 13.23 0.326 0.745 
SES (median)a 2 ± 1.48 2 ± 1.48 6874.5 0.090 
HADS anxietya 4 ± 2.97 3.5 ± 2.22 6064 0.588 
HADS depressiona 1 ± 1.48 1 ± 1.48 6682 0.057 
Age at onset (years) 59.42 ± 11.75    
Diagnostic delay (months; median) 12 ± 8.9    
Riluzole use (% yes) 75.8    
Site of onset (B/U/L/R/M; %) 26/29/35/1/9    
Months since diagnosis (median) 3 ± 2.97    
ALSFRS-R 38.28 ± 6.94    
King’s Clinical Stage (Stages 1/2/3/4; %) 25/28/14/34    
Note. Values are mean  ± one standard deviation. aWilcoxon-Mann-Whitney test. For these and Diagnostic 
delay, values are median ± median absolute deviation. SES = Socioeconomic status; HADS = Hospital 
Anxiety and Depression Scale; Site of onset: B=Bulbar, U=Upper limb, L=Lower limb, R=respiratory, M = 
Mixed onset. Diagnostic delay is the time from symptom onset to diagnosis. ASLFRS-R = ALS Functional 
Rating Scale – Revised. Mood data was unavailable for 12 patients and two controls. SES unavailable for 
7 patients and 1 control.  
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relationship between cognition and behaviour was weaker, with a few exceptions. 
Relationships were observed between sympathy/empathy and executive 
dysfunction (rtet = .37), disinhibition and fluency impairment (rtet = .38), and 
visuospatial impairment with perseveration (rtet = .44) and hyperorality (rtet = .35). 
 
4.4.1 Cognition, Behaviour, and King’s Clinical Disease Staging 
Patients were divided into their respective King’s Clinical Stage at time of testing. 
Demographic and clinical variables are described for each disease stage group 
in Table 4.2. No significant differences were observed between the four patient 
groups for most variables. As expected, ALSFRS-R scores significantly differed 
between disease stages (F(3, 146) = 25.97, p < .0001, 2 = .348). A significant 
dependency was observed between site of onset and disease stage (χ2(6) = 
17.38, p = .008, V = .247) driven by a higher proportion of bulbar onset patients, 
compared to upper-limb onset, in Stages 1 and 4 (standardised residuals of 1.44 
and 1.42), and the inverse for Stages 2 and 3 (residuals of -1.80 and -1.48 
respectively). Differing levels of depressive symptoms as measured by the HADS 
were observed across disease stages (H(3) = 18.18, p < .001). Post-hoc analysis 
showed that Stage 1 significantly differed from Stage 2 (p = .043, r = .262) and 
Stage 4 (p < .001, r = .430). 
 
Table 4.2. Demographic and clinical variables by King’s Clinical Disease Stage  
 Stage 1a 
n = 40 
Stage 2a 
n = 45 
Stage 3a 
n = 22 
Stage 4a 
n = 54 
F or 2 P-value 
Demographic Variables 
 Age at testing  62.15 ± 10.59 60.07 ± 12.25 59.68 ± 12.63 62.63 ± 11.39 0.578 0.630 
 Sex (% male) 72.5 66.7 77.2 59.3 3.07 0.382 




Cognitive performance (represented as a z score calculated against local 
normative data) for patients within each disease stage is presented in Figure 4.1, 
with raw scores presented in Table 4.3. To explore whether cognitive and 
behavioural performance differs between disease stages, Jonckheere Terpstra 
Tests were employed on ECAS raw scores. A significant effect, corrected for 
multiple comparisons, was observed for ALS Specific (TJT = 3804.5, p = .022), 
ECAS Total (TJT = 3845.5, p = .026), and the number of behavioural features (TJT 
= 5295.5, p < .001) demonstrating lower cognitive ability and a higher number of 
behaviour features across advancing disease stages. No significant effect was 
observed for ALS Non-Specific functions. To examine which domains of ALS 
 SES b   2.5 ± 2.22 2.0 ± 1.48 2.0 ± 1.48 2.0 ± 1.48 1.05 0.788 
Clinical Variables 
 Age at onset 60.27 ± 10.78 58.22 ± 11.97 57.59 ± 13.27 60.59 ± 11.80 0.576 0.632 
 Diagnostic delay (months) b 10.5 ± 9.64 12.0 ± 7.41 9.50 ± 8.15 11.0 ± 7.41 0.180 0.910 
 Site of onset:  B/U/L/R/M (%)  41/23/35/0/0 13/47/36/0/4 9/36/41/0/14 34/18/24/4/20 17.38 0.008 
 Regions involved (% yes):  













 Upper limb  22.5 86.7 100.0 85.2 - - 
 Lower  limb 40.0 88.9 100.0 72.2 - - 
 Respiration 0 0 0 85.2   
 Riluzole use (% yes) 80.0 75.6 77.3 72.2 0.788 0.852 
 Time since onset (months)b 15.0 ± 9.3648 14.0 ± 10.38 15.0 ± 13.34 17.0 ± 8.90 0.196 0.899 
 Time since diagnosis 
 (months) b 
3.0 ± 2.97 2.0 ± 2.97 2.50 ± 2.22 3.0 ± 2.97 1.937 0.712 
 ALSFRS-R 43.49 ± 2.94 39.48 ± 4.81 38.10 ± 5.24 33.59 ± 8.01 25.97 < 0.0001 
 HADS Anxiety b   3.0 ± 1.48 4.0 ± 2.97 4.0 ± 3.71 5.0 ± 3.71 2.99 0.393 
 HADS Depression b 0.0 ± 0.0 2.0 ± 2.97 2.0 ± 2.97 3.0 ± 2.97 18.18 < 0.001 
 Anxiety Case level (%)c 5.4 4.8 10 18 - .149 
 Depression Case level (%)c 0 4.8 10 14 - .053 
Note. a Unless otherwise stated, values are mean  ± one standard deviation. b Values are median ± median absolute deviation. 
c Fisher Exact Test; Case level of anxiety ≥ 9; case level of depression  ≥ 8. SES = Socioeconomic status; ALSFRS-R = ALS 
Functional Rating Scale Revised. HADS = Hospital Anxiety and Depression Scale; Site of onset: B=Bulbar, U=Upper limb, 
L=Lower limb, R= Respiratory, M = Mixed onset, for statistical analysis, respiratory onset patients dropped.  
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Specific functions were driving this result, analysis of the ALS Specific and 
behavioural subdomains was conducted.  
 
Figure 4.1. Cognitive performance across King’s Clinical Disease Stages 
  
Note. Patient performance is scaled to a standardised score (z-score) based on the mean and 
standard deviation of local UK and Irish control groups.  
 
Executive functions (TJT = 4061, p = .035) and letter fluency (TJT = 3721.5, 
p = .001) scores significantly related to more advanced disease stages; however, 
after correcting for multiple comparisons, only letter fluency remained significant 
(p = .002). Analysis of the behavioural domains showed that apathy (z = 4.00, p 
< .001), disinhibition (z = 2.65, p = .012), loss of sympathy or empathy (z = 3.06, 
p = .005), perseveration (z = 1.679, p = .036), eating behaviours (z = 2.76, p = 
.012) significantly related disease stages after correcting for multiple 
comparisons (see Figure 4.2). The presence of psychotic features was also more 
common in later disease stages (z = 2.45, p = .014). Thus, cognitive functions 
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specific to ALS (particularly letter fluency), behaviour (apathy, disinhibition, loss 
of sympathy/empathy, perseveration, and disinhibition), and psychosis are 
significantly associated with disease stage with later stages relating to more 
severe neuropsychological symptoms. These findings are consistent when the 




Table 4.3. Cognitive and behavioural data across King’s Clinical Disease Stage  
 
Controla 
n = 80 
Stage 1a 
n = 39 
Stage 2a 
n = 45 
Stage 3a 
n = 22 
Stage 4a 
n = 55 
Cognitive Domains      
 ALS Specific (0-100) 84.26 ± 9.12 78.15 ± 13.32 80.76 ± 9.77 74.76 ± 15.12 73.06 ± 14.67 
  Languageb (0-28) 28.0 ± 0.0 27.0 ± 1.48 27.0 ± 1.48 27.0 ± 1.48 27.0 ± 1.48 
  Executive (0-48) 38.27 ± 5.89 35.00 ± 7.55 36.76 ± 6.24 32.86 ± 8.90 32.72 ± 8.46 
  Fluency (0-24) 19.07 ± 2.95 17.20 ± 4.29 17.87 ± 3.87 15.64 ± 5.51 14.67 ± 5.71 
 ALS Non-Specific (0-36) 29.98 ± 3.76 27.00 ± 6.07 28.00 ± 3.97 27.73 ± 4.41 25.98 ± 6.21 
  Memory (0-24) 18.27 ± 3.43 15.88 ± 4.97 16.20 ± 3.93 16.14 ± 4.17 14.31 ± 5.81 
  Visuospatialb (0-12) 12.0 ± 0.0 12.0 ± 0.0 12.0 ± 0.0 12.0 ± 0.0 12.0 ± 0.0 











Behaviour      
 ECAS Behaviourb (0-5) - 0.0 ± 0.0 0.0 ± 0.0 1.0 ± 1.48 2.0 ± 1.48 
 Psychosis (% yes) - 2.9 2.4 0.0 15.4 
Note. aValues are mean  ± one standard deviation unless otherwise stated. bMedian ± median absolute deviation 
are reported.The language, executive, and visuospatial domains of the ECAS were each missing one data point. 
Behaviour is the number of behavioural dimensions (max 5). Psychosis is defined as the presence one of more 








While Stage 4 is a marker of end-stage disease, it may be considered a 
prognostic indicator rather than indicating more severe spread of pathology. As 
such, data were re-analysed excluding Stage 4 patients without bulbar, upper 
limb, and lower limb involvement (n = 130), with the majority of results 
unchanged. The significant effect for ECAS Total (TJT = 2514, p = .039), ALS 
Specific functions (TJT = 2477.5, p = .017), and behaviour persisted (TJT = 3438, 
p < .001), with behaviour surviving correction for multiple comparisons (p < .001). 
Examination of the ALS Specific domains reveal that letter fluency is significant 
after correction (TJT = 2483, p = .020). Cochran-Armitage tests of behaviour 
domains reveal that apathy (z = 2.85, p = .009), disinhibition (z = 3.73, p < .001), 
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loss of sympathy or empathy (z = 3.15, p = .004), eating behaviours (z = 2.51, p 
= .018) and psychosis (z = 2.07, p = .039) remained significant. Re-analysis of 
data with Stage 4 removed entirely reveals no significant effect for disease stage.  
 
4.4.2. Rates of Neuropsychological Impairment and King’s Clinical Disease 
Stage  
Consistent with the analyses of the raw scores, a significant effect for higher rates 
of impairment was observed across disease stages for ALS Specific after 
correcting for multiple comparisons (See Table 4.4). Of the ALS Specific 
subdomains, a significant relationship was observed (z = 3.54, p < .001) for letter 
fluency impairment (see Figure 4.3). While rates of impairment for ALS Non-
Specific functions differed between Stages 3 and 4, this did not reach statistical 
significance. Rates of behavioural impairment were significantly higher in more 
advanced disease stages.  
Patients were classified as neuropsychologically intact if there was no 
evidence of behavioural impairment and no evidence of cognitive impairment 
(ALS Specific, ALS Non-Specific, ECAS Total). Patients for whom behavioural 
data were unavailable were not included in this classification. A significant effect 
was found for lower rates of neuropsychologically intact patients, such that by 
Stage 4, only 19.6% of patients were free of impairment. The effect of disease 
stage on rates of impairment did not change when data were restricted to incident 
cases. No change in results was observed when Stage 4 patients without 
concurrent involvement of bulbar, upper limb, and lower limb regions were 







Patients with and without neuropsychological impairment were compared 
on demographic and clinical variables (described in Table 4.1) to determine 
which, if any, distinguish the groups. For demographic information, only 
education significantly differed between those patients with and without 
neuropsychological impairment (t(123.93) = -2.44, p = .016). However, after 
correcting for multiple comparisons this was no longer significant (p =.065). 
Regarding clinical features, anxiety (W = 2941, p = .013), depression (W = 
3359.5, p < .001) and the ALSFRS-R (t(133.92) = -3.55, p = .004) significantly 
differed between groups. Thus, patients with neuropsychological impairment 
have higher levels of depression and anxiety, lower ALSFRS-R scores, and 





Table 4.4. Frequency of impairment across King’s Clinical Disease Stages  
 Stage 1a  Stage 2a   Stage 3a   Stage 4a Z P-value 
ALS Specific 17.95 17.78 33.33 38.89 2.65 0.012 
ALS Non-Specific 20.00 13.33 13.64 26.42 1.00 0.158 
ECAS Total 20.51 20.00 33.33 39.62 2.24 0.050 
Behaviour Impairment 17.65 26.83 36.36 65.39 4.77 < 0.001 
Intact 57.58 53.65 57.14 19.61 -3.86 < 0.001 
Note. a Values are percentages. P-Values corrected for multiple comparisons. Only patients with 
complete data reported (n = 146).  
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Figure 4.3. Frequencies of impairment across King’s Clinical Disease Stage for 





4.4.3. Cognition, behaviour, and clinical variables 
Clinical variables were analysed against ALS Specific, ALS Non-Specific, ECAS 
Total, and the number of behavioural features present (see see supplementary 
tables). A significant relationship was observed between the presence of bulbar 
involvement (but not site of onset) and ALS Specific functions (W = 3896.5, p = 
.033) and behaviour (W = 2061, p = .019). Patients were subdivided within each 
stage based on the presence or absence of bulbar involvement (see 
supplementary tables). Subsequent Jonckeere Terpstra Tests revealed that 
patients with evidence of bulbar involvement demonstrated a significantly worse 
ALS Specific (TJT = 887, p = .021), ALS Non-Specific (TJT = 956, p = .028), ECAS 
Total Score (TJT = 875, p = .021), and behavioural features (TJT = 1583, p < .001) 
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after correcting for multiple comparisons. Conversely, patients without bulbar 
signs demonstrated no significant relationship in cognitive or behavioural 
features.  
Depression (rs = .3560, p < .001) and the ALSFRS-R (rs = -.258, p = .009) 
were related to behavioural features. To explore which behavioural domain was 
related to depression, depression scores of patients with and without each 
behavioural feature were compared. Significant differences, after correction, 
were observed for patients with and without apathy (W = 1043, p < .001), 
disinhibition (W = 773.5, p = .018), and loss of sympathy/empathy (W = 1036, p 
< .001). No significant relationship was observed between cognition or behaviour 
and site of onset, diagnostic delay, Riluzole use, weight (KG), upper limb 




The aim of the present study was to determine the relationship between cognitive 
and behavioural symptoms, as measured using the ECAS, and the King’s Clinical 
Staging system. In particular, the present study aimed to evaluate: a) whether 
cognition and behaviour is related to advancing disease stage in a clinically 
representative sample of ALS patients, b) which domains of cognition and 
behaviour are particularly related to disease stage, and c) which, if any, clinical 
variables relate to cognition and behaviour in ALS. 
Our findings demonstrated that cognitive domains which are typically 
affected in ALS (ALS Specific), the ECAS Total performance, and the number of 
reported behavioural features significantly relate to King’s Clinical Disease 
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Stages. Conversely, no such association was observed for cognitive functions 
not typically affected by ALS (i.e., memory and visuospatial functioning). 
Behavioural impairment as defined by the newly updated Strong criteria (Strong 
et al., 2017) also related to disease stage, with all five ECAS behavioural domains 
demonstrating increasing impairment in more advanced stages. These findings 
demonstrate that ALS Specific cognitive functioning and behaviour are 
significantly and negatively related to advancing disease stage. This relationship 
is driven most strongly by letter fluency performance, with executive dysfunction 
possibly also playing a role and global behavioural changes across all types of 
behaviour which characterise bvFTD (Raskovsky et al., 2011).  
Structural and functional neuroimaging has shown that changes in ALS 
include extramotor areas that are involved in higher order cognitive processing 
and behavioural control (see Chiò et al., 2014 for overview). Executive functioning 
(including social cognition), fluency, and language have been associated with 
dysfunction of frontal and temporal regions of brain. For example, executive 
functioning and social cognition in ALS has been related to prefrontal dysfunction 
in ALS (Carluer et al., 2015; Pettit et al., 2013), with white matter tract connectivity 
also implicated (Abrahams et al., 2005b; Agosta et al., 2013; Canosa et al., 2016; 
Sarro et al., 2011). Letter fluency is a sensitive marker of cognitive impairment in 
ALS and has similarly been linked to prefrontal dysfunction (Abrahams et al., 
2004, Pettit et al., 2013). Neuropsychological studies have shown that letter 
fluency impairment may represent a difficulty in cognitive initiation (e.g., 
Abrahams et al., 2000, Kasper et al., 2015) which in turn is related to the high 
frequency of apathy in ALS (Radakovic et al., 2017c). Similar to executive 
functioning and letter fluency, apathy has been associated with reduced fractional 
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anisotropy in the right anterior cingulate cortex (Woolley et al., 2011) and the 
dorsolateral and orbitomedial prefrontal cortex (Tsujimoto et al., 2011). 
Pathological TDP-43 inclusions have been suggested to spread predictably in 
ALS (Brettschneider et al., 2013), beginning in the primary motor cortex, spinal 
cord, and cranial nerves, spreading to the reticular formation of the brainstem, 
the prefrontal cortex, and finally the hippocampus. Executive and fluency 
dysfunction is commonly reported in ALS possibly due to early pathological 
involvement of the prefrontal cortex. However, memory dysfunction is less 
commonly reported, perhaps due to the exclusion of end-stage ALS patients from 
research studies (i.e., those with respiratory insufficiency). Indeed, memory 
impairment may be a feature of end stage ALS, but currently it is under-
recognised. The strength of the relationship between behaviour and disease 
stage may suggest that behaviour is more susceptible to pathological disease 
spread than cognition. Higher rates of cognitive and behavioural dysfunction 
across disease stage therefore implicates progressive involvement of 
frontotemporal regions. However, given that respiratory dysfunction is one of the 
defining features of disease Stage 4, the late-stage involvement of ALS Non-
Specific (e.g., memory) functions may be associated with declining respiratory 
function, which could be ameliorated by appropriately prescribed ventilatory 
support.  
Previous cross-sectional and longitudinal research on cognition in ALS 
has been inconsistent as to whether cognition declines. Clinic-based studies 
have failed to reliably observe a relationship between cognition and disease 
progression (Abrahams et al., 2005a; Gordon, et al. 2010b; Schreiber et al., 
2005). A large population-based longitudinal study from our group has previously 
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shown a relationship between the ALSFRS-R and cognition (Elamin et al., 2013). 
This inconsistency is most likely a function of sample sizes, high attrition rates, 
clinic versus population-based sampling, incident versus prevalence sampling, 
and the variability in metrics used to approximate disease progression (i.e., time 
or the ALSFRS-R).   
As ALS is a heterogeneous condition with different disease trajectories, a 
system that defines progression based on clinical decline rather than as a 
function of time since first presentation is of greater utility when analysing disease 
progression. The King’s Clinical Staging system is designed to overcome 
variability in disease trajectory over time. Our findings of a relationship between 
ALS Specific cognitive and behavioural change and King’s Clinical Disease Stage 
provide additional evidence of spread of degenerative processes in the prefrontal 
cortices. 
These findings have important clinical implications, with 
neuropsychological impairment previously associated with reduced survival 
(Elamin et al., 2011, Govaarts et al., 2016), quality of life (Chiò et la., 2010; 
Goldstein, Atkins, & Leigh, 2002), caregiver burden (Burke et al., 2015; Lillo et 
al., 2012b), and the ability to manage and engage with life-prolonging 
interventions (Olney et al., 2005; Stukovnik et al., 2010). It is therefore possible 
that quality of life and caregiver burden may also relate to disease stage. 
Clinically, it may be necessary to consider intervention programmes for 
caregivers to alleviate the impact of neuropsychological impairment, particularly 
early in the disease course. Furthermore, clinicians should be cognizant of 
current neuropsychological status when prescribing life-prolonging interventions 
to patients, and implement support structures for those with a neuropsychological 
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impairment e.g., providing instructions in simple written or pictorial format to 
reduce cognitive burden. The relationship between disease stage and behaviour 
is of particular importance, given the strength of this relationship relative to 
cognition and its negative impact on patients and caregivers. Behaviour change 
is less commonly reported in the literature compared to cognition, and often 
reported as a unidimensional construct. The profile and impact of behavioural 
change merits further and more detailed investigation in the future. Thus, the 
monitoring of both cognitive and behavioural symptoms across the disease 
course is vital to providing appropriate and timely care and support to patients 
with ALS and their families.  
Consequently, the recently updated UK National Institute for Health and 
Care Excellence (NICE, 2016) guidelines on motor neuron disease assessment 
and management has incorporated cognitive and behavioural assessment as 
integral factors in patient care. Furthermore, the majority of ALS patients and 
caregivers have expressed their desire to be informed about the risk of 
neuropsychological impairment from their physician (Wicks & Frost, 2008). We 
have found that 80% of patients in King’s Stage 4 experience cognitive or 
behavioural impairment. The relatively low frequency of cognitively intact patients 
argues in favour of incorporating cognitive and behavioural screening as a 
standard measure in ALS assessment.  
 We found no significant relationship between cognition, behaviour and 
diagnostic delay, Riluzole use, weight at testing, upper limb involvement, or lower 
limb involvement. However, the present findings suggest that bulbar involvement 
(but not site of onset) significantly relates to cognitive and behavioural 
performance. The relationship between the presence of bulbar symptoms and 
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cognition has been suggested previously (Abrahams et al., 1997). This may, in 
part, explain the slightly better performance in Stage 2 compared to Stage 1, in 
which a lower than expected proportion of bulbar onset patients were found. As 
such, the relationship between cognition, behaviour, and disease stage may be 
exaggerated by the presence of bulbar symptoms. Levels of depressive 
symptoms significantly related to behavioural functioning. There may be some 
overlap between symptoms of depression and behavioural abnormalities, 
specifically apathy. However, in the present study higher depression rates were 
also found in those patients with other behavioural abnormalities, specifically loss 
of sympathy/empathy, and disinhibited behaviour. It is possible that depressive 
symptoms and behavioural features occur concurrently, but further research is 
required to explore this relationship.  
Stage 4 may represent a prognostic disease stage without the same 
degree of underlying pathology of Stages 1-3. However, removal of patients in 
Stage 4 without the clinical features of Stage 3 results in little change to the 
outcomes of this study. Certainly, respiratory insufficiency is a key feature of 
Stage 4 and 85% of patients in this stage showed respiratory involvement. Given 
that the defining characteristics of Stage 4 are respiratory insufficiency or feeding 
intervention because of nutritional deficiency, both of which may have secondary 
confounding effects on cognition, data were analysed for Stages 1 to 3 
separately. The results indicated no significant difference between stages on 
either cognitive or behavioural measures. This may be because Stage 4 data are 
driving the effect as appears to be most likely in the behavioural data. Yet, it is 
important to note that the Jonckheere-Terpstra and Cochran-Armitage tests are 
both based on the assessment of a monotonic effect. The pattern of results for 
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Stages 1-3 appear curvilinear, and therefore the analyses lack the necessary 
power to detect an effect, and the decline from Stages 2 to 3 is not sufficient to 
overcome the removal of Stage 4. 
Strengths of this study include its prospective multi-centre design, with a 
large sample size, and a clinically representative sample. As such, the results of 
this study possess good generalisability. However, an important limitation to this 
study is its cross-sectional design. This restricts the ability to fully explore how 
cognitive and behavioural symptoms evolve as patients transition to later stages 
of the disease. To do so, a longitudinal study is required to track patients’ 
cognitive and behavioural performance in line with disease progression. 
Additionally, it is possible that patients with lower cognitive functioning and more 
severe behavioural abnormalities may have been less likely to participate. As 
such, it may be that the present results underestimate the prevalence of 
neuropsychological impairment across disease stages. 
Cognitive and behavioural impairment is common in patients with ALS and 
present in all stages of the disease. ALS Specific functions (executive, language, 
and fluency) and behaviour are associated with clinical stage as defined by the 
King’s Staging system, whereas ALS Non-Specific (memory, visuospatial) are 
not. Measures of cognitive and behavioural change should be included in the 




In Chapter 4 it was established that neuropsychological function in ALS is 
critically related to disease stage. Cross-sectionally, this provides evidence that 
cognition and behaviour may decline over the course of the disease. However, to 
evaluate this hypothesis, a longitudinal investigation of patient trajectories is 
required. Thus, Chapter 5 reports a longitudinal study of ALS patients, their 
caregivers, and control participants with regard to cognitive and behavioural 
functioning. By monitoring neuropsychological function as patients progress to 
more advanced disease stages, the relationship between cognition, behaviour, 









CHAPTER 5: Longitudinal changes in ALS 




While research on the nature of neuropsychological symptoms in ALS is vast, 
studies exploring longitudinal changes are less so. As discussed in Section 
1.10.2., findings from longitudinal studies of cognition in ALS have been mixed, 
with some reporting a significant decline and others reporting no significant 
change, or even improvement (Abrahams, Leigh, & Goldstein, 2005a; Gordon et 
al. 2010b; Schreiber et al. 2005). One large population-based study found that 
cognitive performance declines over time and that this decline is related to 
functional decline (Elamin et al., 2013). 
Numerous methodological issues exist within the literature limiting the 
reliability of previous findings. Research has been limited by the use of tests 
dependent on motor speed, without adequate accommodations (e.g., Gordon et 
al., 2010b) and the repeated use of the same cognitive test; small sample sizes 
of often only 19-52 participants (Abrahams et al., 2005a; Gordon et al., 2010b; 
Kilani et al., 2004; Robinson et al., 2006; Schrieber et al., 2005; De Silva et al., 
2016); a single follow-up time point (Abrahams et al., 2005a; Robinson et al., 
2006; De Silva et al., 2016); or no appropriate control group (Gordon et al., 2010b; 
Schrieber et al., 2005; De Silva et al., 2016). Small sample sizes reduce the 
power to detect change, while the use of the same cognitive test over time may 
result in performance improvement due to learning test content or test-taking 
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strategies. This has the potential to mask longitudinal decline in ability, or even 
suggest improved functioning.  
Attrition is of real concern in longitudinal cognitive research in ALS. For 
instance, Elamin et al. (2013) reported attrition at each study wave averaging 
59% (n1 = 186, n2 = 98, n3 = 46, n4 = 11). Attrition averaged 28% (n1 = 52, n2 = 
32, n3 = 24, n4 = 19) for Schreiber et al., (2005), and 49% (n1 = 40, n2 = 24, n3 = 
10) for Burkhardt et al., (2017). Similarly, De Silva et al., (2016) lost 60% of 
participants after baseline assessment (n1 = 47, n2 = 19). Yet, no study to date 
has controlled for attrition in its analysis, introducing significant bias. Elamin et al. 
(2013) observed that cognitive impairment was a significant predictor of attrition, 
suggesting that patients with lower neuropsychological functioning are less likely 
to continue participating. Data is therefore collected from only the few most 
cognitively able participants in available longitudinal research. 
Measurement of disease progression in ALS can also be problematic due 
to the heterogeneous rate of decline. For instance, disease duration of ALS is 
approximately 3-4 years from onset and can range from 4 months to 23 years 
(Roche et al., 2012). The ALSFRS-R has been utilised previously as a marker of 
disease progression, with some cross-sectional studies reporting that cognitive 
and behavioural symptoms are related to a decline in functional ability (e.g., 
Gordon et al., 2010b, Murphy et al., 2016). Yet, decline on the ALSFRS-R is also 
heterogeneous and curvilinear, declining more rapidly in the early and late 
phases of the disease (Gordon & Cheung, 2006; Gordon et al., 2010a). 
Fortunately, the King’s Clinical Disease Staging system has demonstrated good 
prognostic utility, and provides a linear and standardised metric of progression 
and burden (Roche et al., 2012; Balendra et al., 2015; Ferraro et al., 2016).  
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Two cross-sectional studies have explored the effect of disease stage on 
cognition and behaviour. One study found that executive and memory functioning 
significantly differed when patients are grouped by disease stage (Trojsi et al., 
2016). However, this study was cross-sectional, did not include a measurement 
of behavioural dysfunction, and utilised an extensive battery of cognitive tests 
that do not control for motor disability resulting in a proportion of patients being 
unable to complete the cognitive assessments. Burke et al., (2017) found a cross-
sectional relationship between behaviour and disease stage, however this 
relationship was not explored in-depth and the study did not provide information 
as to which behaviours related to clinical stage. We overcame some of these 
limitations in Chapter 4 in the utilisation of the ECAS and the analysis of individual 
behavioural domains. It was demonstrated that ALS Specific cognitive functions 
and all behaviour domains are related to clinical disease stage cross-sectionally 
(Crockford et al., 2018), such that by end-stage disease, approximately 80% of 
patients were neuropsychologically impaired. However, the effect of disease 
stage on cognition and behaviour has not been examined longitudinally. 
 In addition to King’s Clinical Disease Stage, cognitive performance has 
been associated with fewer years of education (Beeldman et al., 2016; Elamin et 
al., 2011; Gordon et al., 2011; Massman et al., 1996; Montuschi et al., 2015; 
Murphy et al., 2016; Phukan et al., 2012) and older age of onset (Elamin et al., 
2011; Montuschi et al., 2015; Murphy et al., 2007; Murphy et al., 2016; Phukan 
et al., 2012). The C9orf72 hexanucleotide repeat expansion is a significant 
contributor to both ALS and FTD, and has similarly been associated with cognitive 
and behavioural functioning (Ratti et al., 2012; Snowden et al., 2013), a higher 
prevalence of concomitant FTD in ALS (Byrne et al., 2012; Montuschi et al., 
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2015), and a longitudinal decline in verbal fluency (Irwin et al., 2013). Therefore, 
these variables may play an important role in the longitudinal trajectory of ALS 
neuropsychological functioning.  
Moreover, how change in different cognitive and behavioural domains 
relate to one another has yet to be explored; for instance, whether a decline in 
executive functioning relates to a decline in memory functioning, or whether a 
decline in fluency relates to increased probability of apathy. Previous research 
has shown that not all patients with ALS experience neuropsychological changes. 
As such, there exists apparent subgroups of patients who do and do not 
experience cognitive and behavioural impairment and decline. This is of clinical 
significance in order to provide accurate prognostic information to patients on 
what to expect of the disease, and in informing clinical care. 
 The present study aimed to build on the findings of Chapter 4  to examine 
longitudinal changes in cognition and behaviour in ALS using appropriately 







1) Examine the effect of neuropsychological impairment and disease 
stage/severity on attrition 
2) Examine longitudinal changes in cognition and behaviour over time using 
appropriately specified models which control for attrition 
3) Examine the effect of age of onset, years of education, the presence of 
C9orf72 repeat expansion, and King’s Clinical Disease Stage on 
longitudinal cognitive and behavioural change. 
4) Longitudinally verify the cross-sectional relationship between cognition, 
behaviour and disease stage presented in Chapter 4  
5) Examine how longitudinal changes in cognitive and behavioural domains 
relate to one another 






Patients with ALS (n = 161) and control participants (n = 80) recruited into our 
previous cross-sectional investigation (Chapter 4) were followed longitudinally.  
 
5.2.2. Procedure and Materials 
Data collection procedures and materials for additional time periods follow 
procedures outlined in Chapter 4 (Crockford et al., 2018), with all assessments 
(except for socioeconomic status) administered at each time point. Participants 
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were assessed at four time points of 4 month intervals (± 1 month). To avoid the 
presence of practice effects in cognitive assessment, alternate versions of the 
ECAS (ECAS-A-B-C) were utilised in the present study sequentially (see 
Chapters 2 and 3). The alternate forms have shown to possess a high degree of 
equivalence, test-retest reliability, and inter-rater reliability (Crockford et al., 
2017a; 2017b).  
 
5.2.3. Statistical Analyses  
Demographic, clinical, and neuropsychological data for the patient and control 
groups were compared using a χ2 test for categorical data (or Fisher’s exact test 
when expected cell frequencies fell below 5), Welch t-tests and one-way analyses 
of variance (ANOVA) with Holm-corrected Tukey’s HSD post-hoc for continuous 
between group data, and Pearson or Spearman (as appropriate) correlation to 
explore the relationship between continuous/ordinal variables. When data 
violated statistical assumptions, log or power transformation were applied. When 
transformation failed to correct violations, non-parametric alternatives were used. 
Analyses were conducted using R 3.3.3 with alpha set to .05. 
A cognitive deficit was determined using local validated abnormality cut-
off scores from Scottish and Irish populations (Niven et al., 2015; Pinto-Grau et 
al., 2016). Behavioural impairment (ALSbi) was defined as the presence of two 
or more behavioural features on the ECAS Behaviour Screen, or the presence of 




5.2.3.1. Neuropsychological impairment, disease stage/severity, and attrition 
(Aim 1) 
Aim 1: Examine the effect of neuropsychological impairment and disease 
stage/severity on attrition 
Risk factors for attrition at each follow-up time point were evaluated with step-
wise binomial logistic regression models using predictors from the immediately 
preceding time point. The ALSFRS-R and King’s Clinical Disease Stage were 
included to examine the effect of disease stage/severity on attrition. Disease 
stage was added to the models as a linear and quadratic polynomial. Cognitive 
impairment (ECAS Total Score) and behavioural impairment were added in a 
separate model to explore whether neuropsychological functioning affects 
attrition, while controlling for age and years of education. Disease stage/severity 
(measured using time-specific ALSFRS-R scores and King’s Clinical Disease 
Stage) and neuropsychological (measured using rates of ECAS Total impairment 
and behavioural impairment) variables were initially analysed separately (to 
examine their unique contribution) before being combined in to a single logistic 
model.  
 
5.2.3.2. Latent growth curve models (Aims 2 and 3) 
To examine longitudinal changes in cognition and behaviour Latent Growth Curve 
Models (LGCM) were estimated. The LGCM is a special case of structural 
equation modelling in which change in cognition and behaviour is modelled as a 
function of time (see Beaujean, 2014 for overview). Variables are described as 
manifest if they are directly observed and measured, while latent variables are 
not directly observed but are inferred from manifest variables. An individual 
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growth trajectory is fit for each participant (i.e., random effect). Mean latent (i.e., 
unobserved) intercepts and slopes are estimated based on the random 
(individual) growth parameters of each participant. The mean of the latent 
intercept is the point at which the latent slope crosses the y-axis, and as such, 
can be described as the model-implied baseline level when Time 1 is set to zero. 
LGCMs estimate a number of parameters which can be constrained, or estimated 
freely. Unconstrained LGCMs allow the latent and manifest variables to co-vary 
amongst each other. Latent variable models consist of endogenous (i.e., 
outcome) and exogenous (predictor) variables. The benefit of using LGCM over 
other methods (e.g., mixed effects modelling) is the ability to model the latent 
slope and latent intercept covariance, as well as information on the unexplained 
variance (i.e., error variance). The covariance is a description of whether there is 
a relationship between the intercept (baseline level) and slope (rate of change). 
LGCMs can also easily handle missing data, common in clinical research (Enders 
et al., 2011).  
In addition to modelling cognition and behaviour over time, LGCMs allow 
the addition of covariates in the form of regression equations. Covariates may be 
time-invariant, in that they do not change over time (e.g., biological sex), or time-
variant (e.g., age) which are time-dependent. The latent intercept and latent slope 
are regressed on time-invariant covariates which indicates the effect that 
covariates have the baseline level (intercept) or rate of change (slope). 
Conversely, the endogenous (outcome) variable for each time point is regressed 
on time-variant covariates, which provides a metric of the relationship between 




5.2.3.3. Model specification (Aims 2 and 3) 
LGCM were estimated using the R-package Lavaan (Rosseel, 2012). Time was 
centred at baseline (i.e., Time 1 assessment) coded as 0, 1, 2, and 3 for Times 
1-4. Quadratic growth factors were also modelled by the addition of a latent slope 
coded as 0, 1, 4, and 9. Model fit was evaluated using χ2 goodness-of-fit and 
Root Mean Square Error of Approximation (RMSEA). The χ2 is a discrepancy 
function which measures how well the model-implied covariances match the 
observed sample covariances. A non-significant χ2 value indicates no significant 
discrepancies between model-implied and sample covariances. The RMSEA is a 
parsimony index of model fit which takes account of model complexity. It 
measures whether the model reasonably approximates the data, with values 
closer to zero indicating better fit (Beaujean, 2014) with a p-value testing the 
hypothesis that RMSEA is less than or equal to .05 (i.e., close fit). Missing data 
were handled using Full Information Maximum Likelihood estimation. Residual 
variances were constrained to zero when they were negative within the model 
(estimation instability caused by the proximity of the true estimate to the boundary 
i.e., zero). Models with binary endogenous variables (e.g., presence/absence of 
apathy) are estimated using probit link functions. As such, model coefficients for 
binary data are expressed in terms of probit probability. To further control for 
potential practice effects (in addition to using alternate forms of the ECAS),  
patients’ cognitive scores were converted into standardised z-scores based on 
the mean and standard deviation of local control groups (i.e., UK and Ireland). 
To address the Aims 2 and 3 of this chapter, longitudinal change in each 
cognitive and behavioural domain was examined using unconstrained LGCMs 
controlling for attrition in two steps: a) models examining change as a function of 
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time while controlling for attrition (Aim 2: Basic LGCM), and b) models containing 
both time-invariant and time-variant covariates (Aim 3: Covariate LGCM).  
 
Aim 2: Examine longitudinal changes in cognition and behaviour over time using 
appropriately specified models which control for attrition 
Longitudinal change in cognition and behaviour were examined using 
unconstrained LGCMs, termed ‘Basic LGCM’ (Figure 5.1). These models 
examine the change in neuropsychological performance as a function of time, 
while controlling for attrition. To control for data missing not at random (i.e., 
attrition dependent on manifest variables), the Wu-Carroll selection model was 
employed (Wu & Carroll, 1988). The Wu-Caroll method assumes that attrition is 
a function of each participant’s longitudinal trajectory, such that declining 
cognition is hypothesised to increase the probability of attrition. To incorporate 
the Wu-Carroll selection method for the LGCMs, the latent slope and latent 
intercept were regressed onto a dichotomous attrition variable (constrained to 
linearity), thus providing an estimate of cognitive and behavioural change over 
time corrected for biased drop-out (see Enders et al., 2011 for discussion).  
 
 




Note. Prototypical path diagram for unconstrained latent growth curve model controlling for attrition. Attr2-Attr4 = attrition variable (binary) for Times 2 to Time 4; 
i = intercept (latent); s = slope (latent); Cog1-Cog4 = cognitive outcome for Time 1 to Time 4. Ellipses represent latent variables while squares represent manifest 
variables. Single-headed arrows represent regression coefficients. Double-headed arrows represent variance when restricted to one variable, and covariance 




Aim 3: Examine the effect of age of onset, years of education, the presence of 
C9orf72 repeat expansion, and King’s Clinical Disease Stage on longitudinal 
cognitive and behavioural change.  
The evaluation of Aim 3 is achieved by building on from the Basic LGCM of Aim 
2 with the incorporation of time-invariant and time-variant covariates (Covariate 
LCGM; Figure 5.2). Time-invariant covariates used in this study are age of onset, 
years of education, and the presence of C9orf72 repeat expansion. The time-
variant covariate is King’s Clinical Disease Stage at each time point. The latent 
intercept and latent slope are regressed on age of onset, years of education, and 
C9orf72 status, which indicates the effect that these covariates have the baseline 
level (intercept) and rate of change (slope). The endogenous variable (ECAS 
cognitive and behavioural domains) for each time point is regressed on King’s 
Clinical Disease Stage indicating whether disease stage significantly relates to 
cognition/behaviour within each time point. Changes in parameter estimates from 
the Basic LGCM to the Covariate LGCM indicate the variance captured by the 









Note. Prototypical path diagram for unconstrained latent growth curve model with covariates controlling for attrition; i = intercept (latent); s = slope 
(latent); Cog1-Cog4 = cognitive outcome for Time 1 to Time 4. DS1=DS4 = King’s Clinical Disease Stage for Times 1 to 4. Age = age at onset. Education 
= years of education. C9 = C9orf72 status. Ellipses represent latent variables while squares represent manifest variables. Single-headed arrows 
represent regression coefficients. Double-headed arrows represent covariance. Triangles represent means for latent and manifest variables. C = addition 
of constant to constrain relationship to be linear. Covariances between manifest exogenous variables not shown in diagram. Attrition variables not shown 
in diagram but follow same relationship path as age of onset, education and C9. Numeric partition to latent slope regression paths represents time 
coding. Numeric partition to latent intercept regression paths represents constraints specifying that the latent intercept has equal influence on indicator 
variables across all time points. 
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Aim 4:  Longitudinally verify the cross-sectional relationship between cognition, 
behaviour and disease stage presented in Chapter 4 
King’s Clinical Disease Staging is based on standardised proportions, such that 
each stage of the disease represents a standardised proportion of the disease 
course. While this provides a standardised measurement of disease progression 
relative to other metrics, individual patients do not necessarily progress at the 
same rate. For instance, 6 months for one patient may represent 50% of that 
individual’s disease course with transition to more advanced disease stage. 
Conversely, 6 months for a different patient may only represent 20% of the 
disease course with no progression to a later disease stage. As such, it is not 
possible to estimate LGCMs of cognition and behaviour as a direct function of 
disease stage - rather than time - as patients may provide data for multiple time 
points but for a single disease stage.  
Therefore, patient data were restructured to directly explore the 
longitudinal effect of disease stage on cognition and behaviour, and verify the 
results of Chapter 4 longitudinally. Mean average was calculated and used for 
cognitive scores for which multiple time points represent the same disease stage. 
For behavioural domains (e.g., presence of apathy), the presence of apathy at 
any time point within a disease stage is recorded. For instance, an ALS patient 
provides data for three time points and is in Stage 1 at Time 1, Stage 1 at Time 
2, and Stage 2 at Time 3. The mean z-score for Times 1 and 2 is taken as their 
average score for Stage 1, while their score for Time 3 is taken as their score for 
Stage 2. This individual presented with apathy at Time 1 and Time 3, but not at 
Time 2. As such, they are marked as apathy present for Stage 1 and 2. Rates of 
impairment for disease stages were calculated from raw scores. The same 
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procedure described above was implemented, such that scores for cognitive 
domains within each disease stage were averaged. Impairment was determined 
from the average score within a disease stage based on locally validated cut-offs 
(Niven et al., 2015; Pinto-Grau et al., 2016). 
For continuous data, standardised scores of cognitive domains were 
structured by disease stage were analysed using mixed-effects models. Initially, 
ECAS composite domains were analysed (ECAS Total, ALS Specific, ALS Non-
Specific, behaviour score) followed by subdomains (e.g., executive functioning, 
fluency) when composite domains were found to be significant. The relationship 
between disease stage and the ECAS domains were modelled with linear, 
quadratic, and cubic polynomials. For categorical data (e.g., rates of impairment, 
presence of apathy), main effect analyses were conducted using Cochran–
Mantel–Haenszel χ2 test for matched categorical data. Post-hoc Cochran-
Armitage tests were employed when a significant main effect was observed and 
subjected to Holm-Bonferroni correction for multiple comparisons.   
 
Aim 5: Examine how longitudinal changes in cognition and behaviour relate to 
one another 
To explore the inter-relationship of the ECAS cognitive and behavioural 
subdomains, hierarchical cluster analysis was performed. To examine which 
cognitive and behavioural domains decline at similar rates, model-implied 
random slopes from the basic LGCM of Chapter 5 were extracted and subjected 
to correlational analysis. Slopes from the basic models were utilised as the slopes 
from the covariate models are dependent on disease stage, age of onset, 
education, and C9orf72 status. Euclidean distances, the straight line distance 
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between two points in n-dimensional space, were calculated from the absolute 
values of the correlation coefficients. Complete-linkage clustering, an 
agglomerative approach, was performed in which each domain begins in its own 
cluster and is combined with sequentially larger clusters based on Euclidean 
distances. The slopes for behavioural domains were inverted such that a negative 
slope represents increasing longitudinal probability e.g., a positive correlation 
between cognition and behaviour is interpreted as ‘a faster rate of decline in 
cognitive performance is related to an increased probability of behaviour’.  
 
Aim 6: Evaluate the presence of ALS cognitive and behavioural subgroups 
To identify potential patient subgroups, a similar procedure as Aim 4 was 
performed. LGCMs provide model-implied slopes, in addition to model-implied 
fitted values for each patient at each time point were extracted. Hierarchical 
complete-linkage clustering on model-implied slopes was conducted in which 
each patient begins in his or her own cluster, with patients combined sequentially 
into larger clusters. Clinical and demographic variables were compared between 




5.3.1. Demographic and clinical data 
Clinical and demographic characteristics are presented in Tables 5.1. and 5.2. 
For the longitudinal data (Time 2, 3, and 4), no significant differences were 
observed except for HADS Depression at Time 4 (W = 862, p = .040). C9orf72 
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status was available for 100 patients, of whom, 8% tested positive (> 30 repeats). 
One patient tested positive for intermediate repeat expansion (24 repeats) and 
was treated as positive, bringing the total to 9%. This is in line with Gómez-
Tortosa et al. (2013) who found that patients with expansions of 20-30 repeats 
had similar clinical phenotypes as those with longer expansions.  
The mean interval between testing sessions was 4.4 months for patients 
and 4.40 months for controls. For patients, the mean interval for Time 1 to Time 
2 was 4.4 months (± .86), 4.4 months (± .90) for Time 2 to Time 3, and 4.1 (± .76) 
for Time 3 to Time 4. For controls, the intervals were 4.4 (± .82), 4.0 (± .64), and 
4.1 (± .49) respectively. Attrition was observed at each time point relative to the 
last (37.3% at Time 2, 32.7% at Time 3, and 33.8% at Time 4) and controls 
(27.5%, 12.1%, 29.4% respectively). Reasons for patient withdrawal include: 
declining further participation (n = 76), death (n = 21), and inability to contact (n 
= 20). For control participants, an inability to make contact (n = 29) and declining 
















Table 5.1. Demographics variables by time 
 Time 1 Time 2 Time 3 Time 4 
 ALS 
(n = 161) 
Control 
(n = 80) 
p 
ALS 
(n = 101) 
Control 
(n = 58) 
p 
ALS 
(n = 68) 
Control 
(n = 51) 
p 
ALS 
(n = 42) 
Control 




67.1 60.0 .890 71.3 62.1 .890 72.1 60.8 .890 71.43 55.6 .890 
Age 61.39  11.58 60.83  13.23 .999 60.45  11.90 62.33  13.32 .999 59.65  12.69 62.49  13.57 .990 58.71  11.03 60.78  14.40 .999 
Education 13.93  3.52 14.49  3.31 .491 14.09  3.29 14.48  3.17 .491 14.1  3.14 15.03  3.18 .466 14.20  2.85 15  3.31 .491 
SES† 2  1.48 2  1.48 .300 2  1.48 1  0 .300 2  1.48 1  0 .300 3  2.22 2  1.48 .300 
Anxiety† 4  2.97 3.5  2.22 .761 3  2.97 3  2.97 .761 3  2.97 3  2.97 .746 2  2.97 3  2.97 .746 
Depression† 1  1.48 1  1.48 .171 1  1.48 1  1.48 .999 1  1.48 1  1.48 .999 2  1.48 1  1.48 .040 
Above corrected for multiple comparisons (Holm-Bonferroni correction, 4 comparisons). † = median  median absolute deviation, Wilcoxon Rank Sum Test. Depression and 




Table 5.2. Clinical variables by time 
 Time 1 
n = 161 
Time 2 
n = 101 
Time 3 
n = 68 
Time 4 
n = 42 
Age at onset 59.43  11.75 57.99  12.17 56.53  12.86 55.33  11.27 
Diagnostic Delay (months)† 11  7.41 12  8.9 12  8.9 12  7.41 
Time since onset (months)† 16 ± 11.86 20 ± 10.38 24 ± 10.38 28 ± 8.9 
Riluzole (% Yes) 75.8 80.2 79.4 83.3 
ALSFRS-R 38.28  6.94 34.98  8.13 32.66  8.44 34.08  7.38 
C9orf72 9% 5.8% 6.3% 10 % 
King’s Disease Stage (1/2/3/4; %) 25/28/14/34 13/25/16/47 10/16/22/52 7/14/21/57 
MITOS Stage: (0/1/2/3/4 %) 71/21/7/1/0 63/26/8/2/0 49/34/15/0/2 47/31/22/0/0 
Site of onset (B/UL/LL/R/M; %) 26/29/35/1/9 20/36/33/2/10 13/40/32/2/13 7/43/36/2/12 
Regions involved:      
 Bulbar (% Yes) 51.6 56.4 67.2 75 
 Upper limb (% Yes) 72.1 87.1 92.5 95 
 Lower limb (% Yes) 72.7 84.2 92.5 95 
 Respiratory (% Yes) 29.2 43.6 48.5 57.1 
Note. B = Bulbar, UL = Upper limb, LL = Lower limb, R = Respiratory, M = mixed onset. MITOS Time 1 (n = 150), Time 2 (n = 87). Time 3 (n = 61), 
time 4 (n = 32). Genetic testing Time 1 (n = 100), Time 2 (n = 69), Time 3 (n = 48), Time 4 (n = 30). King’s Clinical Disease Stage information 
missing for two patients in Time 4. † = median  median absolute deviation.  
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5.3.2. Cognition: Comparison between patients and controls  
The domains of the ECAS (language, fluency, executive, memory, and 
visuospatial) in addition to the composite score (ALS Specific, ALS Non-specific, 
and ECAS Total) were compared between patients and controls at each time 
point (See Table 5.3). Significant differences (corrected for multiple comparisons) 
in ALS-Specific (Time 1: t(216.64)= -5.12, p < .001; Time 2: t(155.64)= -4.05, p < 
.001; Time 3: t(114.24)= -2.77, p = .013; Time 4: W = 516, p = .016), ALS Non-
specific (Time 1: t(213.72)= -4.89, p < .001; Time 2: t(143.63) = -2.21, p = .046; 
Time 3: t(114.59)= -2.72, p = .027; Time 4: W = 530, p = .046), and ECAS Total 
Scores (Time 1: t(212.07)= -5.49, p < .001; Time 2: W =  1921, p = .001; Time 3: 
W = 1077.5, p = .001; Time 4: W = 484.5, p = .007) were present across all four 
time points. Language functions between patients and controls significantly 
differed for Time 1 (W = 4614, p < .001), Time 2 (W = 2182, p = .012), and Time 
3 (W = 1194.5, p = .009). Fluency differed for Time 1 (t(232.43) = -5.34, p <.001), 
Time 2 (W = 1894.5, p = .001), and Time 3 (W = 1239, p = .01). Executive 
functions differed for Times 1 (t(202.24)= -4.24, p <.001) and Time 2 (t(153.87)= 
-3.29, p = .004), while memory functions differed for Time 1 (t(213.64.43)= -5.11, 
p <.001), Time 2 (t(143.19)= -2.38, p = .037), and Time 3 (t(116.15)= -2.71, p = 
.024). No significant differences were observed for visuospatial functioning at any 
time point. Examination of mean raw scores suggest no changes in cognitive or 
behavioural functioning over time, with rates of impairment appearing to reduce 




Table 5.3. Cognition and behaviour functioning over time 
 Time 1 Time 2 Time 3 Time 4 
 ALS 
n = 161 
Control 
n = 80 
p 
ALS 
n = 101 
Control 
n = 58 
p 
ALS 
n = 68 
Control 
n = 51 
p 
ALS 
n = 42 
Control 
n = 36 
p 
 Cognition 
ECAS Total 104.07  16.59 114.24  11.65 <.001 108.54  16.17 116.52  10.68 .001 109.94  13.58 116.73  11.15 .001 110.36  15.69 117.17  11.4 .007 
ALS Specific 76.71  13.44 84.26  9.12 <.001 79.88  12.9 86.57  7.83 <.001 81.51  10.06 86.31  8.79 .013 81.48  11.87 86.25  9.31 .016† 
 Language 27.00  1.48 28.00  0 <.001† 27.00  1.48 27.00  1.48 .012† 26.00  2.97 27.00  1.48 .009† 27.00  1.48 27.00  1.48 .066† 
 Fluency 16.32  5.02 19.07  2.95 <.001 17.78  4.57 20.03  1.93 <.001† 18.26  4.07 19.8  2.97 .01† 18.48  3.95 19.50  3.04 .200 
 Executive 34.44  7.84 38.27  5.89 <.001 36.33  8.05 39.83  5.32 .004 37.69  6.08 39.75  5.68 .117 37.07  7.87 40.00  5.51 .117 
ALS Non-Specific 27.04  5.41 29.98  3.76 <.001 28.47  4.73 29.95  3.65 .046 28.43  4.84 30.41  3.11 .023 28.88  5.14 30.92  3.39 .046 
 Memory 15.48  4.94 18.27  3.43 <.001 17.19  4.02 18.55  3.12 .037 17.12  4.22 18.88  2.89 .024 17.26  4.68 19.08  3.41 .051 
 Visuospatial* 12.00  0 12.00  0 .542† 12.00  0 12.00  0 .999† 12.00   0 12.00   0 .999† 12.00   0 12.00   0 .942† 
 Behaviour 
 n = 149 n = 92 n = 61 n = 24 
Dimensions % 
(0/1/2/3+) 
45.0 / 21.5 / 14.1 / 19.5 47.8 / 23.9 / 14.1 / 14.1 44.3 / 26.2 / 11.5 / 18.0  54.2 / 12.5 / 8.3 / 33.33 
Apathy % 30.9 29.3 39.3 29.2 
Disinhibition % 15.4 14.1 18 8.3 
Empathy % 27.5 23.9 26.2 20.8 
Perseveration % 24.8 21.7 29.5 33.3 
Hyperorality % 24.8 17.4 9.8 16.7 
Psychosis % 6.7 4.4 3.3 4.2 
Note. † = non-parametric Mann-Whitney, median and MAD reported. P-values corrected for multiple comparisons (Holm-Bonferroni; comparisons = 4) 
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Table 5.4. Rates of neuropsychological impairment by time 








ECAS Total 28.5 (158) 20.0 (100) 16.2 (68) 14.3 (42) 
 ALS Specific 27.0 (159) 22.0 (100) 19.1 (68) 19.1 (42) 
  Language 21.3 (160) 28.0 (100) 32.4 (68) 38.1 (42) 
  Fluency 30.4 (161) 16.0 (100) 10.3 (68) 14.3 (42) 
  Executive 22.5 (160) 18.8 (101) 8.8 (68) 16.7 (42) 
 ALS Non-Specific 19.4 (160) 12.9 (101) 14.7 (68) 4.8 (42) 
  Memory 16.8 (161) 9.9 (101) 11.8 (68) 7.1 (42) 
  Visuospatial 9.4 (160) 11.9 (101) 13.2 (68) 7.1 (42) 
Behaviour Impairment 39.6 (149) 35.9 (92) 42.6 (61) 33.3 (24) 
Note. Behaviour Impairment measured using the ECAS Behaviour Screen and defined by 






5.3.3. Neuropsychological impairment, disease stage/severity, and attrition (Aim 
1) 
Aim 1: Examine the effect of neuropsychological impairment and disease 
stage/severity on attrition 
The influence of disease stage/severity and neuropsychological status on attrition 
was explored using binomial logistic regression models. Disease stage/severity 
variables (ALSFRS-R and King’s Clinical Disease Stage) significantly predicted 
attrition at Time 2 (X2(4) = 11.96, p = .018), with the ALSFRS-R significant within 
the model (OR = .94, 95% CI: .88 - .99, p = .042) suggesting that a higher 
ALSFRS-R score (better physical function) is related to an increased likelihood 
to participate. Disease severity variables did not significantly relate to attrition at 
Time 3 (X2(4) = 5.83, p = .212) or Time 4 (X2(4) = 7.45, p = .114). 
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The neuropsychological variables model (age, education, ECAS Total 
impairment, and behaviour impairment) was significant for Time 2 (X2(4) = 17.12, 
p = .002). Within the model, older age (OR = 1.04, 95% CI: 1.00 – 1.08, p = .034) 
and the presence of behavioural impairment (OR = 2.64, 95% CI: 1.25 – 5.69, p 
= .012) were significant, relating to increased likelihood of attrition. For Time 3, 
cognitive impairment was significantly related to increasing probability of attrition 
(OR = 3.89, 95% CI: 1.11 – 14.96, p = .038) within the model, however, the overall 
model was not significant (X2(4) = 6.05, p = .195). For Time 4, neuropsychological 
impairment did not significantly predict attrition (X2(4) = 1.25, p = .870). 
The combined model, including disease stage/severity and 
neuropsychological status, was significant for Time 2 (X2(8) = 23.97, p = .002), 
with age uniquely significant (OR = 1.04, 95% CI: 1.01 – 1.09, p = .028). For Time 
3, cognitive impairment was a significant predictor (OR = 5.36, 95% CI: 1.18 – 
28.55, p = .036), but the overall combined model did not significantly predict 
attrition (X2(8) = 8.73, p = .366). At Time 4, age was significant (OR = 1.09, 95% 
CI: 1.02 – 1.20, p = .031), but the overall model did not significantly predict 
attrition (X2(8) = 13.38, p = .099). Therefore, progressive physical disability, older 
age, and the presence of cognitive or behavioural impairment are significantly 
related to increased likelihood of attrition at different time points. As such, it is 
necessary to account for attrition in longitudinal models of ALS patients’ cognitive 






5.3.4. Latent Growth Curve Models (LGCM; Aim 2 and 3) 
5.3.4.1. Evaluation of model fit 
Model fit indices for LGCMs of cognitive variables are presented in Table 5.5. 
Model fit of the attrition-controlled models (Basic LGCM) was poor for ALS Non-
Specific and memory domains, with significant χ2 goodness of fit and RMSEA 
values. Reasonable fit was observed for ECAS Total, ALS Specific, and language 
with significant χ2 values but a non-significant RMSEA. Model fit for fluency, 
executive, and visuospatial functions was good. One outlier was removed from 
the visuospatial model. Negative residual slope variance was observed for 
language and visuospatial functions which were constrained to zero suggesting 
a lack of variability in rates of longitudinal change. The visuospatial functions 
model also possessed negative intercept variance. Therefore, the majority of 
cognitive models possessed good or reasonable model fit. Model fit for 
behavioural data was superior compared to the cognitive data. Only the 
behaviour score model was of poor fit with significant χ2 and RMSEA values. 
However, a greater number of variables contained negative variances which were 
constrained to zero. Loss of sympathy/empathy and eating behaviours 
(hyperorality) possessed the best fit and specification. As such, model fit was 
good or acceptable for all cognitive and behavioural variables, except for ALS 
Non-Specific, memory functions, and behaviour score. The addition of quadratic 
growth factors negatively impacted the fit and specification of models, and as 
such, only linear growth factors were fit to data.  
The addition of covariates (Covariate LGCM) improved the model fit for 
ECAS cognitive domains. Model fit for ECAS Total, ALS Specific, fluency, 
executive, and memory disease stage models was good with non-significant χ2 
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and RMSEA indices. A significant χ2 score was found for language and ALS Non-
Specific, but only language functions had a concurrent significant RMSEA value. 
As such, model fit was poor for language functions and acceptable for ALS Non-
Specific functions. Residual slope variance was constrained to zero for language 
and visuospatial, with slope variance for visuospatial functions also constrained. 
For behaviour, the addition of disease stage improved model fit for behaviour 
score. No behaviour domain had significant χ2 and RMSEA values, except that 
the χ2 (but not RMSEA) index was significant for disinhibition. Constraints on 
residual slope variance was placed on behaviour score, ALSbi, apathy, 
disinhibition, and perseveration.  
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Table 5.5. Model fit indices for Latent Growth Curve models of the ECAS  
 Basic LGCM Covariate LGCM 
 χ2 RMSEA  χ2 RMSEA 
ECAS Total χ2 (12) = 21.14, p = .048 .069 (.006-.116), p = .209 χ2 (30) = 34.29, p = .269 .030 (<.001-.069), p = .763 
 ALS Specific χ2 (12) = 23.94, p = .021 .079 (.030-.124), p = .140 χ2 (30) = 27.46, p = .599 <. 001 (<.001-.053), p = .935 
  Language χ2 (14) = 29.29, p = .010* .082 (.039-.124), p = .097* χ2 (32) = 64.13, p = .001* .079 (.050-.107), p = .048* 
  Fluency χ2 (12) = 19.85, p = .070 .064 (<.001-.112), p = .289 χ2 (30) = 34.72, p = .253 .03 (<.001-.070), p = .749 
  Executive χ2 (12) = 7.56, p = .818 < .001 (<.001-.050), p = .950 χ2 (30) = 20.94, p = .890 < .001 (<.001-.028), p = .992 
 ALS Non-Specific χ2 (12) = 40.73, p < .001 .112 (.082-.164), p = .003 χ2 (30) = 59.14, p = .001 .078 (.048-.107), p = .061 
  Memory χ2 (12) = 31.22, p = .002 .100 (.074-.143), p = .029 χ2 (30) = 40.48, p = .096 .047 (<.001-.080), p = .530 
  Visuospatial χ2 (15) = 14.41, p = .495*† <.001 (<.001-.072) p = .813*† χ2 (33) = 29.15, p = .660*† < .001 (<.001-.048), p = .957*† 
Behaviour score  χ2 (15) = 92.50, p < .001*† .179 (.145-.215), p < .001* χ2 (32) = 44.45, p = .071*  .049 (<.001-.081), p = .486* 
ALSbi χ2 (14) = 12.75, p = .546* < .001 (.030-.124), p = .140* χ2 (32) = 33.95, p = .374* .019 (<.001-.063), p = .848* 
 Disinhibition χ2 (14) = 3.73, p = .997* < .001 (<.001- .001), p > .999* χ2 (32) = 50.54, p = .020* .060 (.024-.090), p = .280* 
 Apathy χ2 (14) = 12.37, p = .576* < .001 (<.001-.068), p = .854*† χ2 (32) = 34.99, p = .328* .024 (<.001-.065), p = .820* 
 Sympathy/empathy χ2 (12) = 7.82, p = .799 < .001 (<.001 -.052), p = .943 χ2 (30) = 38.32, p = .142 < .001 (<.001-.048), p = .615 
 Perseveration χ2 (14) = 2.38, p > .999* < .001 (<.001- <.001), p > .999* χ2 (32) = 26.83, p = .726* < .001(<.001-.045), p = .970* 
 Hyperorality χ2 (12) = 9.73, p = .640 < .001 (<.001-.067), p = .873 χ2 (30) = 22.47, p = .096 < .001 (<.001-.036), p = .986 
Note. χ2  is the chi-square goodness of fit test, RMSEA (Root Mean Square Error of Approximation) 90% confidence interval presented in parenthesis. * Slope residual 
variance constrained to zero. † Intercept variance constrained to zero. When either slope or intercept is constrained, so too is the slope-intercept covariance constrained 
to zero.  
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5.3.5. Evolution of cognitive functioning over time (Aim 2) 
Aim 2: Examine longitudinal changes in cognition and behaviour over time using 
appropriately specified models which control for attrition 
Latent growth curve models were generated for each cognitive and behavioural 
domain of the ECAS (Table 5.6). Figure 5.3 displays the mean and model-implied 
means of the ECAS composite domains using the Wu-Carroll Selection method 
demonstrating the impact that controlling for attrition has on the trajectories of 
change.  
 




Note. Solid lines = mean scores; Dashed lines = model-implied means. Mean scores are the 
mean z-scores for cognitive functions at each time period. The model-implied means are taken 
from the LGCM controlling for attrition (Basic LGCM), demonstrating the bias introduced by not 




Cognition: Significant mean latent intercepts were observed for the ECAS Total 
Score, ALS Specific, and ALS Non-Specific models suggesting a significant 
deviation in baseline estimates of the growth trajectories (i.e., significant deviation 
from the control mean of zero). Significant declines (mean latent slope) in ECAS 
Total score and ALS Specific functions were found. ALS Non-Specific functions 
declined over time but did not reach statistical significance; however, a significant 
slope-intercept covariance was observed suggesting that higher baseline 
performance is related to slower decline.  
Regarding the ECAS cognitive subdomains, significant latent intercepts 
were found for verbal fluency, executive functioning, memory, and visuospatial 
domains. Conversely, only verbal fluency possessed a significant latent slope 
term. Significant intercept-slope covariance was found for memory functions. 
Figure 5.4 display the Basic LGCM model-implied trajectories for the ECAS 
cognitive domains. 
 
Behaviour: For behavioural data, significant mean latent intercepts were 
observed for the behavioural score (i.e., number of behavioural domains 
present), and all individual behavioural domains indicating a significant deviation 
from zero for baseline functioning (see Table 5.6). However, none of the 
behavioural features possessed a mean significant slope, or slope-intercept 
covariance, demonstrating no significant change over time, and no relationship 
between baseline behaviour and change in probability over time.  
As such, the ECAS Total, ALS Specific and fluency significantly declines 
over time once attrition has been included. ALS Non-Specific functions do not 
significantly decline over time, but are related to baseline performance such that 
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higher baseline performance is associated with a slower rate of decline. No 




Figure 5.4. Basic model-implied means for ECAS cognitive domains  
 
Note. Graph represents model-implied means (z-scores) from LGCM controlling for attrition.  





Table 5.6. Results of Latent Growth Curve Models for cognitive and behavioural functioning in ALS 
 Basic LGCM Covariate LGCM 










Cov   
Estimate (SE) 
ECAS Total -3.36 (1.09), p = .002 -1.68 (.716), p = .019 .184 (.109), p = .091 -1.33 (1.55), p = .390 .101 (.906), p = .912 .095 (.077), p = .217 
 ALS Specific -3.45 (1.02), p = .001 -1.83 (.921), p = .048 .117 (.121), p = .332 -1.68 (1.42), p = .238 1.04 (1.13), p = .359 .052 (.086), p = .545 
  Language -.266 (2.21), p = .904 -1.58 (1.01), p = .119 - -.083 (3.14), p = .979 -.593 (1.42), p = .677 - 
  Fluency -3.01 (1.32), p = .023 -2.64 (1.24), p = .033 -.014 (.237), p = .954 -1.77 (1.77), p = .319 .578 (1.59), p = .716 -.148 (.240), p = .538 
  Executive -3.23 (.819), p < .001 -.420 (.960), p = .662 .032 (.100), p = .750 -.901 (1.23), p = .465 1.23 (1.22), p = .313 .032 (.083), p = .702 
 ALS Non-Specific -2.64 (1.18), p = .036 -.782 (.894), p = .382 .378 (.165), p = .005 -.615 (1.64), p = .708 -1.90 (1.717, p = .104 .343 (.103), p = .001 
  Memory -2.34 (.912), p = .010 -.664 (.874), p = .447 .251 (.098), p = .011 -.481 (1.36), p = .723 -1.83 (1.15), p = .111 .251 (.089), p = .005 
  Visuospatial -3.45 (1.07), p = .001 1.08 (1.82), p = .554 - -1.87 (1.83), p = .308 1.21 (2.34), p = .605 - 
 
Behaviour score  
 
2.47 (.910), p = .007 
 




2.47 (1.32) p = .062 
 
-.815 (1.29), p = .526 
- 
ALSbi 2.03 (.292), p < .001 -.220 (.328), p = .503 - 2.15 (.424), p < .001 -.690 (.418), p = .099 - 
 Disinhibition 1.17 (.228), p < .001 .295 (.291), p = .310 - 1.31 (.317), p < .001 -.266 (.376), p = .479 - 
 Apathy 1.63 (.276), p < .001 .229 (.346), p = .508 - 1.78 (.420), p < .001 -.260 (.456), p = .568 - 
 Sympathy/empathy 1.39 (.274), p < .001 .075 (.367), p = .839 -.017 (.018), p = .366 1.53 (.435), p < .001 -.307 (.464), p = .507 -.018 (.017), p = .300 
 Perseveration 1.41 (.262), p < .001 .006 (.308), p = .985 - 1.65 (.405), p < .001 -.331 (.410), p = .420 - 
 Hyperorality 1.67 (.274), p < .001 .275 (.333), p = .409 -.034 (.022), p = .117 1.21 (.400), p = .003 .228 (.418), p = .586 .020 (.012), p = .098 
Note. Cov = covariance. Significant values presented in bold. B coefficients for behaviour are the probit probability.  
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5.3.6. Effect of covariates on longitudinal cognitive and behavioural change 
(Aim 3) 
Aim 3: Examine the effect of age of onset, years of education, the presence of 
C9orf72 repeat expansion, and King’s Clinical Disease Stage on longitudinal 
cognitive and behavioural change.  
To examine the effect of age of onset, years of education, the presence of 
C9orf72 repeat expansion, and King’s Clinical Disease Stage on longitudinal 
cognitive and behavioural change, LGCMs from Aim 2 were expanded. The 
addition of time-invariant (age at onset, years of education, C9orf72 status) and 
time-variant covariates (King’s Clinical Disease Stage) resulted in the loss of a 
significant mean intercept for all cognitive domains (Table 5.6). The significant 
slopes for ECAS Total, ALS Specific, and verbal fluency also became non-
significant. The intercept-slope covariance found for ALS Non-Specific and 
memory functions in the Basic LGCMs persisted once disease stage, age at 
onset, years of education, and C9orf72 status were modelled. The intercept for 
behaviour score was no longer significant once disease stage was added. No 
other changes in behaviour domain models were found. As such, variation in 
baseline performance and rate of decline in cognition is explained by the model 





Table 5.7. Time-Invariant Covariates for full model 
 Latent Intercept  Latent Slope 












ECAS Total -.013 (.010). p = .201 .107 (.033), p = .001 -2.10 (.516), p < .001  -.004 (.003), p = .207 -.003 (.011), p = .757 -.474 (.125), p < .001 
 ALS Specific -.011 (.010), p = .267 .112 (.031), p < .001 -2.14 (.439), p < .001  -.004 (.003), p = .183 -.020 (.012), p = .093 -.513 (.120), p < .001 
  Language .006 (.017), p = .746 .108 (.053), p = .039 -3.50 (.980), p < .001  -.001 (.005), p = .890 .006 (.020), p = .748 .054 (.242), p = .823 
  Fluency -.009 (.012), p = .422 .075 (.039), p = .056 -.980(.587), p = .095  -.010 (.005), p = .047 -.110 (.020), p = .582 -.288 (.272), p = .290 
  Executive -.019 (.009), p = .025 .110 (.028), p < .001 -1.65 (.457), p < .001  -.001 (.004), p = .873 -.020 (.015), p = .193 -.469 (.196), p = .017 
 ALS Non-Specific -.015 (.010), p = .132 .060 (.032), p = .061 -.274 (.656), p = .676  -.005 (.005), p = .268 -.032 (.020), p = .115 -.021 (.304), p = .944 
  Memory -.017 (.009), p = .058 .062 (.029), p = .032 -.046 (.507), p = .928  -.004 (.005), p = .429 .018 (.020), p = .382 -.033 (.329), p = .920 
  Visuospatial -.009 (.012), p = .422 .075 (.039), p = .056 -.980 (.587), p = .095  -.010 (.005), p = .047 -.011 (.020), p = .582 -.288 (.272), p = .290 
Behaviour Score  
-.013 (.009). p = .171 -.102 (.031), p = .001 1.04 (.448), p = .021  -.001 (.005), p = .885 .047 (.020), p = .020 .657 (.257), p = .011 
ALSbi 
-.008 (.003). p = .013 -.020 (.010), p = .054 .448 (.152), p = .003  < .001 (.002), p = .802 .014 (.006), p = .034 .156 (.078), p = .045 
 Disinhibition 
-.008 (.002). p = .001 -.009 (.008), p = .258 .506 (.109), p < .001  .002 (.001), p = .115 .004 (.006), p = .462 -.058 (.098), p = .554 
 Apathy 
-.005 (.003). p = .110 -.014 (.010), p = .174 .229 (.160), p = .152  -.001 (.002), p = .453 .013 (.007), p = .062 .260 (.088), p = .003 
 Empathy 
-.003 (.003). p = .370 -.027 (.010), p = .011 .029 (.144), p = .843  -.001 (.002), p = .421 .023 (.007), p = .001 .288 (.086), p = .001 
 Perseveration 
-.002 (.003). p = .592 -.030 (.010), p = .003 .168 (.143), p = .238  .001 (.002), p = .629 .001 (.007), p = .939 .153 (.086), p = .076 
 Hyperorality 
.004 (.003). p = .201 -.029 (.010), p = .003 .285 (.137), p = .038  -.002 (.002), p = .309 .016 (.006), p = .009 -.056 (.078), p = .477 
Note. Significant values presented in bold. Age = age at onset, education = years of education, C9orf72 = positive or negative for repeat expansion.  
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5.3.6.1. Effect of age at onset, education, and genetic status (Aim 3)   
The impact of age of onset, education, and genetic status are presented in Table 
5.7. Age at onset had a limited effect on cognition, only significantly predicting 
baseline executive functioning, the rate of change for verbal fluency, and 
visuospatial functions. Education was a significant predictor of baseline 
performance of ECAS Total, ALS Specific, language, executive functioning, and 
memory but not on the rate of change. Conversely, C9orf72 status had a 
significant effect on the baseline performance for ECAS Total, ALS Specific, 
language, and executive functioning and significantly predicted the slope of 
ECAS Total, ALS Specific, and executive performance. As such, the presence of 
the C9orf72 repeat expansion significantly related to lower baseline cognitive and 
behavioural functioning and a faster rate of decline, while lower education related 
to lower baseline functioning but a faster rate of decline.  
Age at onset significantly predicted the intercept for ALSbi and 
disinhibition, with education significantly predicting the intercepts of behavioural 
score, loss of sympathy/empathy, perseveration, and hyperorality. C9orf72 status 
predicted the intercept of behaviour score, ALSbi, disinhibition, and hyperorality. 
Regarding slope, age at onset had no effect on rate of change for any behavioural 
variable. Education predicted the rate of change of behavioural score, ALSbi, 
sympathy/empathy, and hyperorality. Conversely, genetic status predicted the 
slope of behaviour score, ALSbi, apathy, and loss of sympathy/empathy. Thus, 
fewer years of education and the presence of the C9orf72 expansion is 




Table 5.8. Time-variant regression coefficients for ECAS domains on disease stage   
 Time 1   
Estimate (SE) 
Time 2   
Estimate (SE) 
Time 3   
Estimate (SE) 
Time 4   
Estimate (SE) 
ECAS Total -.072 (.065), p = .272 -.155 (.069), p = .026 -.186 (.085), p = .029 -.175 (.101), p = .083 
 ALS Specific -.098 (.067), p = .144 -.216 (.076), p = .005 -.132 (.084), p = .117 -.097 (.106), p = .378 
  Language .157 (.107), p = .142 .065 (.094), p = .490 .046 (.111), p = .678 .136 (.150), p = .362 
  Fluency -.143 (.102), p = .159 -.242 (.108), p = .025 -.159 (.124), p = .202 -.054 (.164), p = .741 
  Executive -.127 (.072), p = .079 -.204 (.080), p = .010 -.136 (.097), p = .158 -.218 (.129), p = .092 
 ALS Non-Specific -.047 (.075), p = .530 -.088 (.082), p = .262 -.350 (.118), p = .003 -.521 (.154), p = .001 
  Memory -.076 (.072), p = .293 -.093 (.081), p = .249 -.291 (.116), p = .012 -.514 (.158), p = .001 
  Visuospatial .010 (.124), p = .934 -.151 (.081), p = .061 -.488 (.137), p < .001 -.651 (.207), p = .002 
Behaviour Score  .343 (.083), p < .001 .290 (.086), p = .001 .296 (.116), p = .011 .222 (.174), p = .202 
ALSbi .121 (.028), p < .001 .069 (.028), p = .014 .048 (.038), p = .200 -.045 (.054), p = .409 
 Disinhibition .055 (.021), p = .010 .061 (.022), p = .006 .060 (.032), p = .061 .006 (.047), p = .897 
 Apathy .107 (.028), p < .001 .079 (.028), p = .005 .082 (.039), p = .038 .006 (.059), p = .925 
 Sympathy/empathy .099 (.029), p = .001 .066 (.027), p = .014 .062 (.035), p = .073 .067 (.053), p = .204 
 Perseveration .028 (.027), p = .303 .056 (.026), p = .033 .098 (.037), p = .007 .123 (.055), p = .027 
 Hyperorality .066 (.026), p = .013 .036 (.023), p = .115 .004 (.028), p = .898 .005 (.046), p = .907 
Note. Significant values presented in bold. B coefficients are the probit probability  
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5.3.6.2. Effect of disease stage (Aim 3) 
Disease stage had a significant impact on cognition and behaviour at each time 
point (see Table 5.8). A separation was observed between ALS Specific and ALS 
Non-Specific functions, such that, disease stage significantly predicted ALS 
Specific cognitive functions in Time 2, whereas ALS Non-Specific functions were 
significant in Times 3 and 4. Specifically, disease stage was significant at Time 2 
for ALS Specific, fluency, and executive functions. ALS Non-Specific, memory, 
and visuospatial functions were significantly related to disease stage at Times 3 
and 4. ECAS Total, representing the combination of ALS Specific and Non-
Specific, was significant for Times 2 and 3. The lack of significant effects of 
disease stage at Time 1 is due to the fact that time-invariant covariates (age of 
onset, education, and C9orf72) significantly predicted the latent intercept and 
therefore captured a significant proportion of baseline variability.  
Similarly, behavioural features significantly related to disease stage mostly 
in earlier time points. All domains were significant at Time 1 except for for 
perseveration, and at Time 2 except for hyperorality. By Time 3, only behaviour 
score, apathy, and perseveration were significant, with perseveration the only 
significant behaviour domain at Time 4. As such, time and disease stage interact, 
with behaviour and ALS Specific functions affected more quickly in later disease 
stages, while ALS Non-Specific decline more slowly with advancing disease 





5.3.7. Unexplained Variances: Heterogeneity of neuropsychological functioning 
Significant heterogeneity was present in the cognitive and behavioural data that 
was not fully accounted for by the full latent growth curve models. Residual 
variances are presented in Table 5.9. Residual slope variance was constrained 
to zero for language, visuospatial, behaviour score, ALSbi, apathy, disinhibition, 
and perseveration. Of the variables for which the residual slope variance was not 
constrained, only ALS Non-Specific functions were marginally significant. As 
such, the rate of longitudinal change in ECAS Total, ALS Specific, fluency, 
executive, memory, loss of sympathy, and hyperorality did not significantly differ 
between participants suggesting a homogeneous trajectory of change for the 
majority of cognitive and behavioural domains.  
Contrary to the residual slope, all cognitive and behavioural domains 
demonstrated significant residual variation around the intercept. The significant 
variation suggest that baseline levels of cognitive and behavioural functioning are 
heterogeneous. While covariates included in the models are significant (Table 
5.7), substantial variance remains unexplained. In addition to the slope and 
intercept, heterogeneity continued to exist for cognitive and behavioural 
functioning within each time point. For Time 1 (baseline), all variables except for 
ALS Specific, verbal fluency, and hyperorality, demonstrated significant residual 
variance. All cognitive and behavioural variables exhibited significant residual 
heterogeneity in Times 2 and 3. Conversely, by Time 4, ECAS Total, ALS 
Specific, ALS Non-Specific, fluency, executive, memory, and sympathy/empathy 
contained no significant residual variance. As such, the model explained the 




Table 5.9. Residual variances of Covariate LCGMs 












ECAS Total .327 (.146), p = .025 .550 (.124), p < .001 .746 (.158), p < .001 .125 (.177), p = .482 1.59 (.297), p < .001 < .001 (.032), p = .990 
 ALS Specific .271 (.189), p = .152 1.22 (.218), p < .001 .431 (.111), p < .001 .132 (.165), p = .424 1.31 (.278), p < .001 .010 (.039), p = .803 
  Language 1.24 (.315), p < .001 .482 (.137), p < .001 .493 (.137), p < .001 .777 (.256), p = .002 3.84 (.837), p < .001 - 
  Fluency .433 (.381), p = .256 2.31 (.423), p < .001 .888 (.244), p < .001 .252 (.331), p = .446 2.18 (.424), p < .001 .115 (.094), p = .219 
  Executive .491 (.199), p = .013 1.16 (.207), p < .001 .464 (.124), p < .001 .161 (.172), p = .350 .879 (.245), p < .001 .044 (.043), p = .309 
 ALS Non-Specific .685 (.241), p = .005 .485 (.134), p < .001 1.04 (.217), p < .001 .136 (.238), p = .570 1.30 (.352), p < .001 .115 (.058), p = .048 
  Memory .640 (.184), p = .001 .484 (.119), p < .001 .659 (.176), p < .001 .357 (.240), p = .137 .999 (.250), p < .001 .109 (.057), p = .056 




.676 (.162), p < .001 
 
.853 (.180), p < .001 
 
.703 (.191), p < .001 
 
.960 (.361), p = .008 
 
.907 (.190), p < .001 
 
- 
 ALSbi .076 (.016), p < .001 .094 (.019), p < .001 .086 (.021), p < .001 .067 (.027), p = .014 .094 (.020), p < .001 - 
 Apathy .091 (.020), p < .001 .107 (.021), p < .001 .084 (.022), p < .001 .093 (.036), p = .010 .073 (.019), p < .001 - 
 Disinhibition .059 (.012), p < .001 .076 (.015), p < .001 .093 (.022), p < .001 .042 (.020), p = .038 .033 (.010), p = .001 - 
 Sympathy .085 (.032), p < .001 .123 (.024), p < .001 .104 (.028), p < .001 .094 (.056), p = .092 .092 (.033), p = .005 .003 (.011), p = .797 
 Perseveration .091 (.017), p < .001 .069 (.016), p < .001 .089 (.022), p < .001 .101 (.036), p = .005 .081 (.016), p < .001 - 
 Hyperorality .056 (.033), p = .091 .102 (.019), p < .001 .070 (.017), p < .001 .138 (.050), p = .006 .092 (.034), p = .007 .008 (.011), p = .470 
Note. Non-significant values presented in bold  
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5.3.8. Latent Growth Curve Model Summaries  
With regard to Aim 2, ECAS Total, ALS Specific, and fluency performance is 
found to significantly decline over time when attrition is controlled for. The 
significant decline in cognitive functioning over time is explained by advancing 
disease stage, the presence of the C9orf72 repeat expansion, and to a lesser 
degree age of onset (Aim 3). Time and disease stage have an interactive impact 
on cognitive functioning, such that differences in ALS Specific cognitive 
performance across disease stages appear quickly, while differences in ALS 
Non-Specific functions take longer to becomes apparent. The probability of 
behavioural features being present does not rely on time, but rather become more 
likely overall with fewer years of education, the presence of C9orf72 expansion, 
and advancing disease stage, with differences appearing quickly. Thus, ALS 
Specific and Non-Specific functions progress at different rates with disease 
progression. Lower baseline performance in ALS Specific functions is explained 
by fewer years of education, an older age of onset, and the presence of the 
C9orf72 mutation, with the C9orf72 mutation also contributing to a faster rate of 
decline. Lower baseline performance in ALS Non-Specific functions is related to 
fewer years of education, while the longitudinal trajectory is related to baseline 
levels i.e., better performance at baseline results in slower progression. A 












Table 5.10. Summary of time-invariant associations for ECAS domains  
 Predictors of baseline performance Predictors of rate of change 
 Age   Education  C9orf72  Age   Education  C9orf72  
 Cognition 
ECAS Total -   - -  
Specific -   - -  
 Language -   - - - 
 Fluency - - -  - - 
 Executive    - -  
Non-Specific - - - - - - 
 Memory -  - - - - 
 Visuospatial - - -  - - 
 Behaviour 
Behaviour Score -   -   
ALSbi  -  -   
 Disinhibition  -  - - - 
 Apathy - - - - -  
 Empathy Loss -  - -   
 Perseveration -  - - - - 
 Hyperorality -   -  - 







Table 5.11. Summary of disease stage associations for ECAS domains  
 Time 1   Time 2  Time 3  Time 4   
 Cognition 
ECAS Total -   - 
Specific -  - - 
 Language - - - - 
 Fluency -  - - 
 Executive -  - - 
Non-Specific - -   
 Memory - -   
 Visuospatial - -   
 Behaviour 
Behaviour Score    - 
ALSbi   - - 
 Disinhibition   - - 
 Apathy    - 
 Empathy Loss   - - 
 Perseveration -    
 Hyperorality  - - - 
 = significant relationship; - = non-significant relationship 
 
 176 
5.3.9. Direct effect of disease stage on cognitive and behavioural functioning 
(Aim 4) 
Aim 4: Longitudinally verify the cross-sectional relationship between cognition, 
behaviour and disease stage presented in Chapter 4  
 
5.3.9.1. Raw Data 
Data was restructured by disease stage, z-scores for which are presented in 
Table 5.12. The trend of cognitive performance across disease stage follows the 
same pattern as presented cross-sectionally in Chapter 4. Mixed effects models 
were conducted on the ECAS, ALS Specific, ALS Non-Specific, and behaviour 
domains, specifying a random intercept. Disease stage was treated as a fixed 
effect due to the lack of significant variation around the slopes of the latent growth 
curve models.  
The addition of disease stage was significant against the baseline ECAS 
Total model (χ2(3) = 14.50, p = .002), with a significant linear polynomial 
(t(110.42) = -3.25, p = .002). A similar finding was observed for ALS Specific 
model (χ2(3) = 13.02, p = .004) with a linear polynomial (t(133.68) = -3.23, p = 
.002). The addition of disease stage for ALS Non-Specific was marginally 
significant over the baseline model (χ2(3) = 7.95, p = .047), with a quadratic 
polynomial trend (t(101.06) = -2.01, p = .047). All models were transformed to 
meet residual normality assumptions. The behavioural features model was 
significant (χ2(3) = 27.83, p < .001) with a significant linear polynomial (t(140.03) 
= 4.45, p < .001). Polynomials for ECAS Total (p = .005), ALS Specific (p = .005), 
ALS Non-Specific (p = .047), and behaviour (p < .001) survived correction for 
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Figure 5.5 displays the pattern of change for the ECAS composite 
cognitive domains, demonstrating a decline in ECAS Total, driven by ALS 
Specific functions, from Stage 2. ALS Non-Specific functions, similar to cross-
sectional data, declined from Stage 3. To examine whether this pattern is driven 
Table 5.12. Cognition and behaviour by King’s Clinical Disease Stage 
 Stage 1 
(n = 40) 
Stage 2 
(n = 55) 
Stage 3 
(n = 37) 
Time 4 
(n = 87) 
ECAS Total -.89  1.98* -.69  1.33 -1.22  1.82* -1.33  1.87 
 ALS Specific -.78  1.71* -.62  1.35 -1.35  2.05* -1.25  1.76 
  Language† -.13  1.02*  -.08  .960  -.50  1.58 -.21  1.03 
  Fluency -.70  1.53 -.42  1.24 -1.43  2.47 -1.43  2.18 
  Executive -.65  1.40 -.48  1.27 -.99  1.64* -.97  1.56 
 ALS Non-
Specific 
-.80  2.03 -.61  1.28 -.51  1.09 -1.07  1.82 
  Memory -.66  1.51 -.63  1.27 -.51  1.04 -1.04  1.71 
  Visuospatial† .29  .390 .29  .390 .29  .440 .13 ± .630 
 Stage 1 
(n = 35) 
Stage 2 
(n = 50) 
Stage 3 
(n = 37) 
Time 4 
(n = 83) 
Behaviour Score† 0  0  0  0  .67  .99  2  1.48  
 Apathy 25.7 20.0 29.7 57.8 
 Disinhibition 11.4 10.0 16.2 33.7 
 Sympathy 17.1 30.0 24.3 48.2 
 Perseveration  22.9 18.0 27.0 41.0 
 Hyperorality 17.1 18.0 24.3 38.6 
Psychosis 2.9 2.0 0.0 13.3 
Note. Cognitive data is standardised z-score ± standard deviation; behavioural 
domains are percentages. * = one missing data point (i.e., n - 1). † = median and 
median absolute deviation presented.  
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by Time 1 data (Chapter 4), data was also plotted with Time 1 data removed, and 
without patients who did not advance through disease stages over the course of 
the study. Overall, the removal of Time 1 data or patients who did not progress 
had no large impact on the pattern of decline. The separation of ALS Specific and 
ALS Non-Specific functions at Stage 3 persisted. As such, the cross-sectional 






































 Stage 1  Stage 2  Stage 3  Stage 4 
Note. (a) All ALS patients’ data (N = 161); (b) Data from Times 2, 3, and 4 (no Time 1; n = 
101); (c) Data from patients who progressed to more advanced disease stages over the course 
of the study (n = 54). 




5.3.9.2. Rates of impairment  
Rates of impairment for ECAS cognitive and behavioural domains are presented 
in Table 5.13. Cochran-Mantel-Haenszel χ2 test for count data was conducted on 
the ECAS Composite domains (ECAS Total, ALS Specific, ALS Non-Specific, 
and ALSbi). A significant effect was observed across disease stages for 
increasing rates of impairment (χ2MH (3) = 20.14, p < .001). Post-hoc Cochran-
Armitage tests revealed that rates of ALS Specific impairment marginally related 
to advancing disease stage (z = 1.69, p = .046). However, this did not survive 
correction for multiple comparisons. Rates of ALSbi were significant after 
correction (z = 4.14, p < .001). 
 
 
Table 5.13. Rates of impairment by King’s Clinical Disease Stage 
 Stage 1 Stage 2 Stage 3 Stage 4 
ECAS Total 17.9 (n = 39) 18.2 (n = 55) 28.6 (n = 35) 27.9 (n = 86) 
 ALS Specific 15.4 (n = 39) 18.2 (n = 55) 34.3 (n = 35) 26.7 (n = 86) 
  Language 21.1 (n = 38) 32.7 (n = 55) 36.1 (n = 36) 29.1 (n = 86) 
  Fluency 15.0 (n = 40) 20.0 (n = 55) 25.0 (n = 36) 31.4 (n = 86) 
  Executive 15.0 (n = 40) 9.1 (n = 55) 28.6 (n = 35) 20.9 (n = 86) 
 ALS Non-Specific 18.0 (n = 39) 9.1 (n = 55) 5.6 (n = 36) 18.6 (n = 86) 
  Memory 17.5 (n = 40) 9.1 (n = 55) 2.7 (n = 37) 17.4 (n = 86) 
  Visuospatial 12.8 (n = 39) 3.6 (n = 55) 2.8 (n = 36) 15.1 (n = 86) 
ALSbi 28.6 (n = 35) 30.0 (n = 50) 40.5 (n = 37) 62.7 (n = 83) 
Impaired 42.4 (n = 33) 46.0 (n = 50) 48.6 (n = 35) 72.0 (n = 82) 
Unimpaired 57.6 (n = 33) 54.0 (n = 50) 51.4 (n = 35) 28.1 (n = 82) 
Note. Data is percentage. N = total sample for each cell. ALSbi classified as per Strong (2017) 
consensus guidelines. Impaired = presence of ECAS Total, ALS Specific, ALS Non-Specific 
impairment, or ALSbi. Unimpaired = absence of ECAS Total, ALS Specific, ALS Non-Specific 
impairment, or ALSbi. 
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 Patients were classified as impaired if they possessed an impairment in 
the ECAS Total, ALS Specific, ALS Non-Specific, or behaviour domains. All other 
patients were considered unimpaired. Only patients with complete data for each 
domain were included. At Stage 1, 42.4% (n = 14) had a neuropsychological 
impairment, with 46% (n = 23) at Stage 2, 48.6% (n = 17) at Stage 3, and 72% (n 
= 59) at Stage 4.  
Cochran-Mantel-Haenszel χ2 tests were conducted on the cognitive 
subdomains (language, fluency, executive, memory, and visuospatial functions). 
A marginally significant effect was observed across disease stages for increasing 
rates of impairment (χ2MH (3) = 8.20, p = .042). Post-hoc Cochran-Armitage tests 
revealed that rates of fluency impairment significantly related to advancing 
disease stage (z = 2.18, p = .015), however this did not survive correction for 
multiple comparisons. No other cognitive domain was individually significant. 
Cochran-Mantel-Haenszel test for behavioural domains (apathy, disinhibition, 
loss of sympathy/empathy, perseveration, hyperorality, and psychosis) was 
significant across disease stages (χ2MH (3) = 74.57, p < .001). Post-hoc Cochran-
Armitage tests corrected for multiple comparisons demonstrate that apathy (z = 
4.30, p < .001), disinhibition (z = 3.43, p = .002), loss of sympathy/empathy (z = 
3.31, p = .002), perseveration (z = 2.68, p = .007), hyperorality (z = 2.90, p = 
.006), and psychosis (z = 2.60, p = .007) significantly increase across disease 











5.3.10. Relationship between rates of change in cognitive and behavioural 
domains (Aim 5) 
Aim 5: Examine how longitudinal changes in cognition and behaviour relate to 
one another 
Individual (random) model-implied slopes were extracted from the separate basic 
LGCMs to examine relationships among rates of change of ECAS subdomains. 
A Spearman correlation matrix of the relationship between the ECAS cognitive 
and behavioural domains is presented in Table 5.14, and displayed in Figure 5.7. 
The majority of slopes significantly correlated with each other, even after 
correcting for multiple comparisons. The strongest relationships were observed 
between language, fluency, apathy, and disinhibition. Interestingly, visuospatial 
functions related negatively with language, fluency, apathy, and disinhibition. This 
suggests a slower rate of visuospatial decline is related to a faster rate of decline 
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for language, fluency, apathy, and disinhibition. However, caution should be used 
in interpreting the model-implied values of visuospatial functioning, given the 
constraints placed on this model. The dendogram of clusters is presented in 
Figure 5.8. Of note, visuospatial functions and perseveration cluster together 
positively (r = .75), while executive functions and memory also form a cluster (r = 
.44). Fluency, language, apathy, and disinhibition form a single cluster, with 








Table 5.14. Correlation matrix of model-implied slopes for the ECAS cognitive and behavioural Domains 
 Language Executive Fluency Memory Visuospatial Apathy Disinhibition Sympathy Perseveration Eating 
Language  .49 .85 .37 -.43 .84 .96 .39 -.29 .51 
Executive < .001  .57 .44  -.08 .60 .50 .14 .13 .34 
Fluency < .001 < .001  .49 -.29 .85 .88 .30 -.09 .50 
Memory < .001 < .001 < .001  -.20 .40 .40 -.02 -.02 .16 
Visuospatial <. 001 > .999 .005  .306  -.04 -.45 -.12 .77 -.12 
Apathy < .001 < .001 < .001 < .001  > .999  .86 .42 .13 .69 
Disinhibition < .001 < .001 < .001 < .001 < .001 < .001  .43 -.29 .54 
Sympathy < .001 > .999 .005 > .999 > .999 < .001 < .001  -.10 .34 
Perseveration .006  > .999 > .999 > .999 < .001 > .999  .005 > .999  .12 
Eating < .001  .001 < .001 > .999 > .999 < .001 < .001 < .001 > .999  




Figure 5.7. Heatmap of model-implied slopes correlations for the ECAS 
cognitive and behavioural Domains 
 
 
Note. Heatmap displays correlation coefficients (Spearman) for LGCM implied slopes, clustered 
by strength of relationship.  Slopes for behavioural domains had their sign inverted (i.e., -
multiplying slope by -1) to aid interpretation. Pairwise cells without colour circle are non-

























5.3.11. Identification of patient subgroups (Aim 6) 
Aim 6: Evaluate the presence of ALS cognitive and behavioural subgroups 
Hierarchical cluster analysis was also conducted on individual patients’ model-
implied slopes to evaluate the presence of patient subgroups. The dendogram 
revealed a four-group solution (Group A: n = 67, Group B: n = 72, Group C: n = 
20, and Group D: n = 2). Severe cognitive and behavioural impairments were 
observed in Group D patients. One patient’s ECAS Total z-score at Time 1 was -
6.12 which declined to -10.12 by Time 4. Conversely, their behaviour (4 
behavioural features) and depression (HADS depression = 17) improved from 
Time 1 to Time 4 (two behavioural features and HADS depression score of 2). 
 
 187 
This patient transitioned from Stage 2 to Stage 4 over the course of the study. 
The second patient was in Stage 1 but dropped-out after Time 1. An ECAS total 
z-score of -11.69, 5 behavioural features, and psychosis were observed. This 
patient was previously excluded as an outlier from the visuospatial model. Due to 
the small sample size, Group D was not analysed further. 
The mean model-implied trajectories of patients’ cognitive and behavioural 
functioning by group membership are displayed in Figure 5.9. Patients in Group 
A (40.4% of sample) demonstrate no decline in cognitive functioning and no 
increase in the probability of behavioural features. Groups B (44.1%) and C 
(14.3%) demonstrate a longitudinal model-implied decline in cognitive and 
behavioural functioning, with Group C showing a faster decline in memory 
functions, in addition to lower baseline performance in all domains except for 
visuospatial. As such, Groups A to C demonstrate a gradation of rates of decline.  
Demographic and clinical variables were compared between patient 
subgroups, with significant results reported in Table 5.15. No demographic 
variables (years of education, gender, SES) significantly differed between 
groups. Clinical disease variables (age of onset, diagnostic delay, Riluzole use, 
ALSFRS-R, depression, anxiety, C9orf72 status, site of onset, and disease 
stage) were compared between groups. A gradation of older age of onset, lower 
ALSFRS-R score, and more advanced disease stage was observed across 
groups with faster rates of decline. For site of onset, Group A had fewer than 
expected bulbar onset patients and more than expected upper limb onset patients 
(standardized residuals of -1.8 and +1.8 respectively), while for Group B the 
inverse pattern was observed (+1.1 and -.85 respectively). Group C had fewer 
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upper limb (-1.5) and a greater number of bulbar onset patients (+1.01). However, 
when results were corrected for multiple comparisons, none survived (all p > .05) 
 
 
Table 5.15. Significant demographic and clinical comparisons of hierarchical 
clusters 
 Group A 
n = 67 
Group B 
n = 72 
Group C 
n = 20 
F or X2 p 
Age at onset 56.40  12.92 61.53  10.63 62.15  9.91 3.70 .027 
ALSFRS-R 39.95  6.04 36.85  7.77 37.20  5.65 4.35 .015 
Site of onset % 
(B/UL/LL/R/M) 
 
13/39/33/2/13 33/25/36/1/4 35/10/40/0/15 11.68 .020 
Disease Stage* 2  1.48 2  1.48 4  0 6.89 .032 
Note. B = Bulbar, UL = Upper Limb, LL = Lower Limb. For site of onset, only B, UL, and LL were 
analysed. * = median reported  median absolute deviation. P-values not corrected for multiple 





Figure 5.9. Cluster-based subgroups of model-implied means  
 
 
Note. Subgroups were determined based on model-implied slopes. Graphs above represent the mean of each patients’ model-implied scores for each 






The aims of this chapter were to 1) examine the effect of neuropsychological 
impairment and disease stage/severity on attrition; 2) examine longitudinal 
changes in cognition and behaviour over time using appropriately specified 
models which control for attrition, 3) examine the effect of age of onset, years of 
education, the presence of C9orf72 repeat expansion, and King’s Clinical 
Disease Stage on longitudinal cognitive and behavioural change; 4) 
Longitudinally verify the cross-sectional relationship between cognition, 
behaviour and disease stage presented in Chapter 4; 5) examine how longitudinal 
changes in cognition and behaviour relate to one another; and 6) evaluate the 
presence of ALS cognitive and behavioural subgroups. 
Cognitive functioning was found to significantly decline over time, 
particularly the ECAS Total, ALS Specific, and verbal fluency scores. This is in 
contrast to previous studies that did not control for attrition, which may have 
masked a decline. Furthermore, cognitive and behavioural impairment was found 
to significantly predict attrition, highlighting its importance in longitudinal analysis. 
The effect of time was attenuated when covariates of interest (age of onset, years 
of education, C9orf72 status, and King’s Clinical Disease Stage) were modelled 
suggesting that longitudinal changes were dependent on these covariates. No 
significant decline in behavioural functioning was found (i.e., an increase in probit 
probability), however, behaviour was found to be related to disease stage in 
addition to the presence of C9orf72 mutation and education. ALS Non-Specific 
functions and memory did not demonstrate a significant decline over time, but the 
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rate of change was related to baseline performance such that higher baseline 
performance resulted in a slower rate of decline.  
When data was restructured by disease stage, cognitive and behavioural 
functioning were found to decline in the same pattern as observed cross-
sectionally (Chapter 4). In particular, ALS Specific functions declined from earlier 
disease stages whereas ALS Non-Specific functions were driven by end-stage 
disease. When rates of decline in different ECAS subdomains were examined, 
distinct but overlapping clusters were observed. Apathy, fluency, language, and 
disinhibition strongly correlated. Executive functions and memory formed its own 
related cluster, while visuospatial functions and perseveration formed a separate 
cluster. In analysing subgroups of patients, a four-group solution was observed 
with sequentially more severe cognitive and behaviour decline.  
 
5.4.1. Longitudinal changes in cognition and behaviour 
Previous longitudinal studies of cognition in ALS has produced inconsistent 
findings. Attrition has significantly challenged the appropriate modelling of 
longitudinal outcomes in ALS, with cognitive impairment linked with increased risk 
of attrition (Elamin et al., 2013), which was also found in the present study. It is 
demonstrable from the present findings that longitudinal studies of cognition and 
behaviour in ALS must account for non-random attrition in appropriately specified 
models. Mean scores displayed in Table 5.3 suggest an improvement over time. 
However, once attrition was controlled for, cognitive functions were found to 
decline. This point has important implications when previous longitudinal results 
are considered. It is likely that the inconsistency of previous research is, in part, 
due to biased statistical procedures. 
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Furthermore, previous research has suffered from the use of tests 
dependent on motor speed, the presence of practice effects, small sample sizes, 
limited follow-up occasions, high rates of attrition, and the lack of a control group. 
The present study included the ECAS (Abrahams et al., 2014) and its alternate 
forms (Crockford et al., 2017a; 2017b) which allowed for the measurement of 
cognition, independent of motor speed and robust to practice effects. The addition 
of a matched control group, allowed for the conversion of patient raw scores to 
standardised scores, further reducing the potential impact of practice effects. The 
present study included a large multicentre sample of 161 patients, measured over 
four time points, with acceptable rates of attrition improving the sensitivity to 
detect a longitudinal effect. Therefore, the present study addresses the 
methodological restrictions which limited the interpretation of previous reports.  
Once attrition is accounted for, cognitive functioning was found to decline 
significantly over time. Different cognitive domains are affected by time in different 
ways. As displayed in Figure 5.4, the model-implied trajectories suggest that the 
rate of decline for ECAS Total, ALS Specific, and fluency differ from those of ALS 
Non-Specific, executive, memory, and language functions. All ECAS cognitive 
domains except for visuospatial functions demonstrate a mean model-implied 
decline over time, with ECAS Total, ALS Specific, and fluency declining at a faster 
rate and significantly. The significant intercept-slope covariance for ALS Non-
Specific and memory functions suggests that higher baseline performance 
relates to a slower rate of change. Elamin et al. (2013) similarly observed that 
ALS patients with non-executive cognitive impairment (e.g., memory impairment) 
at baseline declined more quickly in memory functions compared to patients with 
a profile of executive impairment at baseline. 
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Executive functions, memory, and language declined over time but the 
trajectory of the latent slope was not significant. Of importance, however, is the 
significant decline in verbal fluency performance. Verbal fluency has been 
identified as the most sensitive marker of cognitive impairment in ALS. Recently 
updated consensus guidelines suggest that verbal fluency impairment alone is 
now sufficient to categorise ALS patients as cognitively impaired (Strong et al., 
2017). In addition to the extensive work by Abrahams and colleagues (e.g., 2004), 
it has been observed that the majority of ALS patients with executive dysfunction 
have verbal fluency impairment (Phukan et al., 2012), and that when clinical 
neuropsychological tests are re-organised into functional domains, cognitive 
initiation is most common impairment (Kasper et al., 2015).  
Despite a consistent positive trend for increasing probability, no significant 
changes in behaviour were observed over time. Yet, our previous cross-sectional 
findings (Crockford et al., 2018; Chapter 4) suggest that behaviour is significantly 
related to disease stage. It is possible that time may be a poor indicator of 
longitudinal behaviour changes. Alternatively, this may suggest that changes in 
behaviour are at a slower pace than changes in cognitive functioning, or may 
come secondary to cognitive decline.  
 
5.4.2. Longitudinal neuropsychological functioning and disease stage 
In Chapter 4 it was observed that disease stage is an important factor in cognitive 
and behavioural features of ALS. When covariates were added to LCGMs, the 
significant decline observed for ECAS Total, ALS Specific, and fluency functions 
is ameliorated suggesting that longitudinal decline in cognitive functioning is 
dependent on the covariates rather than time. Rate of change in ALS Non-
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Specific functions remained dependent on baseline levels of functioning, even 
after the inclusion of covariates. ALS Specific functions and behaviour were found 
to significantly relate to disease stage in earlier time points, while ALS Non-
Specific functions and perseveration are dependent on disease stage in later time 
points. The interactive relationship between disease stage, time, and cognitive 
domains demonstrate that ALS Specific and Non-Specific functions react 
differently to disease stage, as suggested cross-sectionally in Chapter 4.  
In Chapter 4 it was shown that largest difference in disease stage for ALS 
Specific cognitive functions was from Stage 2 to Stage 3. ALS Non-Specific 
functions, conversely, differ the most between Stage 3 and 4. Longitudinally, 
patients in earlier disease stages were seen to transition to later disease stages, 
with the majority of patients in end-stage disease in Times 3 and 4. Given this, 
Times 1 and 2 are optimal to detect the effect of disease stage on ALS Specific 
functions as it provides greater coverage of Stages 1-3. Similarly, Times 3 and 4 
are optimal to detect an effect of disease stage on ALS Non-Specific functions 
due to the greater coverage of Stages 3 and 4. As such, the estimate of disease 
stage within the LGCMs corroborate the cross-sectional findings in Chapter 4. 
Furthermore, the patterns of change observed in cognitive and behaviour 
functioning longitudinally supports the hypothesis presented in Chapter 4, that 
underlying disease pathology may explain the relationship between cognition, 
behaviour, and disease stage. Specifically, it has been proposed that disease 
spread in ALS follows a predictable pattern whereby TDP-43 inclusions beginning 
in the primary motor cortex, spinal cord, and cranial nerves, spreading to the 
reticular formation of the brainstem, the prefrontal cortex, and finally the 
hippocampus (Brettschneider et al., 2013). Based on this hypothesis, we would 
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expect to see deterioration in ALS Specific functions early in the disease course 
with ALS Non-Specific functions developing later, which was observed. There is 
no current research available on the neural correlates of the King’s Clinical 
Disease Stage and therefore one cannot assume that disease stage necessarily 
reflects pathological disease spread. Rather, disease stage represents clinical 
disease progression which may or may not decline at a similar rate to pathological 
progression. As such, the time by stage by cognitive domain interaction seen in 
the present study may reflect the differences in clinical and pathological disease 
spread.  
To further explore the relationship between disease stage and 
neuropsychological functioning, in addition to verifying the results of Chapter 4 
longitudinally, data were restructured by disease stage rather than time. When 
disease stage is modelled directly, ECAS Total, ALS Specific functions, and 
behaviour features were significantly and linearly related to disease stage, while 
ALS Non-Specific functions possessed a marginally significant quadratic curve. 
Interestingly, none of the individual cognitive domains reached significance 
suggesting an aggregative effect. However, this may also be due to a lack of 
power to detect individual trajectories. When data are restructured by disease 
stage, a loss of information occurs such that the pairwise coverage of adjacent 
disease stages is reduced. Similar findings were observed for rates of 
impairment, such that a significant main effect for ECAS composite domains was 
observed. The cognitive subdomains did not reach statistical significance on 
post-hoc analysis, however, behavioural features (apathy, disinhibition, loss of 
sympathy, perseveration, hyperorality, and psychosis) did.  
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While it was observed that attrition is significantly predicted by 
neuropsychological impairment, it is not possible to control for attrition in the 
mixed effects analysis of disease stage, nor the analysis of impairment rates. 
Indeed, these findings are biased such that patients with more severe cognitive, 
behavioural, and physical features were less likely to continue taking part. 
Therefore, the rates of impairment observed longitudinally likely underestimate 
the true rates of impairment. We observed that neuropsychological impairment 
was present in 80% of Stage 4 patients cross-sectionally and 72% of patients 
longitudinally. Thus, longitudinal results largely corroborate findings of cross-
sectional analyses (Chapter 4). 
 
 
5.4.3. Longitudinal neuropsychological functioning and age of onset, years of 
education, and the C9orf72 mutation 
Age of onset, years of education, and C9orf72 status have previously been 
associated with cognitive and behavioural impairment (e.g., Beeldman et al., 
2016; Byrne et al., 2012; Elamin et al., 2011; & Trojsi et al., 2016). A small number 
of significant associations were found between age of onset and baseline 
executive functioning, behavioural impairment, and disinhibition, in addition to 
rate of visuospatial and fluency decline. The comparatively few significant 
relationships between age of onset and neuropsychological functioning suggests 
that cognitive decline in ALS is not entirely a product of age-related cognitive 
decline. Time-variant covariates were largely predictive of baseline behaviour 
and ALS Specific functions, particularly years of education and the presence of 
C9orf72 mutation. Years of education and C9orf72 was also related to the 
 
 197 
increased probability of behavioural features. Conversely, the C9orf72 mutation, 
and not education, was associated with the rate of change in ALS Specific 
functions. Therefore, ALS specific functions and behaviour are dependent on 
disease stage, education, and the presence of C9orf72 repeat expansion. The 
relationship between covariates and the latent intercept explain the lack of 
significant associations between Time 1 data and disease stage, in that these 
covariates explain a significant proportion of baseline performance. 
Cognitive reserve may be a factor in the effect of education, defined as 
“individual differences in how people process tasks allowing some to cope better 
than others with brain pathology” (Stern, 2009, pp. 2016). Cognitive reserve 
describes the lack of direct relationship between severity of pathology and degree 
of impairment (Stern, 2002; Scarmeas & Stern, 2003) and the use of 
compensation strategies, such that participants recruit intact brain structures to 
overcome pathological structures. For example, participants may recruit aspects 
of intact executive functioning to complete memory performance. Years of 
education has been shown to contribute to cognitive reserve (Kaplan et al., 2009) 
and significantly relate to lower incidence of dementia (Valenzuela & Sachdev, 
2006). Montuschi et al. (2015) classified a cohort of ALS patients as ALS-FTD, 
ALS-NECI (non-executive cognitive impairment), ALS-ECI (executive cognitive 
impairment), ALS-Bi (behavioural impairment), and ALS-NCCI (non-classifiable 
cognitive impairment), and cognitively intact. The authors report that ALS-FTD 
patients had lower education compared to all other patient subgroups, suggestive 
of cognitive reserve. Cognitive reserve has been related to reduced metabolism 
in the dorsolateral prefrontal cortex (Dodich et al., 2018). However, education 
was not found to relate to the rate of change in cognitive functions. This may 
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suggest that the protective influence of cognitive reserve only has a non-
significant effect  
It is perhaps unexpected that years of education is related to behavioural 
functioning, yet, such a theory has previously been suggested. Premi et al., 
(2013) explored the concept of behavioural reserve in the context of FTD 
observing that FTD patients with higher education levels possessed a higher 
degree of frontotemporal hypoperfusion, despite similar disease severity and 
disinhibition scores. Behavioural changes in FTD have been associated with 
hypometablism in frontotemporal regions, including the anterior cingulate and 
temporal cortex, and the dorsolateral prefrontal cortex (Borroni et al., 2012). As 
such, educational attainment may be protective in trajectories of ALS behaviour, 
or allow for the use of compensation strategies.  
The C9orf72 expansion accounts for up to 50% of familial cases and 8% 
of sporadic ALS cases (De Jesus-Hernandez et al., 2011; Hardiman et al., 2016; 
Majounie et al., 2012). Genetically, the presence of FTD in ALS has been 
associated with the C9orf72 expansion, seen in approximately 12% of familial 
FTD cases and 24% of familial ALS cases (Byrne et al., 2011; De Jesus-
Hernandez et al., 2011). C9orf72 has been associated with higher rates of 
cognitive and behavioural impairment, dementia and neuropsychiatric features 
(Byrne et al., 2012; Hardiman et al., 2016; Snowden et al., 2013). Westeneng et 
al., (2016) found widespread cortical and subcortical grey matter differences 
between C9orf72 carriers and non-carriers, in addition to reduced white matter 
integrity of the inferior and superior longitudinal fasciculus. In the present study, 
C9orf72 carriers had worse baseline cognitive and behavioural functioning 
(ECAS Total, ALS Specific, language, executive, behaviour score, hyperorality), 
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in addition to faster rates of decline in the ECAS Total, ALS Specific, executive, 
behaviour score, apathy, and loss of sympathy/empathy. However, given the 
small number of patients identified as carriers, caution should be used in 
interpreting these results. Of the 38% of patients for whom genetic status was 
unavailable, it is highly likely that there exists C9orf72 carriers in this subsample. 
This likely contributes, in part, to the significant residual variation present in the 
latent variable models.  
 
5.4.4. Relationship among individual ECAS domains  
With regards to Aim 5, cognitive and behavioural subdomains formed distinct but 
related clusters. Executive functioning and memory formed a subgroup, related 
to the fluency, language, apathy, and disinhibition subgroup suggesting that 
these domains tend to decline at similar rates. The relationship between 
executive functioning and memory in ALS has been previously examined in the 
literature, with the suggestion that memory impairment observed in ALS may be 
partly explained by executive dysfunction (Christidi et al., 2012; Machts et al., 
2014; Mantovan et al., 2003). Indeed, the hierarchical cluster analysis 
established a significant relationship between the rate of change for memory and 
executive functioning, demonstrating that the rate of change in memory relates 
to the rate of change in executive functions. This finding appears at odds with the 
observation that executive functions are affected at earlier disease stages than 
memory functions. However, the decline in executive functions begins in earlier 
stages and continue into end stage disease, converging with memory functions 
by Stage 4. Additionally, these correlations are based on random (individual) 
latent slopes, suggesting that at least a proportion of patients’ executive and 
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memory functions co-vary. Thus, executive decline may be partially driving the 
decline in memory functions, or vice versa.  
Verbal fluency, apathy, language, and disinhibition additionally group 
together. Verbal fluency has previously been associated with apathy, with the 
suggestion that this profile of neuropsychological impairment may represent a 
deficit in cognitive and behavioural initiation (e.g., Radakovic et al., 2017c). Our 
findings similarly suggest that the rate of decline in verbal fluency is strongly 
associated with an increased probability of apathy. In addition to the extensive 
work by Abrahams and colleagues (e.g., 2004), it has been observed that the 
majority of ALS patients with executive dysfunction have verbal fluency 
impairment (Phukan et al., 2011), and that when clinical neuropsychological tests 
are re-organised into functional domains, cognitive initiation is most common 
impairment (Kasper et al., 2015). In our analysis, verbal fluency and executive 
functions did not form a unique cluster, but did correlate strongly (r = .57).  
Visuospatial functioning and perseveration formed a discrete group, 
correlating positively and strongly. Interestingly, visuospatial functions and 
perseveration were negatively related to domains of the first grouping (language, 
disinhibition, and fluency) suggesting separation. Visuospatial functions and 
perseveration also possessed unique properties in the LGCMs. While most 
cognitive domains demonstrated a decline in functioning over time (significant or 
non-significant), visuospatial functioning was the only domain to demonstrate a 
flat slope. Perseveration, instead, was the only behavioural domain to relate to 
disease stage in later time points. While visuospatial functions did not 
demonstrate a declining slope in the latent growth curve models, this does not 
indicate that no patient declined, but rather than the group mean was flat. As 
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such, patients who declined in visuospatial functions also had an increased 
probability of having perseverations, and similarly, those who demonstrated no 
change in visuospatial functions showed no change in the probability of 
perseveration. However, it should be noted that the models for visuospatial 
functions and perseveration possessed numerous constraints, suggesting 
instability in the LGCMs and caution should be used in interpreting these models’ 
outputs.  
 
5.4.5. Identification of model-implied patient subgroups  
Individual patients were clustered into three groups (once two outliers were 
removed; Group D) characterised by progressively faster rates of longitudinal 
decline in neuropsychological functioning. A faster rate of decline was associated 
with a constellation of clinical and demographic features, namely older age of 
onset, lower ALSFRS-R scores, site of onset, and more advanced disease stage. 
The findings that age of onset, and disease stage significantly differ between 
groups supports their inclusion in covariate LGCMs. While these comparisons did 
not survive correction for multiple comparisons, they indicate that the rate of 
decline in neuropsychological functioning is complex and multicomponent, with 
no conspicuous contributing risk factors. However, the relationship with the 
ALSFRS-R and King’s Clinical Disease Stage support the findings of the latent 
growth curve models that cognitive and behavioural functioning is related to 
disease progression. Yet, an important limitation to note is that these subgroups 
are theoretical in nature. The values utilised in establishing subgroups are 
inferred from the models, with missing data points estimated. Given the 
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relationship between neuropsychological impairment and attrition, Groups B and 
C with the fastest decline also contain patients more likely to drop-out.  
 
5.4.6. Limitations and conclusions  
The present study aimed to overcome limitations of previous longitudinal 
research in ALS, namely, small sample sizes, bias introduced by attrition, use of 
cognitive tests not appropriate for reduced motor speed, presence of practice 
effects, and the use of time as the only proxy of progression. Indeed, the 
methodological design of this study overcame many of the issue, yet some 
important limitations should be considered. The model fit in this study utilised 
linear slopes, i.e., that change over time follows a linear pattern. However, it is 
possible that a quadratic growth function would also be appropriate for such data. 
The present data unfortunately did not accept the quadratic slopes due to loss of 
fit and misspecification. The negative variances observed in language and 
visuospatial functions point to the lack of variability in performance between 
patients, which may be in part due to the ceiling effects present in the raw data. 
As such, the models with poorer fit or issues around specification should be 
interpreted with caution. For instance, the full covariate models for language, ALS 
Non-Specific, and disinhibition possess poor or acceptable fit. Additionally, 
visuospatial functions and all behaviour domains except loss of 
sympathy/empathy and hyperorality required model constrains. Additionally, 
given the impact that attrition has on the trajectory of changes, it was not possible 




In summary, significant ALS Specific cognitive and behavioural decline is 
apparent in patients with ALS, and is related to advancing clinical disease stage. 
Fewer years of education related to worse cognitive and behavioural functioning, 
and the presence of C9orf72 repeat expansion related to worse a faster rate of 
decline in ALS Specific cognitive and behavioural functioning. ALS Non-Specific 
functions are related to disease stage and age of onset at baseline, with the rate 
of change dependent on baseline performance. ALS Specific and Non-Specific 
interact with disease stage and time in their progression profiles, such that ALS 
Specific functions (in addition to behaviour) decline more quickly than ALS Non-
Specific functions.  
The observations from Chapters 4 and 5 indicate that cognition and 
behaviour decline over the ALS disease course and are critically related to 
disease stage. Given the prominent impact that neuropsychological impairment 
on burden, quality of life, survival, and medical care, and the suggestion that all 
patients with ALS should undergo neuropsychological screening (e.g., NICE, 
2016; Strong et al., 2017), the question arises as to the practices of clinicians 
caring for people with ALS. The following chapter will examine clinicians’ attitudes 
and barriers to cognitive and behavioural screening. 
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CHAPTER 6: Clinicians’ attitudes toward cognitive and 
behavioural screening in motor neurone disease 
 
In Chapters 2-3, the development of alternate forms of the ECAS was described 
to allow for repeated assessment of cognition in ALS. Chapters 4-5 describe the 
application of these new ECAS forms in describing cognition and behaviour 
across King’s Clinical Disease Stages. It was observed that ALS-Specific 
cognitive changes and behaviour was critically associated with advancing 
disease stage. Given the prevalence of cognitive and behavioural impairment in 
ALS, and the findings herein that cognitive functioning declines over the course 
of the disease, it is important to understand how neuropsychological assessment 
and clinicians interact.  
 Chapter 6 describes a qualitative investigation of clinician’s attitudes 
toward neuropsychological assessment in ALS and the barriers to such 
assessment. The following chapter, in its current form, was accepted for 
publication in the British Journal of Neuroscience Nursing (DOI: https://doi.org/ 
10.12968/bjnn.2017.13.3.116). Chapter 6 was not published open-access, and 
therefore represents the pre-proof version of the manuscript. 
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6.1. Abstract  
Amyotrophic Lateral Sclerosis (ALS), the most common variant of Motor Neurone 
Disease, is a fatal neurodegenerative condition marked by progressive motor 
disability. Cognitive and behavioural changes occur in approximately 50% of 
patients, which may impact caregiver burden, adherence to life-prolonging 
interventions, and care planning. The aim of this study was to explore the 
attitudes and practices of Health Care Professionals working with ALS patients in 
Scotland towards cognitive and behavioural screening.  Structured interviews 
with ALS Healthcare Professionals were conducted and subjected to thematic 
analysis. While 93% of clinicians in this study believed that cognitive and 
behavioural screening should be routinely applied for all patients, it is not 
currently common practice, nor are formalised screening tools widely used. 
Participants noted that barriers to screening include other members of staff, 
limited resources, and issues concerning patients and their families. Participants 
suggested that increased education and training, making screening a 
standardised protocol to all patients and increased psychology input may help 




1. Cognitive and behavioural screening in MND is important in the 
management and care of patients and their families, as highlighted by 
recently updated guidelines from the National Institute for Health and Care 
Excellence (NICE).  
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2. While the majority of Health Care Professionals in this study recognise its 
importance, cognitive and behavioural assessment is at present not 
provided to all patients and methods of evaluation are often informal.  
3. Barriers exist to implementing screening programmes including a lack of 
resources, perceived attitudes of other staff members, and of patients and 
their families.  
4. Increased resources, education, and psychology input may assist in 
overcoming these barriers and providing modern holistic care to patients 




Motor neurone diseases (MND) is an umbrella term for neurodegenerative 
syndromes marked by degeneration of the upper and/or lower motor neurons of 
the brain and spinal cord. Half of patients with MND die within 30 months of 
symptom onset, most commonly due to failure of the respiratory system. 
Amyotrophic Lateral Sclerosis (ALS), the most common form of MND, is classified 
by involvement of both the upper and lower motor neurons, presenting as muscle 
rigidity, wasting, and weakness (Strong et al., 2009). 
 However, in addition to the physical symptoms, it is now recognised that 
impairments in cognition and behaviour are common in patients with ALS. 
Difficulties in executive functions (e.g., problem solving, decision making, social 
perception), language (e.g., word finding, comprehension), and behaviours such 
as apathy are commonly reported (Raaphorst et al., 2012a; Beeldman et al. 
2016). It is estimated that approximately 50% of ALS patients experience some 
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changes in cognition and behaviour, of which approximately 15% meet diagnostic 
criteria for frontotemporal dementia (Goldstein and Abrahams, 2013). A clinical, 
pathological, and genetic overlap has been established between and 
frontotemporal dementia confirming that the two conditions constitute a spectrum 
disease (Turner et al., 2013).  
 Changes in cognition and behaviour have important implications for 
patient management (Abrahams, 2013b) and have been associated with 
significantly shorter survival time in patients with ALS (Elamin et al., 2013; Caga 
et al., 2016). People with ALS and cognitive change have shown less compliance 
with life-prolonging interventions (Olney et al., 2005; Martin et al., 2014), and 
have a reduced ability to plan and organise medications (Stukovnik et al., 2010). 
Furthermore, behavioural symptoms are one of the greatest contributors to 
caregiver burden, perhaps over and above physical symptoms (Lillo et al., 
2012b). Thus, the accurate and timely understanding of patients’ cognitive and 
behavioural profile is of vital importance. Recently updated guidelines from the 
National Institute for Health and Care Excellence have incorporated 
recommendations for cognitive and behavioural assessment in patients with 
MND (NICE, 2016). These guidelines note that a patients’ cognitive and 
behavioural status has implications for end of life planning, the type of 
medications that should be prescribed, the use of gastronomy, and the use of 
respiratory interventions. Additionally, discussions around care should be tailored 
to each person’s needs, communication ability, cognitive status, and mental 
capacity (NICE, 2016).  
 Unfortunately, measuring cognition in patients with ALS has been 
historically difficult. Standardised cognitive screening, and neuropsychological 
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assessment more generally, rely on a person’s ability to either speak or write their 
responses, often under timed constraints. Additionally, evidence suggests that 
clinicians are poor at detecting cognitive impairment using clinical judgement 
when compared to formal cognitive screening (Cohen et al., 1993; Crawford et 
al., 2001; Burleigh et al., 2002; Bouwmans and Weber, 2011; Mitchell et al., 
2011), particularly in cases of mild cognitive deficits (Dungen et al., 2011). While 
no identifiable research is available on the practices of clinician’s caring for 
patients with ALS, within elderly primary care settings some research suggests 
that cognition appears to be evaluated principally using clinical judgement. For 
example, Bush et al. (1997) found that 72.8% of primary care physicians 
evaluated cognitive status using clinical judgement while only 27.2% used a 
formal test. More recently, Galvin, Meuser and Morris (2012) found that formal 
screening tools, such as the Mini Mental State Examination, are used widely by 
healthcare professionals.   
 For patients with MND, tools such as the Mini Mental State Examination 
are not appropriate due to the requirement for intact motor skills. Fortunately, in 
recent years, a number of ALS-specific screening tools have been developed, 
most notably the ECAS (Edinburgh Cognitive and Behavioural ALS Screen; 
Abrahams et al., 2014) which has been validated on Scottish, German and Italian 
populations (Lulé et al., 2015; Niven et al., 2015; Loose et al., 2016; Poletti et al., 
2016). The ECAS has been shown to be sensitive to cognitive impairment against 
extensive neuropsychological investigation (Niven et al., 2015) and is possible to 
administer in patients with even severe motor disability (Lulé et al., 2015). The 
ECAS is designed for use by non-neuropsychologist staff, such as doctors, 
clinical care specialists, and other medical professionals.   
 
 210
 While the importance of understanding the cognitive and behavioural 
profile of neurological patients is clear, a number of barriers have been identified 
in the implementation of cognitive screening in primary care settings; for example, 
Bush et al. (1997) found that a lack of time, patients becoming offended or 
resisting, lack of proven benefit, and inadequacy of available tests all posed 
problems. Similarly, Boustani et al. (2005) identified increased time burden, no 
referral access to neuropsychology, patient refusal, and that physicians do not 
fully understand the operating characteristics of screening tests. Yet, more 
recently, Fowler et al. (2012) found that patient refusal of cognitive screening is 
low, and more unlikely in patients who perceive there to be benefits. 
 However, there exists a dearth of knowledge as to the attitudes and 
practices of Health Care Professionals (HCPs) in ALS services with regards to 
cognitive and behavioural screening.  
 The aim of this study was to explore HCPs’ attitudes to screening, and 
more specifically, views on the importance of screening, practices around 
screening, and what barriers exist to the implementation of screening for cognitive 




Structured interviews consisting of both open-ended and forced-choice questions 
were undertaken with participants. Thematic analysis was used to analyse the 
data.  This study received ethical approval from the Psychology Research Ethics 





Participants were HCPs working with patients with ALS and recruited from 6 NHS 
health boards in Scotland. Fourteen HCPs took part in this study, including 5 ALS 
clinical care specialists, 5 neurologists (3 consultant neurologists and 2 specialist 
registrars in neurology), and 4 psychologists (2 clinical psychologists and 2 
clinical neuropsychologists). Participants, on average, had spent 10.04 years in 
their current role, and an average of 11.64 working with patients with ALS. Clinical 
care specialists were recruited through MND Scotland, while neurologists and 
psychologists were recruited via chain-referral sampling methods.   
 
6.3.2. Procedure 
Participants were contacted by email and invited to take part in this study. 
Participants were given the option to complete the interview by telephone, in 
person, or to complete an online form. In all cases, questions posed to 
participants were identical. Twelve participants were interviewed by telephone, 
while two completed the online form. Those who chose the online form stated 
that this was due to time restrictions. Responses of participants who completed 
the online form did not thematically differ from those who completed an interview. 
Interviews were conducted between February and May 2015 and lasted 
approximately 20-30 minutes. Interviews were audio-recorded, transcribed 
verbatim (transcripts were anonymised to protect confidentiality), and subjected 
to thematic analysis. Thematic codes emerged post-hoc based on participant 









6.4.1. Attitudes and practices to screening 
Participants were asked how important they viewed screening for cognition and 
behaviour on a five-point Likert-type scale. Figure 6.1 shows that all but one 
participant believed screening to be either important or very important. 
Table 6.1. Overview of analysis themes 
 



















Care provision & 
planning 
a. Person-centred care All 
 b. How staff communicate All 
Capacity a. Consent to interventions All 
















Staff barriers a. Perceived unimportance All 
 b. Negative patient outcomes All 
 c. Lack of awareness All 
 d. Lack of confidence All 
 e. Who should administer? Psychology 
Resources a. Time All 
 b. Staff CCS, Neurology 
 c. Training/Education CCS, Neurology 
 d. ALS-Specific tools Psychology 
Patient/family barriers a. Refusal CCS, Psychology 
















Increased resources a. Increased education/training All 
 b. Increased psychology input All 
 c. Increased CCS staff CCS, Neurology 
Standardisation a. Screening as standard protocol CCS, Psychology 
Other a. Technology CCS 
 b. ALS-Specific Tools Psychology 










 Participants were asked to qualify their judgement of perceived 
importance, and additionally, asked whether they perceived there to be benefits 
to screening. For participants who reported screening to be important or very 
important, two categories emerged for the importance of screening: a) care 
provision and planning, and b) decision making and mental capacity.  
 
a) Care provision and planning: The majority of participants noted that screening 
allows HCPs to provide holistic, person-centred, and individualised treatment, as 
opposed to addressing ALS as solely a physical condition. Participants 
additionally reported that screening allows clinical staff to tailor the way in which 
they communicate with patients and with their families.  
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“Informing clinicians who are working with patients about what their 




b) Decision making and mental capacity: Participants noted that screening 
assists in the determination of mental capacity and decision making abilities, 
which is important as there are end-of-life decisions to make, such as power of 
attorney, and that medical interventions can be invasive (for example, 
percutaneous endoscopic gastrostomy). As such, it is important that patients’ 
capacity to consent is established.  
“There’s a lot of invasive medical procedures involved sometimes 
in ALS and you have to ask the question of whether the person’s 
got capacity to make these decisions” 
-Psychologist 
 
The methods by which HCPs screen for cognitive and behaviour change, and the 
frequency of such screening, were explored. Participants were asked a forced 
choice question as to whether all patients diagnosed with ALS should be 
screened for cognitive and behaviour change as standard. Of the 14 participants, 
13 (92.86%) responded ‘yes’ and one participant responded ‘no’. When asked 
how often participants in this study evaluated patients’ cognitive and behavioural 
status, 71.43% stated always or often, 21.43% stated sometimes or seldom, with 








 However, of the participants who did evaluate cognition and behaviour, 
61.54% reported using their clinical judgement solely, with 38.46% using a formal 
screening tool, or a combination of a screening tool and clinical judgment (Figure 
6.3). Neurologists, clinical care specialists, and psychologists all reported that 
cognitive and behaviour assessments was currently conducted within their 















6.4.2. Perceived barriers to screening 
Participants were asked what, if any, barriers existed to the implementation of 
screening. From participants’ responses, three categories of barriers were 
identified: a) staff-specific barriers, b) resource barriers, and c) patient/family 
barriers.  
 
a) Staff-specific barriers: These concern other members of staff or disciplines 
reported by participants of this study. All of the participants in this study (i.e., all 
HCP disciplines) reported at least one barrier relating to other members of staff, 
in particular, that staff held negative attitudes toward screening. These attitudes 
include a perceived unimportance of screening, the perceived negative 
psychological impact that identifying a cognitive or behavioural deficit might 
cause to patients, a lack of clinician awareness of cognitive or behavioural 
change, a lack of confidence in administering screening, and concern around who 
should administer screening.  One participant reported that clinical staff feel “that 
it’s not an important exercise to put patients through […] a sense that the physical 
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wellbeing is sometimes more important than the emotional and cognitive 
wellbeing.” -Psychologist 
 
 However, one of the most commonly cited staff-specific barriers was in 
reference to Neurology specialists, as opposed to other professions. For 
example, that Neurologists miss the subtleties of cognitive and behavioural 
change, and the effects that this can have.  
“I mean even ten years ago people were told that well don’t you 
worry because ALS doesn’t affect the mind in any way. And in fact 
there are some consultants that still say that” 
 
b) Limited Resources: In addition to other staff, resources were commonly noted 
as a barrier to screening, in particular time, staffing levels, access to training, and 
appropriate assessment tools. Despite the desire to implement screening, the 
length of each consultation was deemed insufficient to administer formal 
screening. Moreover, staff viewed screening as a sensitive issue and that HCPs 
needed to build a rapport with the patient first, adding additional time 
requirements. Further to this, participants reported that insufficient training was 
provided in the administration of screening tools and that services were 
understaffed.  
 
c) Patients and families: A number of participants, particularly psychologists, 
noted that patients themselves may be a barrier to screening, such that, patients 
and carers may refuse. Additionally, the presence of cognitive or behavioural 
symptoms was suggested to pose a challenge in and of itself. However, 
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participants expressed that this is a rare occurrence and that, in all cases, that 
this was only a perceived barrier, rather than from experience with patients. 
“I think some of the barriers can be patients themselves not wanting 
to engage in it because it’s another assessment tool that’s 
highlighting weaknesses in their profiles…. for me, in my experience 





6.4.3. Suggested solutions  
In addition to identifying barriers to screening, participants were asked if they had 
views on how barriers may be overcome. Three common solutions were offered 
by participants: a) increased education, b) increased psychology input, and c) 
screening all patients as standard practice. Three other solutions were also 
offered: increased number of ALS clinical care specialists, use of technology, and 
development of ALS-specific screening tools.  
 Most commonly, participants suggested that education may overcome 
barriers to screening. Education referred to patient/caregiver and staff. The 
majority of participants felt that it is important to increase awareness, highlight the 
benefits of screening, and increase the opportunities for formal training. 
Commonly reported, was that participants felt psychology should have a larger 
input into patient assessment, specifically, that dedicated psychologists should 
be part of the multidisciplinary team. However, some disagreement emerged as 
to who should administer screening. While neurologists felt that both clinical care 
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specialists and psychologists should be responsible, psychologists were 
sceptical of non-specialists administering cognitive/behavioural screening due to 
a lack of formal training and experience. Currently, participants in this study noted 
that screening was not specific to any one discipline.  
 An additional recommendation to increase screening in ALS was to make 
it standard practice for all patients and in so doing, patients may not feel singled 
out or at risk. Finally, other less-reported solutions include the increased staffing 
of clinical care specialists in Scotland, and the utilization of technology in 




The aim of this study was to explore HCPs’ attitudes to cognitive and behavioural 
screening in ALS. Fourteen HCPs were interviewed and asked their opinion as 
to the importance of screening, their practices around screening, and what 
barriers they perceive to exist. This study found that the majority of HCPs deemed 
screening to be important or very important due to its implications for care 
provision and end of life planning, and for issues surrounding decision making 
and mental capacity. Specifically, participants noted that assessment of cognition 
and behaviour allowed for the provision of person-centred, holistic and 
individualised treatment that sees MND as more than a physical disease. Given 
the rapid rate of disease progression, important decisions are necessary with 
regards to end of life planning and treatment. Thus, it is was seen as crucial to 
understand the ability of a patient to make such decisions, and what additional 
supports may be required to do so. These findings suggest that HCPs are largely 
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in agreement with the recently updated NICE guidelines on assessment and 
management of ALS (NICE, 2016).  
 Ninety-three percent of participants stated that screening for cognition 
and behaviour in ALS should be standard practice for all participants, but only 
71.43% stated that they evaluate always or often. Of the HCPs who evaluated 
cognition and behaviour seldom or more frequently, only 38.46% reported 
formally evaluating cognitive and behavioural status of ALS patients using a 
screening tool.  
 The discord between attitudes and practice may be that in reality, HCPs 
are only formally screening patients when cognitive and behavioural symptoms 
are severe or overt, such as cases of comorbid dementia. Yet, the majority of 
patients with ALS will present with mild cognitive and behavioural changes that 
may not be explicitly evident on observation. Research has demonstrated that 
even mild changes can have significant impact on caregivers (Lillo et al. 2012b), 
affect the patients’ ability to manage their medications (Stukovnik et al. 2010), 
and reduce engagement with life prolonging interventions (Olney et al. 2005; 
Martin et al. 2014). Therefore, it is important to offer screening to all patients, 
regardless of whether overt symptoms are present, closing the gap between 
attitudes and practice.  
 Even in those cases were cognition and behaviour is evaluated, clinical 
judgement is the most common method employed. Based on previous research 
citing the poor accuracy of clinical judgement to detect cognitive and behavioural 
impairment (e.g., Mitchel et al. 2011), and the frequency by which this method 
was employed by participants in this study, it is highly likely that patients with 
cognitive and behavioural changes are not being identified. With the development 
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of short ALS-specific tools such as the Edinburgh Cognitive and Behavioural ALS 
Screen, and the growth of multidisciplinary care systems, it should be possible 
for HCPs to include screening as standard practice for all patients. Given this, 
clinicians should be moving away from informal assessment and toward a 
standard screening procedure using a validated formal test.  
 
6.5.1. Barriers to Cognitive and Behavioural Screening 
When HCPs were questioned as to what barriers existed in implementing 
cognitive and behavioural screening, three themes were identified: a) staff-
specific barriers, b) resource barriers, and c) patient/family barriers. While the 
majority of HCPs in this study believed screening to be important, all participants 
also noted that a significant barrier was other staff. Perceived unimportance, lack 
of awareness, and potential negative consequences to patients were cited as 
possible obstacles to the implementation of screening. In particular, participants 
reported that neurologists’ attitudes posed a significant barrier. This perception 
may be a by-product from the current care structure of neurology-led clinics in 
which medical or palliative facets of care are prioritised. Moreover, as noted by 
participants, appointment times between patients and neurologists are short, and 
there may not be sufficient time for cognitive/behavioural symptoms to be evident. 
As such, the barrier may be the clinical context.  
 Participants in this study suggested that the perceived unimportance and 
lack of awareness may be ameliorated by staff educational programmes and 
awareness campaigns which highlight the importance of cognitive/behavioural 
screening in line with NICE Guidelines. HCPs in this study suggested that 
education may alleviate some of the barriers, which may take the form of clinical 
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training workshops, or continuing professional development courses. Galvin, 
Meuser and Morris (2012) demonstrate that a training programme targeted at 
HCPs can be effective in improving medical knowledge, confidence in diagnosis 
and treatment, and enhancing clinical practice.  Staff-specific barriers may be 
partly explained by HCPs have insufficient training in how to practically 
incorporate a patient’s cognitive and behavioural status into practice. Therefore, 
such training and educational opportunities for staff may help overcome a number 
of the barriers cited in this study; for instance, if clinicians were more aware of 
the benefits to screening, how to administer such a screen, and what to do with 
that information, the barriers of perceived unimportance, lack of awareness, and 
lack of confidence may be reduced.  
 Unfortunately, enhancing and increasing educational and training to staff 
is constrained by services already identified as under-resourced. HCPs here 
report having insufficient time, and insufficient staff numbers to implement 
screening for all patients. To fully adhere to NICE guidelines and provide 
cognitive and behavioural assessment to patients with MND, increased funding 
and resources may be unavoidable. However, it is possible that short-term 
funding solutions may provide initial increased education and training that could 
be maintained with normal resources thereafter.  
 However, there was disagreement among participants as to who should 
administer screening tools. A number of participants suggested that increased 
screening may be achieved by increased input from psychologists. This may 
mean psychologists undertaking the assessment themselves, or that 
psychologists provide supervision to non-specialist HCPs. A dual pathway model 
where both of these routes are operationalised would maximize the service to 
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capture a larger proportion of ALS patients, including both those who are willing 
to attend psychology services, in addition to those who do not want to or are 
unable to attend. Geographical, financial, and staffing restrictions may 
necessitate that individual health boards or centres operationalise screening 
programmes according to their unique capabilities.  
 Interestingly, HCPs expressed that patients and their families might 
themselves present a barrier to cognitive and behavioural screening. While this 
is possible, participants herein could not provide examples where this had 
actually occurred. In a large study of screening in primary care, Fowler et al. 
(2012) found that patient refusal was low (10.3%), and significantly less likely in 
those who perceive there to be benefits to screening. This concern may in fact 
reflect HCPs desire to avoid causing distress to patients by identifying a cognitive 
or behavioural symptoms. As such, this barrier may be perceived rather than 
based on actual practice or experience with patients and families and further 
research should address this issue.  
 The barriers which emerged in this study echo some of those previously 
reported specifically, lack of time and potential negative consequences to 
patients, clinicians’ perceptions of screening instruments, and negative 
psychological outcomes for patients posed barriers. (Bush et al. 1997; Boustani 
et al. 2005)  Thus, the barriers highlighted herein may not be unique to ALS 
services, but instead may be common to cognitive and behavioural screening 
generally and lessons can be learned from other setting in overcoming these 
barriers in ALS services.  
 While the results of this study provide the first insights into screening 
practices and HCP attitudes in Scotland, the sample size for this study was small, 
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and incorporated opinions from different professions working in different health 
boards. While this provides a diverse range of opinions, it is not possible to 
determine whether the opinions of one profession or health board will translate to 
another. Further research is required to better understand whether these results 
generalise to the larger HCP workforce in ALS services and to explore whether 
consensus can be agreed. Additionally, the interviews in this study were 
conducted prior to the release of the NICE guidelines, and as such, it is unclear 
whether these new guidelines could directly impact on service provision.  
 
6.5.2. Conclusions 
Cognitive and behavioural screening should be an integral aspect of care 
services provided to patients with ALS. While clinicians in this study recognised 
the importance of cognitive and behavioural assessment, not all patients are 
being offered this service. Furthermore the use of clinical judgement rather than 
screening tools may provide a false estimation of patients’ abilities. HCPs in this 
study identified that barriers exist to cognitive and behavioural screening in the 
form of other members of staff, a lack of resources, and in patients’ themselves 
and their families. When examining the barriers to screening, increasing 
education and training to staff, and increased psychology input may, in turn, 
increase HCP awareness, increase the perceived importance of screening, and 
increase non-specialists’ confidence in the administration of standardised 
screening. Additionally, making screening standard to all patients, a belief held 
by 93% of HCPs in this study, may reduce the likelihood of causing distress to 
patients and their families and ensure that MND patients receive appropriate care 
provision and planning. While individual health boards may require different 
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approaches to adequately implement screening programmes, a national strategy 





Chapter 7 demonstrates that clinicians recognise the importance of cognitive and 
behavioural screening, but that it may not be common practice and important 
barriers exist to the implementation of neuropsychological screening as standard 
practice. These barriers include staff, resources, and issues concerning patients 
and their families. As such, Chapter 7 addresses Aim 4; names, to explore 
clinicians’ attitudes and practices around cognitive and behavioural screening in 







CHAPTER 7: General discussion 
The central aim of this research was to examine the evolution of cognitive and 
behavioural functioning over the course of ALS, and provide a means of 
longitudinal assessment. Specifically, this research aimed to: 1) develop alternate 
forms of the Edinburgh Cognitive and Behavioural ALS Screen to accommodate 
repeated longitudinal assessment in ALS; 2) examine how cognition and 
behaviour relate to clinical disease stages in ALS; 3) evaluate how cognitive and 
behavioural symptoms evolve over the course of the disease in ALS; and 4) 
explore clinicians’ attitudes toward cognitive and behavioural screening in ALS. 
These aims will be discussed in the context of the novel findings presented 
herein, followed by a discussion of how these aims interrelate and future 
directions of the field. 
 
 
7.1. Cognitive assessment in ALS 
Historically, cognitive and behavioural research in ALS has been impeded by the 
use of assessment tools which do not accommodate physical disability. Many 
common cognitive tasks, for example, the Trail Making Test and verbal fluency 
tests, rely on intact motor speed. Muscle wasting and weakness, a hallmark of 
ALS, can exaggerate impairment or imply impairment where none exists. This is 
evident in research which has reported motor-corrected and uncorrected scores 
(Stukovnik et al., 2010). Conversely, the use of tests dependent on motor speed 
may also mask a decline in functioning such that patients with more severe 
concomitant physical and neuropsychological impairments are unable to 
complete the assessments. Fortunately, efforts have been made in recent years 
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to modify and develop novel assessment tools to account for motor speed in ALS. 
  
The ECAS was designed specifically for ALS and is independent of motor 
speed. The ECAS measures cognitive domains commonly affected in ALS 
(executive functions, verbal fluency, language, social cognition) as well as those 
less commonly reported (memory and visuospatial functions), providing a 
comprehensive overview of cognitive functions (Abrahams et al., 2014). The 
ECAS additionally includes a caregiver behaviour interview based on diagnostic 
criteria for frontotemporal dementia. The ECAS has been successfully 
implemented in research and clinically, and has been translated and validated in 
numerous languages and demographics (Loose et al., 2016; Lulé et al., 2015; 
Mora et al., 2018; Niven et al., 2015; Pinto-Grau et al., 2016; Poletti et al., 2016; 
Ye et al., 2017). While the development and subsequent implementation of the 
ECAS has been successful in provided an accurate and rapid assessment of 
cognition and behaviour in ALS, limitations do exist.  
Recent large-scale studies have begun to suggest that neuropsychological 
functioning may decline with disease progression (e.g., Elamin et al., 2013) 
suggesting that multiple regular assessments are necessary. There are three 
methods by which cognition can be assessed serially: a) administration of two 
different tests that purportedly measure the same cognitive domain(s), b) 
administration of the exact same test(s) on more than one occasion, or c) 
administration of a test that incorporates alternate forms. 
 Administering different cognitive tests at different occasions is 
problematic. The interpretation of change is limited and tests must be chosen 
which purportedly measure the exact same cognitive domain, in the same way, 
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and to the same degree. This method therefore assumes the presence of multiple 
competing but complementary assessment tools, which is not the case in ALS. 
The second method, administering the same cognitive test serially, suffers its 
own problems. Presenting patients with the same cognitive test more than once 
increases the well documented risk of practice effects, in which patients’ 
performance improves over time due to learning test content or test-taking 
strategies. As with most cognitive tests, the ECAS has shown to have practice 
effects with repeated administration of up to one year (Burkhardt et al., 2017). 
These practice effects are problematic in that they provide an exaggerated 
estimate of current functioning, and may mask a decline longitudinally. Indeed, 
Burkhardt et al. (2017) found that practice effects with repeated administration of 
the ECAS were present for control participants but not for patients, which implies 
that patients may have declined over the study period but that this decline was 
obscured. It is possible to correct for practice effects statistically, assuming 
sufficient variability in scores and the presence of a representative control group. 
Unfortunately, ceiling effects exist within a small number of ECAS domains 
resulting in an inability to correct for practice effects statistically i.e., data cannot 
be accurately corrected statistically when censored. As such, the best option for 
repeated assessment in ALS is to develop alternate versions of the ECAS.  
 
7.1.1. Summary of findings and discussion 
A primary aim of this research was to develop alternate forms of the ECAS to 
accommodate repeated serial testing in ALS. Two alternate forms of the ECAS 
(B and C) were developed. The alternate forms of the ECAS were administered 
to five independent groups of healthy adults. One of these groups was used to 
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pilot and select appropriate stimuli, two were utilised to establish normative data, 
and two to evaluate the relative practice effects of using the same versus different 
versions of the ECAS. The findings of this study provided strong evidence of the 
equivalence of the alternate forms to the original ECAS-A, and in validating the 
amelioration of practice effects when using the alternate versions.  
 When administered to independent groups, matched by age, gender, and 
education to the control sample used in the ECAS validation study (Niven et al., 
2015), all three ECAS forms were statistically equivalent. Indeed, no significant 
differences observed in domain scores, with Bayesian statistics provided 
evidence in favour of the null hypothesis (i.e., that the different forms come from 
the same sample). Cut-off scores demonstrated parity across versions and as 
such, with ECAS-A cut-off scores were retained for the alternate forms. 
Furthermore, significant practice effects were observed in using the ECAS-A 
serially whereas no significant improvement was found when using different 
versions. Finally, inter-rater reliability for all three versions of the ECAS was found 
to be excellent, suggesting that with appropriate training highly similar scoring 
outcomes are observed. These findings provide strong proof-of-concept evidence 
for the use of the ECAS in serially assessment. While this was an important step, 
to enable the interpretation of change on a case-by-case basis, further research 
was necessary.  
 Reliable change indices are statistical methods which evaluate normal 
variation over time (test-retest reliability, measurement error) and provide cut-offs 
for significant change (two-tailed 90% confidence interval). A further sample of 
healthy adults were recruited and administered the alternate forms of the ECAS 
over a clinically relevant interval of 4 months. Test-retest reliability was found to 
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be good over this interval (i.e., the majority of subtests scoring .70 or above) and 
again, no significant practice effects were observed. Four metrics of change were 
calculated (two reliable change indices and two regression-based methods) with 
cut-off values for all four methods provided. Given the similarity across the four 
methods, conservative recommendations for clinical use were provided i.e., a 
change of  8,   4, and   9 for ALS-Specific, ALS Non-Specific, and ECAS Total 
Score constitutes a statistically reliable change.  
 
7.1.2. Comparison to previous cognitive tests incorporating alternate forms   
Alternate forms have been developed for a limited number of common 
neuropsychological tests, including the Wechsler Memory Scale (Margolis, Dunn 
& Taylor, 2001; Sullivan, 2005), Symbol Digit Modalities Test (Benedict et al., 
2012; Hinton-Bayre & Geffen, 2005), Trail Making Test (Wagner et al., 2011), 
Montreal Cognitive Assessment (Costa et al., 2012), Neuropsychological 
Assessment Battery (Yochin, Kane & Muller, 2009); Zgaljardic et al., 2013), and 
Rey Auditory Verbal Learning Test (Ryan et al., 1986). However, the methods 
used to evaluate the properties of these alternate forms has been inadequate and 
the methodological design implemented in the development of the ECAS-B and 
ECAS-C was intended to overcome these limitations. 
The process by which alternate stimuli have been develop in other 
cognitive tests are rarely, if ever, reported. The evidence-based development of 
alternate stimuli for the ECAS was conducted through painstaking consultation 
and piloting processes in which the linguistic, physical, and cognitive 
characteristics of items were considered (see Appendix II for summary). Alternate 
forms have also largely been studied using undergraduate students (Sullivan, 
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2005), or using clinical populations such as depression (Ryan et al., 1986; 
Wagner et al., 2011), substance abuse (Ryan et al., 1986), neurodegenerative 
disease (Benedict, 2005; Costa et al., 2012b; Margolis, Dunn, & Taylor, 2001), 
and concussion (Hinton-Bayre & Geffen, 2005). This is problematic owing to the 
fact that the psychometric properties of a test (i.e., the equivalence of alternate 
forms) should be based on normal healthy performance and variation. The unique 
characteristics of different clinical syndromes limits the generalisability of a tests’ 
psychometric properties to the cohort studied, and rarely are matched control 
groups included. Furthermore, some clinical populations would be expected to 
decline progressively and therefore confound the trajectory of data over repeated 
assessments. It is for these reasons that the ECAS was standardised on a 
sample of healthy older adult who reflect the demographic characteristics of ALS 
patients.  
Most previous studies only include a single repeat testing group where 
participants are assessed serially. Alternate form equivalence cannot be 
determined from such a design due to the potential that some forms are more 
difficult (i.e., score reduction) but that practice effects persist (i.e., score increase) 
which statistically cancel each other out. In the ECAS, the alternate forms were 
presented to multiple independent groups who either completed a single version 
of the ECAS or multiple ECAS forms serially. For the groups who completed one 
ECAS form, no significant differences were observed across forms and for the 
group who completed the ECAS forms serially, no significant difference was 
observed between forms.  
In addition to methodological oversights, very little previous research 
performed accurate statistical analysis. Commonly, Pearson correlation 
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coefficients (e.g., Yochin, Kane & Muller, 2009; Zgaljardic et al., 2013), t-tests 
(e.g., Costa et al., 2012b), and ANOVAs (e.g., Sullivan, 2005; Wagner et al., 
2011) are used as evidence of equivalence. However, this is a fundamental 
misunderstanding of Null Hypothesis Significance Testing (NHST). NHST is 
based on the rejection or rejection failure of the null hypothesis and does not 
directly test the null hypothesis. In other words, a failure to reject the null 
hypothesis is not evidence for the null hypothesis. Most studies falsely claim that 
a non-significant t-test or ANOVA demonstrates alternate form equivalence. 
Furthemore, correlation coefficients do not demonstrate equivalence. 
Correlational analysis simple measures the strength of a relationship, not 
equivalence. For instance, if one test form is consistently more difficult than an 
alternate test form, these two will possess a high correlation despite potentially 
large mean differences. Finally, the majority of statistical tests used previously 
are comparisons of means. While this is an important metric, it does not measure 
distributional differences such as skew and kurtosis. Theoretically, two test forms 
could possess the same mean score but with differences in standard deviation 
and distribution shape. The statistical analyses conducted for the ECAS were 
chosen to overcome these limitations. ANOVA was implemented to evaluate 
whether significant differences exist in mean scores; Kolmogorov-Smirnov tests 
were implemented to determine whether significant differences exist in 
distributional shape; and Bayesian statistics were used to directly test the 
evidence in favour of the null hypothesis.  
Thus, the methodological design of developing ECAS alternate forms 
overcomes the limitations present with other measures. Strong evidence of 
equivalence exists between forms, in addition to strong evidence that the forms 
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ameliorate practice effects in repeated assessment. Therefore, the ECAS-A-B-C 
provide an accurate and reliable method in measuring cognition in ALS 
longitudinally, and in interpreting change on a case-by-case basis.  
 
 
7.2. Cognition across the ALS disease course 
The question as to whether cognition and behaviour declines over the course of 
the disease in ALS has been unresolved. Small sample sizes and attrition reduce 
the power to detect mild changes, and not controlling for attrition results in only 
the healthiest participants remaining in the study (e.g., Elamin et al., 2013). 
Inappropriate disease metrics result in confounded measurement of cognition 
and a non-linear and variable measure of progression. Short test-retest intervals 
and limited follow-up occasions reduce the possibility of observing disease 
progression. The present study combined specific and standardised measures of 
cognition, behaviour, and disease progression to overcome issues with previous 
ALS studies. Participants were tested on four occasions every four months to 
maximise the possibility of detecting disease progression. The median disease 
duration for ALS is three years, and diagnosis occurs after approximately 12 
months (Al-Chalabi & Hardiman, 2013). As such, a one year testing period 
represents approximately 50% of the remaining median disease course after 
diagnosis.  
Cross-sectionally, neuropsychological functions were seen to relate to 
disease stage, with patients in more advanced disease presenting with worse 
cognitive and behavioural symptoms. Specifically, verbal fluency, apathy, loss of 
sympathy and empathy, perseveration, disinhibition, and hyperorality were more 
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impaired in later disease stages. This observed relationship was mediated or 
moderated by the presence of bulbar symptoms. Contrary to previous reports, 
bulbar onset patients were not more likely to have cognitive impairment, rather, 
the presence of bulbar features was an important factor. This may explain the 
inconsistently with which bulbar-onset has been linked with cognitive and 
behavioural impairment. Previous studies were confounded by the presence of 
patients with bulbar involvement in groups of spinal onset patients. As such, the 
onset of bulbar features in ALS may represent a unique turning point in the 
disease course. Current staging systems in ALS do not incorporate cognition and 
behaviour, however, the evidence here suggest that neuropsychological 
functioning should be an important consideration in future systems. Alternatively, 
or in addition, neuropsychological functioning may be included in functional rating 
scales such as the ALSFRS-R. Cognitive/behavioural impairment may simply 
represent an additional ‘region’ (in addition to upper limb, lower limb, bulbar, and 
respiration/nutrition) expanding King’s staging to 5 stages. In such a case, a 
patient with cognitive impairment and bulbar involvement would be in Stage 2, 
progressing to Stage 5 at the onset of respiratory insufficiency.  
However, given the decline in neuropsychological function, cognitive and 
behavioural stages reflective of impairment severity (e.g., mild, moderate, 
severe/FTD) may be practical. One study examined behavioural disease stages 
in ALS patients using the Frontotemporal Dementia Rating Scale (Hsieh, Lillo, 
Kiernan, Hodges & Mioshi, 2013). ALS patients’ behavioural stages (30.8% mild, 
63.1% moderate, and 6.2% severe) corresponded poorly to the ALSFRS-R 
suggesting that motor and neuropsychological symptoms progress at different 
rates requiring the assessment of both. The King’s Clinical Disease Stage could 
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be expanded in an ‘ABC’ manner (i.e., A = ALS disease stage, B = Behavioural 
impairment, C = Cognitive impairment). For instance, a patient in King’s Clinical 
Stage 2 with mild cognitive impairment and no behavioural features would be 
classified as A2B1C0. How such a system would relate to the disease course as 
per Roche et al. (2012) remains to be seen.  
Longitudinal results corroborate the findings of our cross-sectional 
analysis. ECAS Total, ALS Specific, and fluency were shown to decline 
significantly over the course of the study. Latent growth curve models (LGCMs) 
that accounted for non-random attrition were utilised, with attrition predicted by 
disease severity and neuropsychological impairment. As such, the analysis in this 
study was the first to produce unbiased estimates of change which has been 
lacking previously. This is evidenced by examination of the raw scores of patients 
over time which, when unadjusted, suggests no change or even improvement 
over time. Furthermore, no study to date has used neuropsychological 
evaluations that are not biased by motor impairment or practice effects. The 
development and utilisation of the ECAS alternate forms reduces the potential for 
practice effects, pervasive in many previous longitudinal studies.  
While the observation of a significant decline in cognitive functioning over 
time is important in its own right, of value is the relationship observed between 
longitudinal neuropsychological functioning and disease stage. Disease duration 
(i.e., time), is of little clinical value in prognosis of patients with ALS. Disease 
stage, conversely, is a standardised metric which is not dependent on time, but 
represents a measure of each persons’ disease course. When disease stage was 
modelled, it captured and explained the effect of time with all cognitive and 
behavioural domains significantly affected. As with the cross-sectional analysis, 
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ALS Specific and Non-Specific functions reacted to disease stage differently. ALS 
Specific functions declined with disease stage early and quickly, while ALS Non-
Specific functions declined more slowly and were dependent on baseline 
performance. Longitudinal data, when re-organised to directly assess the effect 
of disease stage, resulted in similar findings as our cross-sectional analysis. 
ECAS Total, ALS Specific, and behavioural features were found the decline 
linearly with disease stage. Of novelty however, ALS Non-Specific functions were 
longitudinally related to disease stage quadratically. This is explained by a 
‘turning point’ at Stage 3 to Stage 4 re-iterating the importance of end-stage 
disease, and therefore respiratory involvement, in ALS Non-Specific trajectories.  
Additional relationships were found between baseline ALS Specific 
neuropsychological functioning and age of onset, years of education, and the 
presence of the C9of72 expansion. Longitudinal decline was additionally related 
to these variables, however, years of education was predictive of behavioural, 
rather than cognitive decline. As such, these variables represent risk factors for 
worsening cognitive and behavioural performance, even after accounting for 
disease stage. The relationship between education, C9orf72 status, and ALS 
specific neuropsychological functions has been previously suggested. For 
example, Beeldman et al. (2016) found that fewer years of education was related 
to impairment in executive functioning, while the presence of C9orf72 repeat 
expansion has been consistently related to worse cognitive and behavioural 
performance (e.g., Byrne et al., 2012; Ratti et al., 2012; Snowden et al., 2013). 
ALS Non-Specific functions were less dependent on model covariates, 
suggesting that they are perhaps secondary to ALS Specific functions, or 
dependent largely on advancing disease processes. The current findings 
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reiterate the role that the C9orf72 expansion plays as a risk factor in ALS specific 
cognitive and behavioural decline. The significant effect of education on baseline 
levels and decline in behavioural functioning possibly indicate behavioural 
reserve (Kaplan et al., 2009; Premi et al., 2013; Stern, 2009).  
Cross-sectionally in Stage 4, 80% of our patients experienced cognitive or 
behavioural impairment, while re-organisation of longitudinal data similarly found 
72% of Stage 4 patients impaired. This point has important clinical implications. 
Stage 4 is defined by the need for nutritional or respiratory intervention. At this 
point in the disease, numerous important disease-specific decisions are expected 
of people with ALS, including life-prolonging interventions and power of attorney. 
ALS patients are regularly recruited into research studies, including clinical trials, 
and asked to make decisions about genetic testing. However, given the rates of 
cognitive and behavioural impairment present in ALS, the ability to make such 
decisions has yet to be fully explored, nor whether cognitive and behavioural 
impairment affects initiation of and adherence to medical intervention. The UK’s 
Mental Capacity Act (Department of Health, 2005), and more recently, the Irish 
Assisted Decision-Making Act (Health Service Executive, 2015) describe 
decision-making capacity as the ability to understand, retain, use, and 
communicate information. These abilities rely on the neuropsychological domains 
of memory, executive functioning, and language abilities. The prevalence of 
impairment in these domains in ALS raises concerns as to patients’ ability to 
make and communicate decisions and engage appropriately with medical care 
and research. 
Paradoxically however, decisions about medical treatment are often made 
when patients are least likely to be capable of making such decisions. 
 
 240
Behavioural change, in particular apathy (Caga et al., 2016), and cognitive 
change, in particular executive dysfunction (Elamin et al., 2011), have shown to 
be negative prognostic indicators in ALS, with a reduction in survival time of 
approximately one year. While this may suggest that neuropsychological 
impairment represents an ALS phenotype with a more rapid disease course, it is 
also possible that cognitive and behavioural impairments are moderating the 
disease course by affecting the uptake of medical treatments, or the adherence 
to recommendations. ALS patients have been shown to be less compliant with 
respiratory and nutritional interventions (Olney et al., 2005; Martin et al., 2014; 
Chio et al., 2012) and less able to schedule medication use (Stukovnik et al., 
2012). These results highlight the potential impact that declining cognitive 
impairment can have on intervention engagement, compliance, and survival; 
however, this area has yet to be robustly investigated. These results call into 
question the implications of neuropsychological impairment on patients’ ability to 
negotiate social, medical, and legal aspects of their illness. Clinicians should 
therefore be cognizant of the effect that disease stage has on neuropsychological 
functioning, particularly in patients testing positive for the C9orf72 expansion, and 
the effect this may have on medical decision making and treatment compliance.  
The patterns observed cross-sectionally and longitudinally suggest a 
different pattern of change for different cognitive domains, such that functions 
typically associated with the prefrontal cortex (e.g., verbal fluency) decline at 
Stages 2-3, whereas temporal-lobe mediated functions (e.g., memory) decline at 
Stages 3-4. This pattern follows the same neuropathological staging suggested 
by Brettschneider et al. (2013). Here, TDP-43 depositions in the prefrontal cortex 
were described in Stage 3 while pathological depositions in the hippocampus 
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were described in Stage 4. The pattern in our results may reflect underlying 
pathological disease spread expressing as cognitive dysfunction. The King’s 
Clinical Disease Staging may be temporally related to pathology such that the 
King’s Stages occur at similar times to the pathological stages. However, without 
corresponding imaging data this hypothesis cannot be tested.  
 
 
7.3. Clinician’s attitudes to neuropsychological screening 
As previously noted, cognitive and behavioural impairment have important clinical 
implications to patients with ALS and their caregivers. Behavioural symptoms in 
ALS have been associated with increased caregiver burden (Andrews et al., 
2017; Chiò et al., 2010), quality of life and depression (Chiò, 2010), activities of 
daily living (Mioshi et al., 2012), and relationship intimacy (Goldstein et al., 1998), 
over and above the impact of physical disability (Lillo et al., 2012b; Tremolizzo et 
al., 2016). While little research has been conducted on the impact of cognitive 
impairment, Goldstein, Atkins and Leigh (2002) found that subjective cognitive 
lapses negatively impact patients’ quality of life. Furthermore, cognitive and 
behavioural impairment has been linked to negative medical outcomes, including 
worse prognosis and reduced uptake and adherence to medical interventions 
(e.g., Caga et al., 2016; Chiò et al., 2012; Elamin et al., 2011; Martin et al., 2014; 
Olney et al., 2005). Given the impact that neuropsychological impairment can 
have on the ALS disease course and psychological health of patients and their 
families, surprisingly little research is available on clinicians’ attitudes and 
practices toward screening. The aim of this study was a first step in addressing 




7.3.1. Summary of results and discussion 
Participants of this study (Neurologists, Psychologists, and Clinical Care 
Specialists) noted that cognitive and behavioural screening in ALS is important in 
providing holistic person-centred care and in relation to decision making capacity. 
Indeed, all but one participant noted that screening should be standard practice 
to all patients. In contrast, less than half of participants stated that they always 
screen for neuropsychological symptoms, and when screening does occur, the 
majority of clinicians use their clinical judgement. However, there exists no 
evidence as to the accuracy of clinicians’ judgement in assessing 
neuropsychological impairment. Certainly, evidence from other areas would 
suggest that clinical judgement has poor accuracy in detecting cognitive 
impairment.  
Bouwmans and Weber (2012) examined the accuracy of neurologists’ 
evaluation of cognitive impairment against a formal neuropsychological 
assessment in Parkinson’s disease. The authors found that the sensitivity of 
neurologists in detecting cognitive impairment was low (33%), the agreement 
between neurologists was .74 (Kappa value), and the agreement between 
neurologists and patients’ own evaluations was low (Kappa = .39). In a meta-
analysis of available literature, Mitchell, Meader and Pentzek (2011) examined 
GP’s ability to recognise cognitive impairment from clinical judgement. The 
accuracy in the recognition of dementia against a formal diagnostic interview was 
73%. However, this reduced to 45% for mild dementia or mild cognitive 
impairment. Against a formal neuropsychological assessment, sensitivity of 
clinical judgement was 63% with 93% specificity. Therefore, while detection of 
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neuropsychological impairment in the extremes was reasonably accurate, in 
cases of milder impairment, clinicians’ accuracy was poor. This is important given 
the predominantly mild cognitive and behavioural impairment observed in ALS.  
Participants in the present study noted important barriers to cognitive and 
behavioural screening, specifically, that other members of staff held negative 
attitudes to screening. Negative attitudes were commonly attributed to 
neurologists, which poses a difficulty given the neurology-led services present in 
the UK health service.  
Additional barriers include a lack of resources such as time, staffing, 
training, and appropriate assessment tools. As such, clinicians report that 
cognitive and behavioural screening is not common practice in ALS care services, 
that clinicians hold negative attitudes toward screening, prefer to use their 
judgement, but that this judgement is likely inaccurate. This is particularly 
pertinent given the findings presented in Chapters 4 and 5, which suggest that 
cognitive and behavioural impairment declines over the course of the disease. If 
clinicians are not measuring or accurately detecting impairment, and this 
impairment is progressive, it is unlikely that the cognitive and behavioural needs 
of patients with ALS and their families are being met through current clinical 
practice. Furthermore, if cognitive and behavioural impairment interacts 
negatively with medical care, it is possible that the care that is provided is being 
undermined. Given the ubiquity with which the ECAS and other screening 
instruments are present in the literature, there is a discord here between 
availability of assessment tools and clinicians’ knowledge. Participants believed 
that increasing education, psychology input, and making screening standard to 
all patients would help overcome these barriers. However, the availability of the 
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ECAS and its ongoing development already provides an avenue for increasing 
assessment procedures. Perhaps, better promotion and training of the ECAS 
would help increase the frequency and improve the methods by which cognitive 
and behavioural health is addressed clinically.  
 
 
7.4. Strengths, limitations, and future directions 
The present research is the first to explore cognitive and behavioural change 
longitudinally. However, the cognitive and behavioural features in ALS remain 
heterogeneous and more work is needed to understand why some patients 
experience neuropsychological deficits while others do not. The present findings 
of a decline in cognitive and behavioural functioning across a standardised metric 
of disease progression is novel. However, not all patients presented with 
cognitive or behavioural impairment. Patients who do and do not experience 
neuropsychological impairment may possess distinct neural correlates or 
patterns of progression; for instance, whether ALS begins in the prefrontal cortex 
and spreads in a caudal fashion toward to motor cortex. Indeed, the present study 
demonstrated that cognitive and behavioural impairment can occur very early in 
the disease, potentially before the onset of motor symptoms. Neuroimaging 
studies, combining staging and the ECAS may elucidate subgroups which are yet 
unidentified, in addition to explaining the involvement of ALS non-specific 
functions. 
Studies exploring the atypical presentation of cognitive dysfunction are 
relatively uncommon, particularly concerning memory and visuospatial 
functioning. Degeneration of the temporal lobes support this proposition (see 
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Chiò et al., 2014), in addition to pathological observations of hippocampal 
involvement in end-stage disease (Brettschneider et al., 2013). Alternatively, 
respiratory dysfunction resulting in hypoxia may also impact memory functions in 
late-stage patients. While the effect of respiratory insufficiency in ALS has 
previously been examined (Newsom-Davis et al., 2001), the evidence is lacking 
and no real progress has been made in almost two decades. Therefore, the 
impact of respiratory function on cognition and behaviour may explain some of 
the observed heterogeneity. The findings herein suggest that memory functions 
may be compromised, particularly in end stage disease, and predicted by 
baseline ability. Further research is required, which does not explicitly exclude 
end-stage patients, in order to profile the late-stage cognitive and behavioural 
changes associated with ALS. Moreover, it is possible that memory and 
visuospatial deficits are largely due to a cross-over effect from other cognitive 
domains. The degree to which cognitive domains are affected by primary deficits 
in ALS specific functions (e.g., executive functioning, language, fluency) remains 
unclear. Longitudinal studies, using appropriate and detailed cognitive tests, 
while controlling for interference from other cognitive domains are also needed. 
The overlap in cognitive and behavioural decline additionally highlights the need 
for a better understanding of the underlying mechanisms of behavioural change 
in ALS, and whether cognitive and behavioural symptoms represent truly distinct 
categories.   
The evolution of behaviour longitudinally has largely been ignored in 
research. A novelty of this research is in the examination of behaviour 
longitudinally, and the exploration of individual behavioural domains. One of the 
main difficulties in behavioural research in ALS is the imprecise way in which 
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behaviour is measured. There is a lack of high standard and externally validated 
measures of behaviour in ALS. Questionnaires suffer from imposing limitations 
to the presentation of very particular behaviour symptoms. While the ECAS 
behaviour interview overcomes this issue, interview-based assessments 
introduce researcher variability. No current scale examines an appropriately 
extensive list of behaviours, address how long behaviours have been present, 
the frequency and severity of such behaviours, and provide information on overall 
behavioural impairment and individual behaviour-specific metrics – all of which 
are of interest. It is possible that exploring the mechanisms behind behaviours, 
and the cognition-behaviour relationship, may provide more objective measures 
of behavioural function. 
Much of the literature has focused on the profile of cognitive and 
behavioural impairment, but relatively little has been done on the impact of mild 
neuropsychological dysfunction on patients’ day-to-day lives. It is understood that 
behavioural symptoms can impact caregiver burden (Andrews et al., 2017; Chiò 
et al., 2010; Tremolizzo et al., 2016), quality of life and depression (Chiò, 2010), 
and that executive dysfunction is a negative prognostic indicator (Chiò et al., 
2012; Elamin et al., 2011; Gordon et al., 2010b; Gordon et al., 2011; Hu et al., 
2013). However, the extent to which neuropsychological symptoms impact 
activities of daily living, medical decision making, or adherence to medical 
recommendations is unresolved. One study (Mioshi et al. 2012) found that 
behavioural symptoms did impact on activities of daily living, but it is not known 




An additional strength and novel aspect of this research was in controlling 
for attrition and the use of the ECAS’s alternate forms, which have biased 
previous longitudinal studies. Attrition was indeed acceptable in the present 
study, yet patients who continued participating were less likely to demonstrate 
disease progression (i.e., transitioning to more advanced stages). The bias 
introduced by attrition was controlled for using advanced structural equation 
modelling. However, the power to detect changes across disease stage was 
reduced. The ECAS and its alternate forms was chosen as it is specific to ALS 
and reduces the burden of participation, thereby minimising potential attrition and 
practice effects. Given the evidence of equivalence between forms, the 
assumption may be made that sensitivity and specificity data also transfers 
across test forms. However, future developments of the ECAS may include full 
neuropsychological validation of the alternate forms to confirm this. 
As such, the present study supports the need for timely and ongoing 
assessment of neuropsychological impairment in ALS. Yet, the practices and 
attitudes of clinicians in implementing such procedures was unexplored. The 
barriers to cognitive and behavioural screening noted in Chapter 7 may 
additionally necessitate the development of an ECAS short form, or digital test, 
to maximise its use in busy clinic environments. Conversely, there exists no 
comprehensive and internationally agreed test battery for ALS. Therefore, the 
ECAS may also benefit from extension in situations when a more detailed 
evaluation is required. Such a development may see the lengthening of current 
subtests and the inclusion of novel tasks based on research developments, while 
retaining its strength as a motor-free assessment. This may address the ceiling 
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effects present in some subdomains of the ECAS, particularly language and 




When appropriately specified models are estimated, cognitive and behavioural 
functioning are seen to decline, particularly with disease stage. Advanced 
disease stage, fewer years of education, and the presence of the C9orf72 
expansion may be considered risk factors for declining neuropsychological 
abilities. As such, decisions about medical care should be made early in the 
disease to maximise the potential for capacity. The newly developed ECAS 
alternate forms provide a method by which neuropsychological functioning can 
be measured longitudinally. However, further outreach and resources may be 
required in order to maximise the inclusion of cognition and behaviour in the 
clinical care management of patients with ALS. In doing so, the quality of care 
provided to patients and their families will be improved, and the focus of care will 
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 Cognitive Domains Measured 
Article Population Impaired Intact Exe Flu Soc Lan Mem Vis Prof 
Abrahams et 
al. (1997) 
52 ALS (24 
with 
pseudobulbar 
ALS & 28 
without) & 28 
controls 
Fluency (letter); Executive 
(planning: Tower of Hanoi; 
concept formation: WCST 
errors and categories); 
language (word recognition: 
RMT). NOTE: Impairment 
more pronounced in those 
with pseudobulbar ALS 
Memory (Paired Associates 
Learning Test, KOLT); social 
cognition (RMT); object 
memory (KOLT); Executive 
(inhibition/attention: Stroop) 




ALS & 22 
controls 
Fluency (letter and category 
- animals) 
Fluency (design, category); 
language (naming: GNT; 
word generation: Hayling 
Sentence Completion part A) 





ALS & 18 
controls 
Fluency (letter: spoken and 
written); memory (letter 
span); language (GNT) 
Fluency (category and 
design); executive 
functioning (ECST, PASAT); 
memory (Paired Associate 
Learning, Recognition 
Memory Test, KOLT); 
language (Hayling Sentence 
Completion part A); 
visuospatial (BLOT).  
       
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 Cognitive Domains Measured 
Article Population Impaired Intact Exe Flu Soc Lan Mem Vis Prof 
Ash et al. 
(2015) 
26 ALS (3 with 
FTD) & 19 
controls 
Fluency (letter); memory 
(forward digit span). ALS 
produced fewer words, more 
articulation errors, and fewer 
well-formed grammatical 
sentences. NOTE: Same 
population as ASH et al. 
(2014).  
Executive (working memory: 
Reverse digit span); 
language (BNT); fluency 
(category). No difference for 
frequency of verbs or nouns 
produced per 100 words.  
       
Burke et al. 
(2016a) 
59 ALS (20 
bulbar onset, 
39 limb onset) 
and 59 
controls 
Patients vs controls: Fluency 
(letter and category); 
executive (working memory: 
backward digit span) 
Bulbar vs Limb: social 
cognition (RME) 
Patients vs controls: 
Executive functions (Brixton 
Spatial Anticipation Test; 
Stroop); social cognition 
(Judgement of Preference 
Test; RME); memory 
(forward digit span) 
Bulbar vs Limb: Executive 
functions (Brixton Spatial 
Anticipation Test; Stroop; 
backward digit span); 
memory (forward digit span); 
fluency (letter and category); 
social cognition (Judgement 
of Preference) 
       
Burke et al. 
(2016b) 
106 ALS & 50 
controls 
Social cognition (Emotional 
recognition: RME) - 
(observed in ALS with 
concomitant executive 
dysfunction) 
         
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 Cognitive Domains Measured 
Article Population Impaired Intact Exe Flu Soc Lan Mem Vis Prof 





controls (23 for 
cognitive tests 




A; inhibition: Hayling 
sentence completion); 
fluency (VFI); social 
cognition (cognitive ToM: 
original false belief task). 
NOTE: ToM deficits 
significantly associated with 
executive functioning, and 
dorsomedial and 
dorsolateral prefrontal 
cortices using imaging 
techniques.  
Executive functions (working 
memory: letter-number 
sequencing from WAIS) 
       
Cavallo et al. 
(2011) 
15 ALS (6 with 
bulbar signs, 9 
without) & 22 
controls 
Fluency (letter); language 
(GNT); social cognition 




executive functions (Hayling 
Sentence Completion test 
part A and B; Brixton Spatial 
Anticipation); social cognition 
(ToM: RME; Story 
completion - non-social 
context). NOTE: No 
difference in ToM 
performance between 
patients with and without 
bulbar signs. 
       
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 Cognitive Domains Measured 
Article Population Impaired Intact Exe Flu Soc Lan Mem Vis Prof 








Memory (immediate and 
delayed recall, memory 
encoding and consolidation: 
RAVLT) 
Memory (retrieval: RAVLT)        




, sporadic ALS 
(19 included in 
imaging study) 
& 55 controls 
23% classified as ALSci, 9% 
as ALSbi, 4% ALScbi, 64% 
intact. Social cognition 
(emotion recognition: Ekman 
Faces - Anger, disgust). 
Findings related to right 
lateralised microstructural 
changes in white matter 
tracts connecting frontal, 
temporal and occipital lobes.  
Social cognition (emotion 
recognition: Ekman faces - 
sadness, surprise, 
happiness, fear) 
       
Cuddy et al. 
(2012) 





Task; Phelps Recall Task). 
42% impaired on emotional 
word recognition on Brierley-
Medford Sentence 
Task, 32% impaired on 
positive word recall (Phelps 
positive word recall 
task) 
Memory (immediate and 
delayed, free and cued 
recall, recognition: CVLT) 
       
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 Cognitive Domains Measured 
Article Population Impaired Intact Exe Flu Soc Lan Mem Vis Prof 
Fiori et al. 
(2013) 
23 ALS & 23 
controls 
Visuospatial (Hand Laterality 
Task) 
Visuospatial (Mirror letter 
discrimination task) 









Social cognition (ToM: 
cartoons and stories, mental 
and physical conditions). 
NOTE: Social cognition 




memory (Hopkins Verbal 
Learning); executive 
(concept formation: WCST); 
fluency (letter) 
       
Girardi et al. 
(2011) 
Study A: 19 
non-demented 
sporadic ALS 
& 20 controls 
Study B: 14 
non-demented 
sporadic ALS 
& 20 controls 
Study A: Executive functions 
(affective decision making: 
IGT). NOTE: Affective 
decision making related to 
behavioural executive 
dysfunction (FrSBe) 
Study B: Memory 
(immediate recall: WMS); 
language (GNT); social 
cognition (ToM: Judgement 
of preference Task - social 
condition; emotion 
recognition: Facial 
Expressions of Emotions 
Test) 
Study A: Language (GNT); 
fluency (letter) 
Study B: Memory (delayed 
recall - WMS, KOLT); 
executive (inhibition: Hayling 
Sentence Completion; 
Brixton Spatial Anticipation 
Test); fluency (letter); social 
cognition (ToM: Judgement 
of preference Task - control 
condition; emotion 
recognition: RME - marginal) 
       
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Cognitive impairment at 
35.3%. Composite action 
and object word abilities 
generated (matching 
verb/noun with appropriate 
picture and matching 
verbs/nouns with 
description). ALS performed 
poorly on measures of action 
knowledge relative to noun 
knowledge.  
         
Hammer et 
al. (2011) 
20 ALS & 20 
controls  
Language (WAIS vocabulary 
subtest); fluency (Ruff 
Figural: strategies, letter) 
Executive functions (working 
memory: digit span, reading 
span; concept formation: 
WCST; attention/inhibition: 
TAP) 




ALS & 13 
controls 
Executive functions (working 
memory/attention: backward 
digit span, Continuous 
Performance Test; Delayed 
Recognition Test, Serial 
Digit Learning Test, Stroop, 
Trail Making B-A); fluency 
(letter and category); 
Language (BNT); Memory 
(delayed recall: CVLT); 
Visuospatial (BLOT, WAIS 
Block Design) 
Memory (forward digit span; 
immediate recall, intrusions, 
recognition: CVLT, face 
recognition: Benton Facial 
Recognition) 
       
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 Cognitive Domains Measured 
Article Population Impaired Intact Exe Flu Soc Lan Mem Vis Prof 
Hartikainen 
et al. (1993) 
24 ALS, 22 
PD, & 26 
controls 
ALS vs controls: visuospatial 
(Digit Symbol and Block 
Design); executive functions 
(attention/switching: TMT A- 
B); memory (list learning, 
immediate story recall) 
ALS vs controls: memory 
(delayed story recall); fluency 
(category) 
       
Kasper et al. 
(2015) 
98 ALS & 70 
controls 
41.4% cognitively impaired 
based on Strong Criteria. 
Most common impairment in 
executive functioning: 
shifting (TMT, fluency letter 
and category); initiation 
(fluency letter and category); 
memory (learning: Verbal 
Learning and Memory Test, 
CVLT) 
        
Kasper et al. 
(2016) 






19.35% cognitively impaired, 
4.3% ALS-FTD, 65.59% 
unimpaired.  
        
Lange et al. 
(2016) 
20 ALS (1 with 
FTD) & 21 
controls 
Executive functions 
(perseverative and rule 
errors: WCST) 
FAB, ECAS (ALS Specific 
and ALS Non-Specific); 
Executive Functions (WCST: 
total score) 
       
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 Cognitive Domains Measured 
Article Population Impaired Intact Exe Flu Soc Lan Mem Vis Prof 
Lepow et al. 
(2010) 






13 were intact, 
17 mild 
impairment, 7 
FTD) & 25 
controls 
ALS vs Controls: Fluency 
(letter & category fluency 
total score).  
ALS intact vs ALS mild vs 
ALS-FTD: difference in letter 
and category fluency, 
number of clusters and 
switches for letter fluency, 
size of clusters for semantic 
fluency. Impairment shows 
gradient in line with cognitive 
grouping.  
ALS intact vs ALS mild vs 
ALS-FTD: size of cluster for 
letter fluency, number of 
clusters and switches for 
category fluency 
       
Leslie et al. 
(2015) 
36 ALS (19 
with ALS-
FTD); 22 SD, 
& 26 controls 
ALS vs Controls: ACE-R 
(Attention; memory; fluency 
VFI; language) - SYDBAT 
(naming; comprehension) 
ALS-FTD vs Controls: ACE-





ALS vs ALS-FTD: ACE-R 
(attention; memory; fluency); 
SYDBAT (naming; 
comprehension; semantic 
associations). NOTE: 35.7% 
ALS and 78.9% ALS-FTD 
had semantic impairment.  
ALS vs Controls: ACE-R 
(visuospatial); SYDBAT 
(semantic associations) 
ALS-FTD vs Controls: ACE-
R (none) 
ALS vs ALS-FTD: ACE-R 
(visuospatial) 
       
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 Cognitive Domains Measured 
Article Population Impaired Intact Exe Flu Soc Lan Mem Vis Prof 
Libon et al. 
(2012) 
41 ALS 
Executive functions (concept 
formation: D-KEFS free and 
recognition sorting) 
         
Lillo et al. 
(2012) 
20 ALS, 20 
FTD, 20 
controls 
ALS vs Controls: Executive 
functions (Inhibition: Hayling 
Sentence Completion Test; 
decision making: IGT) 
ALS vs FTD: inhibition 
Executive functions (Hayling 
Test) 
FTD vs Controls: executive 
functions (working memory: 
digit span backward; 
inhibition: Hayling Test; 
decision-making: IGT); 
emotional recognition  
ALS vs Controls: Executive 
functions (working memory: 
Digit span backwards; 
decision-making: Iowa 
Gambling)); social cognition 
(emotion recognition: Ekman 
faces - marginal) 
ALS vs FTD: executive 
functions (working memory: 
digit span backwards; 
decision-making: IGT); social 
cognition (emotion 
recognition: Ekman faces - 
marginal) 
FTD vs Controls: executive 
functions (decision making: 
initial trials of IGT) 
NOTE: No effect of site of 
onset 
       
Lulé et al. 
(2005) 
12 sporadic 
ALS & 18 
controls.  
Fluency (design); processing 
speed (SDMT); social 
cognition (emotional 
processing: international 
Affective Picture System - 
increased positivity, reduced 
arousal)  
Fluency (letter); executive 
functions (concept formation: 
WCST) 
       
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 Cognitive Domains Measured 
Article Population Impaired Intact Exe Flu Soc Lan Mem Vis Prof 
Machts et al. 
(2014) 




ALS vs Controls: fluency 




ALS vs MCI: visuospatial 
(ROCFT) 
ALS vs Controls: executive 
functions (working memory: 
digit span backwards; 
cognitive flexibility: TMT B-
A); memory (learning, 
immediate and delayed 
recall: RAVLT; digit span 
forward) 
ALS vs MCI: fluency (letter 
and letter alternation); 
cognitive flexibility (TMT B-
A); working memory (digit 
span backward); memory 
(RAVLT: learning, delayed 
and immediate recall, 
recognition; digit span 
forward) 
       
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Based on normative 
percentiles, patients scored 
the lowest on verbal fluency 
(FAS), immediate recall 
(CVLT) and attention (VSAT 
time to complete). 
Performed relatively well on 
recognition memory (CVLT). 
35.6% performed below 5th 
percentile on at least two 
measures. Dysarthria, 
functional ratings (despite 
similar duration), lower 
education, higher premorbid 
IQ, and lower ALS motor 
score related to cognitive 
impairment.  
NOTE: No significant 
difference between 
cognitively impaired and 
intact was found for age, 
gender, symptom duration, 
respiratory dysfunction 
(though difference in score); 
or depression.  
       




& 18 controls 
Social cognition (ToM: Faux 
pas test - social conditions 




(functional decision making: 
Holiday Apartment Task - 
most difficult condition only); 
fluency (letter and category) 
Social Cognition (ToM: Faux 
pas test - control 
comprehension conditions); 
Executive (Probabilistic 
Reversal Learning Test)  
       
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12.6% ALS-FTD; 19.7% 
executive impairment; 5.5% 
had non-executive cognitive 
impairment; 6% had 
behavioural impairment; 6% 
with non-classifiable 
cognitive impairment. NOTE: 
Patients with FTD & those 
with executive impairment 
had higher proportion of 
bulbar onset. ALS-FTD 
associated with lower 
education.  Survival was 
lowest for FTD or non-
executive impairment (1.9 
years and 2 years 
respectively) compared to 
behavioural impairment (3 
years); cognitively intact (3.1 
years) and executive 
impairment (2.6 years) 
No group differences were 
observed with FVC or 
ALSFRS-R. However, 
severity of bulbar symptoms 
on the ALSFRS-R was lower 
in ALS-FTD group. 
       




Possible FTD per cognitive 
impairment detected in 6.5% 
of ALS. Non-FTD cognitive 
impairment found in 54.2%.  
Cognitive function not 
associated with ALSFRS-R 
or respiratory function, 
emotional lability, or site of 
onset.  
       
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Article Population Impaired Intact Exe Flu Soc Lan Mem Vis Prof 
Palmieri et al. 
(2009) 
32 ALS, 6 
PLS, 1, PBP, 1 




Memory (visual: Corsi block 
tapping) 
Memory (digit span forward, 
prose story); executive 
functions (working memory: 
digit span backward; concept 
formation: WCST; 
attention/switching: TMT); 
fluency (letter and category) 
       




ALS & 10 
controls 
ALS demonstrated no 
enhancement for 
remembering unpleasant 
words compared to controls 
Executive functions (Trail 
Making B-A; digit span 
backward; WCST); memory 
(digit span forward; Corsi 
blocks; word recognition 
memory test; prose memory 
test); language (BNT; Token 
Test); visuospatial (ROCFT); 
fluency (letter & category) 
       




& 27 controls  
Fluency (letter and 
category); numerical 
calculations 
Executive (switching: TMT-A, 
TMT-B, TMT-A/B; working 
memory: digit span 
backward); memory (Prose 
story, digit span forward); 
language (BNT) 
       




& 20 controls 
Social cognition (Emotion 
memory i.e., enhancement 
for emotionally charged 
material: The Sentence 
Task) 
Social cognition (emotion 
recognition with Ekman's 
Faces, ratings of 
approachability) 
       
 
 303 
 Cognitive Domains Measured 
Article Population Impaired Intact Exe Flu Soc Lan Mem Vis Prof 
Pettit et al. 
(2015) 
30 ALS (26 





Memory (immediate and 
delayed recall and 
recognition logical memory, 
digit span forward - WMS); 
executive functions (working 
memory: digit span 
backward divided attention: 
digit span backward, 
experimental dual-task 
paradigm); fluency (letter & 
spoken) 
Language (Graded Naming); 
visuospatial memory (spatial 
span forward and backward 
from WMS); fluency (written); 
executive (Brixton Spatial 
Anticipation Test; processing 
speed (Visual Inspection 
Time Test; Rapid Serial 
Letter Identification Task) 
       
Phukan et al. 
(2012) 
160 ALS & 110 
controls 
Entire cohort: 28% cognitive 
impaired, 14% ALS-FTD. Of 
those with cognitive 
impairment, differences in 
executive functioning, 
language functioning, and 
memory functioning 
compared to controls. 
Executive dysfunction 
associated with disease 
progression, older age, 
lower education and 
premorbid IQ. Letter fluency 
was the most sensitive task 
to executive impairment, 
with 93.8% of patients with 
executive dysfunction also 
demonstrating verbal fluency 
dysfunction.  
The frequency of non-
executive cognitive 
impairment between patients 
and controls was not 
significant. 
       
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ALS & 20 
controls 
Fluency (letter and design); 
executive functions 
(selective attention: TAP - 
incompatibility task).  
Executive functions 
(selective attention/inhibition: 
Stroop task); fluency 
(category) 





(3 familial) & 
21 controls 
Memory (Immediate prose 
recall impaired in 23% 
RBMT, story recall subtest); 
executive functions (letter-
number sequencing, Stroop 
- colour naming only); 
fluency (letter); language 
(BNT).  
Executive (working memory: 
digit span forward and 
backward; concept formation: 
WCST); fluency (category); 
memory (visual: Doors A and 
B; verbal: RBMT, 15 words 
test); visuospatial functioning 
(JOLO) 
       
Ringholz et 
al. (2005) 
279 ALS & 129 
controls 
Cluster analysis showed that 
49% of patients and 95% of 
controls were 'intact', 32% of 
patients had mild 
impairment, and 19% had 
moderate-severe cluster. 
Errors in tests of attention 
and working memory 
accounted for 50% of the 
variance between groups, 
with visual recall accounting 
for 16%, and naming adding 
2% to the model. 43 patients 
held a diagnosis of 
dementia. Patients with 
cognitive impairment were 
more likely to have 
dysarthria 
Site of onset was not 
significant between groups.  
       
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Article Population Impaired Intact Exe Flu Soc Lan Mem Vis Prof 
Savage et al. 
(2014) 
29 ALS (16 
with FTD); 25 
FTD, & 30 
controls 
FTD (with or without ALS) 
showed deficits on social 
cognition (emotion 
recognition: Ekman Faces; 
Awareness of Social 
Inference Test). Differences 
on negative emotions anger, 
disgust, fear, sadness. 
Sadness (FTD-ALS group 
only)  
ALS without dementia 
showed no social cognitive 
deficit on any measure or 
emotion 
       
Schmolck et 
al. (2007) 
26 ALS & 40 
controls (3 
groups 
including 14 of 
whom had 
heart failure) 
Patients with ALS rated 
faces as more approachable 
than controls. This 
specifically related to faces 
that were deemed less 
approachable than control 
groups.  





& 21 controls 
Fluency (letter); executive 
(planning: Medication 
Scheduling Task; switching: 
TMT) 
Executive (working memory: 
Tower of London; 
inhibition/attention Stroop); 
fluency (category) 
       
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Article Population Impaired Intact Exe Flu Soc Lan Mem Vis Prof 
Taylor et al. 
(2013) 
51 ALS & 35 
Controls 
Composite domains: 31% of 
patients impaired on 
executive functions, 43% on 
language.  
Executive (D-KEFS sorting; 
Brixton Spatial Anticipation 
Test errors); fluency (letter); 
language (BNT, TROG, 
KDT; Judgement of 
Synonyms Subtest from 
Psycholinguistic Assessment 
of Language Processing in 
Aphasia; British Picture 
Vocabulary Scale; Category 
Specific Names Test; Spot 
the Word Test; Graded 
Difficulty Spelling Test) 
Executive functions (D-KEFS 
description score; Hayling 
latency score); fluency 
(category); language (PPT; 
Oral and Written Naming of 
Nouns and Verbs errors; 
Cookie Theft Picture 
Complexity). NOTE: no 
relationship between 
impairment and site of onset.  
       
Tsermentseli 







excluded) & 26 
controls 
Executive functions 




complexity and fluency: 
Cookie Theft picture 
description task; Token Test, 
TROG, KDT) 
Executive functions (fluency, 
Hayling Sentence completion 
latency, WCST); memory 
(CVLT); visuospatial ability 
(JOLO, VOSP); language 
(GNT, British Picture 
Vocabulary Scale, PPT, 
Cookie Theft Task: 
proportions of verbs/nouns) 
       
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Article Population Impaired Intact Exe Flu Soc Lan Mem Vis Prof 
van der Hulst 
et al. (2015) 
33 non-
demented ALS 
& 26 controls 
Fluency (letter); language 
(GNT); ToM (judgement of 
preference). Affective ToM 
deficit in 12%, cognitive ToM 
deficit in 3%, 24% with 
combined dysfunction.  
Executive (Brixton Spatial 
Anticipation); visuospatial 
(VOSP) 
       




& 15 controls 
Executive functions (set 
shifting: WCST; selective 
attention: auditory tone 
task); memory (object and 
face recognition: RBMT) 
Executive functions (concept 
formation: WCST); language 
(verbal comprehension: 
Aachener Aphasie Test).  
       
Watermeyer 
et al. (2015) 
55 non-
demented ALS 
& 49 controls 
Composite scores: 
Executive functioning, social 
cognition. Within executive 
composite: concept 
formation (D-KEFS); fluency.  
Within social cognitive 
composite: ToM (Happé 
Stories Test). NOTE: 
Executive function predicted 
social cognition (after 
controlling for mood and 
behaviour) 
Executive functions (Brixton 
Spatial Anticipation Test); 
ToM/emotion recognition 
(The Awareness of Social 
Inference Test, Reading the 
Mind in the Eyes) 
       





& 47 controls 
Executive functions (TMT B-
A; Stroop; perseverations: 
WCST; concept formation: 
similarities of WAIS)  
Concept formation (WCST 
categories); switching 
(WCST errors). No difference 
between bulbar and spinal 
onset.  
       
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 Cognitive Domains Measured 
Article Population Impaired Intact Exe Flu Soc Lan Mem Vis Prof 
 = domain is measured in study.  
Exec = executive functions, Flu = fluency, Soc = social cognition, Lan = Language functions, Mem = Memory, Vis = Visuospatial Functions, Prof = 
cognitive profile i.e., proportion of patients impaired and/or profile of impairment.  
ACE-R = Addenbrook’s Cognitive Examination – Revised; ALSbi = ALS behaviour impairment; ALSci = ALS cognitive impairment; BLOT = Benton 
Line Orientation Test; BNT = Boston Naming Test; CVLT = California Verbal Learning Test; D-KEFS = Delis-Kaplan Executive Function System; 
ECAS = Edinburgh Cognitive and Behavioural ALS Screen; FAS = Verbal fluency with letters F, A, and S; FrSBe = Frontal Systems Behaviour 
Scale; FTD = Frontotemporal Dementia; FVC = Forced Vital Capacity; GNT = Graded Naming Test; JOLO = Judgement of Line Orientation; KOLT 
= Kendrick Object Learning Test; IGT = Iowa Gambling Test; KDT = Kissing and Dancing Test; PPT = Pyramid and Palm Trees Test 
RAVLT = Rey Auditory Verbal Learning Test; RBMT = Rivermead Behavioural Memory Test; RME = Reading the Eyes in the Mind; ROCFT = 
Rey-Osterrieth Complex Figure Test; SDMT = Symbol Digit Modalities Test; TAP = Testbatterie zur Aufmerksamkeitsprüfung; TEA = Test of 
Everyday Attention; TMT = Trail-Making Test; ToM = Theory of Mind; TROG = Test for Receptive of Grammar; VFI = Verbal Fluency Index; VOSP 
= Visual Object and Space Perception Battery; WAIS = Wechsler Adult Intelligence Scale; WMS = Wechsler Memory Scale; WCST = Wisconsin 



























Naming The original ECAS consists of 8 pictures including both living and non-living things, and manipulable and 
non-manipulable objects. For each picture in ECAS-A, a selection of alternative objects was chosen that 
matched the properties of the original pictures. For example, alternative objects for helicopter remained as 
modes of transport such as tractor and caravan. Alternative stimuli were also matched in terms of word 
frequency and difficulty based on their reported frequency within the British National Corpus (BNC). Once 
finalised, all objects were designed and drawn by the University of Edinburgh’s graphic department.   
Comprehension As with the ECAS-A, questions were developed using the naming objects as target stimuli. Questions were 
designed to target ‘hidden’ features of each object i.e., features that cannot be easily ascertained from the 
picture alone. As such, the questions maximised the need for a true understanding of what the object 
is/does. Questions were additionally designed to rely on the understanding of both nouns and verbs for 
successful completion. Finally, target stimuli were used multiple times to avoid participants using a process 




Spelling The original ECAS spelling words were of low to medium frequency and included nouns, verbs and 
compound words. Alternative spelling words matched the original words on the same components. Word 
frequencies were assessed using the BNC. Special attention was paid to the grammatical and 
orthographical forms of the words to ensure the closest match possible.  
 
Executive Subtests 
Backward digit span Random samples of numbers were generated using RStudio and the ‘sample’ function. For example, to 
generate a random series of 6 numbers the following code was used: 
 
> array <- c(1,2,3,4,5,6,7,8,9)  
> sample(x=array, size = 6, replace = FALSE) 
 
Alternation No changes were deemed possible in this subtest without fundamentally altering the nature of the task. As 
such, this subtest was unchanged for the alternate forms.  
Sentence completion Alternate sentences were constructed to include a combination of verbs and nouns, different grammatical 




Social cognition  Alternate pictures for this task were not developed to avoid introducing unnecessary confounding 
elements. Rather, the target item which the face likes is altered for each version. During pilot testing, each 
participant’s own favourite for each box was recording. The face’s favourites were chosen to avoid 
common participant favourites. For example, the item ‘bed’ is extremely popular among participants and as 
such, this item was excluded as a possibility for the face’s favourite.  
 
Fluency Subtests 
Free fluency Borkowski, Benton and Spreen (1967) classified letters as hard (Q, J, V, Y, K, U), moderate (I, O, N, E, G, 
L, R), and easy (H, D, M, W, A, B, F, P, T, C, S). As the letter ‘S’ from the ECAS-A falls into the Borkowski 
et al (1967) ‘easy’ category, selection of alternate letters was restricted to the same category.  An 
additional consideration was those letters incorporated in the most common test of verbal fluency, the 
COWAT.  Letter combinations used in variations of the COWAT are F, A, S (Benton, 1976; Spreen & 
Benton, 1969); C, F, L and P, R, W (Benton et al., 1994). As such, letters were chosen based on their 





Restricted fluency Like the free fluency task, letters for the restricted fluency were chosen based on their presence in 
Borkowski et al.’s (1967) ‘easy’ category. However, unlike the free fluency, greater attention was paid to 
the letters’ word frequency as the COWAT does not include a four-letter restriction condition.  
 
Memory Subtests 
Story recall Alternative short stories were formulated in the style of a newspaper article with a similar structure and 
affect. Stories included a name, a job, and two numbers. In total, there were 10 items to be recalled that 
converted to a total score of immediate recall. It was ensured that the stories did not have a highly emotive 
storyline that may aid recall. 
 
Visuospatial Subtests 
Dot counting  Alternate dot counting stimuli were developed while retaining the same number of dots, but changing the 
dots’ location. The order of presentation was also retained to enhance equivalence.  
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Cube counting Alternate cube counting stimuli were developed while retaining the same number of cubs, but changing the 
formation of the structures. This is true bar one stimulus. For the ECAS-C, the third structure (which in 
ECAS-A and ECAS-B has 10 cubes) only has 8 cubes. This is because the 8-cube structure matched most 
closely in terms of accuracy during piloting.   





Benton, A. L., & Hamsher, S. K. (1978). Multilingual aphasia examination. Iowa City, IA: University of Iowa Press 
Borkowski, J. G., Benton, A. L., & Spreen, O. (1967). Word fluency and brain damage. Neuropsychologia, 5(2), 135-140. 
 Spreen, O. & Benton, D. F. (1969). Neurosensory Center of Comprehensive Examination for Aphasia: Manual of directions. 







Supplementary Table 2.2. Cut-offs for impairment using the ECAS-A-B-C 
DOMAIN SUBTESTS MAX SCORE A-B-C 
Language Naming, Comprehension, Spelling /28 26 
Verbal Fluency Fluency Letter S, Fluency Letter T /24 14 
Executive 
Reverse Digit Span, Alternation, Sentence Completion, 
Social Cognition 
/48  33 
ALS-SPECIFIC: /100 77 
Memory  
Immediate recall, Delayed recall score,  
Delayed recognition 
/24 13 
Visuospatial Dot Counting, Cube Counting, Number Location /12 10 
ALS NON-SPECIFIC: /36 24 






Supplementary Table 2.3. Practice effects for the ECAS subtests (A-A-A and A-B-C)  















Language† 28.00 (0) 28.00 (0) 28.00 (0) .283 28.00 (0) 28.00 (0) 28.00 (0) .524 
Fluency 18.70 (4.17) 19.70 (3.33) 20.00 (3.24) .283 21.05 (2.53) 20.42 (2.06) 20.95 (2.70) .803 
 Free 10.10 (1.65) 10.30 (.98) 10.40 (1.05) .999* 10.53 (1.31) 10.11 (1.24) 10.32 (1.20) .999 
 Restricted 8.50 (3.24) 9.40 (2.91) 9.60 (2.56) .447 10.63 (1.50) 10.32 (1.20) 10.63 (1.77) .999 
Executive 37.65 (3.76) 38.4 (5.27) 39.75 (5.09) .030 41.37 (3.74) 42.05 (3.75) 42.53 (4.53) .693 
 Digit Span 6.4 (1.73) 7.2 (1.91) 7.6 (1.6) <.001 7.53 (2.14) 8.00 (2.05) 8.63 (2.34) .087*§ 
 Sentence Completion 9.15 (1.63) 10.05 (1.32) 10.65 (1.42) <.001 11.05 (1.08) 11.05 (1.08) 11.26 (.65) .999 
 Social Cognition† 12.00 (0) 12.00 (0) 12.00 (0) .999 12.00 (0) 12.00 (0) 12.00 (0) .999 
Memory 17.90 (2.34) 21.65 (2.37) 22.40 (1.88) <.001 19.74 (2.45) 19.47 (1.87) 20.05 (2.20) .803 
 Immediate Recall 6.70 (1.75) 8.50 (1.24) 9.10 (.91) <.001 7.63 (1.26) 7.53 (1.54) 7.21 (1.47) .999 
 Delayed Recall  9.15 (.81) 9.70 (.66) 9.65 (.81) .130*§ 9.21 (.98) 9.26 (.73) 9.47 (.70) .999 
 Recognition  2.10 (1.12) 3.45 (.89) 3.65 (.67) <.001* 2.89 (1.10) 2.65 (.95) 3.37 (.68) .604 
ALS Specific 83.65 (7.32) 85.55 (8.36) 87.25 (8.21) .007* 89.53 (6.13) 89.95 (5.86) 90.74 (7.35) .999 
ALS Non-Specific 29.60 (2.46) 33.35 (2.46) 34.25 (1.80) <.001 31.58 (2.65) 31.21 (1.99) 31.74 (2.35) .999 
ECAS Total 113.25 (8.66) 118.90 (9.86) 121.50 (9.20) <.001 121.11 (7.53) 121.16 (7.34) 122.47 (9.09) .999 
Note. Due to ceiling effects present in the data, some subtests/domains were not analysed and excluded from the above table.  * Greenhouse-Geisser 
correction applied to p-value.  † = Non-parametric Friedman’s Test employed, with median and median absolute deviation reported instead of mean and 
SD. § = p-value significant prior to multiple comparison correction. Holm corrections applied for multiple comparison adjustment for different groups of 
comparisons (i.e., Group 1=ALS Specific, ALS Non-Specific, ECAS Total = 3 comparisons; Group 2 = Cognitive domains with 4 comparisons, and Group 

























Supplementary Table 3.1. RCI thresholds for the ECAS-A, ECAS-B, and ECAS-C 






 ?̅?1 ?̅?2 ?̅?3 S1 S2 rxx1 rxx2 rxx3 SEm SEdiff SEm SEdiff SEm SEdiff 
ALS Specific 
85.65 86.39 86.20 8.56 8.55 .87 .91 .90 3.11 4.40 2.77 3.92 2.59 3.66 
ALS Non-
Specific 
30.14 29.89 30.41 3.73 3.66 .85 .88 .86 1.44 2.04 1.37 1.94 1.28 1.81 
ECAS Total 115.79 116.28 116.61 115.79 116.28 .90 .94 .93 3.54 5.00 3.09 4.37 2.85 4.04 
Note. ?̅?1 is the mean of ECAS-A, ?̅?2 is the mean of ECAS-B, ?̅?3 is the mean of ECAS-C,  S1 is the standard deviation of ECAS-A,  S2 is the standard 
deviation of ECAS-B, rxx1 is the intraclass correlation coefficient of ECAS-A-B,  rxx2 is the intraclass correlation coefficient of ECAS-B-C,  rxx3 is the 
intraclass correlation coefficient of ECAS-A-C, SEm is the standard error of the measurement, SEdiff is the standard error of the difference.    
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Supplementary Table 3.2. Test-retest reliability of alternate versions of the ECAS         
 
ECAS-A to ECAS-B ECAS-A to ECAS-C ECAS-B to ECAS-C 
ECAS-A to ECAS-B to ECAS-
C 
 ICC   95% CI p ICC 95% CI p ICC 95% CI p ICC 95% CI p 
ALS Specific .87 .78 - .92 <.0001 .91 .84 - .95 <.0001 .90 .82 - .94 <.0001 .93 .89 - .96 <.0001 
 Language .87 .77 - .93 <.0001 .88 .77 - .93 <.0001 .89 .80 - .94 <.0001 .93 .88 - .96 <.0001 
 Fluency .73 .54 - .84 <.0001 .80 .65 - .89 <.0001 .79 .63 - .88 <.0001 .84 .75 - .90 <.0001 
 Executive .72 .52 - .83 <.0001 .71 .51 - .84 <.0001 .79 .63 - .88 <.0001 .82 .72 - .89 <.0001 
ALS Non-Specific .85 .75 - .91 <.0001 .88 .80 - .93 <.0001 .86 .76 - .92 <.0001 .91 .85 - .94 <.0001 
 Memory .86 .77 - .92 <.0001 .87 .77 - .92 <.0001 .87 .77 – 92 <.0001 .91 .85 - .94 <.0001 
 Visuospatial .30 -.15 - .58 .082 .31 -.19 - .60 .089 .46 .05 - .69 .02 .47 .16 - .68 .003 


























Table e-1. Patient and Control Cognition and Behaviour 
 Controlsa ALSa t or W P-value r or D 
Cognitive Domains      
 ALS Specific 84.26 ± 9.12 76.71 ± 13.44 -5.12 < 0.0001 0.658 
  Languageb  28.0 ± 0 27.0 ± 1.48 4614.0 < 0.001 0.237 
  Executive 38.27 ± 5.89 34.44 ± 7.84 -4.24 < 0.001 0.553 
  Fluency 19.07 ± 2.95 16.32 ± 5.02 -5.34 < 0.0001 0.668 
      
 ALS Non-Specific 29.98 ± 3.76 27.04 ± 5.41 -4.89 < 0.0001 0.629 
  Memory 18.27 ± 3.43 15.48 ± 4.94 -5.11 < 0.0001 0.657 
  Visuospatialb 12.0 ± 0  12.0 ± 0 5826.0 0.136 - 
      
 ECAS Total 114.24 ± 11.65 104.07 ± 16.59 -5.49 < 0.0001 0.709 
 
Behaviour 
     
 ECAS Behavioura  1.0 ± 1.48    
 Psychosis (% yes)  6.7    
aValues are mean  ± one standard deviation. bMedian ± median absolute deviation are reported. r = effect 
size for Wilcoxon-Mann-Whitney Test, and D = Cohen’s D. P-values corrected for multiple comparisons.  
Behaviour is the number of behavioural dimensions (max 5). Psychosis is defined as the presence one of 




Table e-2. Tetrachoric correlation coefficients of the cognitive and behavioural features  
  
ALS Specific ALS Non-Specific Behaviour 
  








Language 1          
Fluency .46 1         












Memory .49 .45 .34 1       









Apathy .10 .08 .24 .18 .23 1     
Disinhibition .23 .38 .31 .25 .24 .57 1    
Sympathy .24 .23 .37 .25 .09 .64 .79 1   
Perseveration .12 .22 .28 .17 .44 .53 .37 .46 1  
Eating  .05 .27 .28 .17 .35 .66 .51 .40 .59 1 
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Table e-2. Relationship between cognition, behaviour, and clinical disease variables. 
(uncorrected) 
 ALS Specific ALS Non-Specific ECAS Total Behaviour 
Site of onset  
F(2,139) = .215, p  = 
.807 
F(2, 140) = .046, p = 
.955 
F(2,138) = .241, p = 
.786 
H(2) = 2.28, p = .320 
Diagnostic delay rs = .078, p = .326 rs = -.018, p = .826 rs = .053, p = .520 rs = -.110, p = .182 
Riluzole Use W = 2651, p = .214 W = 2466, p = .673 W = 2571.5, p = .312 W = 1989.5, p = .871 
ALSFRS-R rs = .117, p = .156 rs = .041, p = .619 rs = .118, p = .156 rs = -.258, p = .002 
Weight at testing rs = .132, p = .100 rs = .084, p = .30 rs = .134, p = .097 rs = -.041, p = .626 
Bulbar involvement W = 3896.5, p = .011 W = 3605.5, p = .163 W = 3749, p = .028 W = 2061, p = .005 
Upper limb involvement W = 2679, p = .567 W = 2395, p = .465 W = 2608.5, p = .698 W = 2040, p = .527 
Lower limb involvement W = 2142, p = .136 W = 2337, p = .411 W = 2112, p = .125 W = 2036, p = .621 
HADS-D rs = -.169 , p = .041 rs = -.096 , p = .248 rs = -.168, p = .043 rs = .360, p < .001 
HADS-A rs = -.084 , p = .312 rs = -.040, p = .633 rs = -.093, p = .264 rs = .20 p = .019 
Note. Site of onset compared bulbar, upper limb, and lower limb. HADS-D = Hospital Anxiety and Depression 
Scale (Depression Score). HADS-A = Hospital Anxiety and Depression Scale (Anxiety Score); F = one-way 
ANOVA; H = Kruskal-Wallis rank sums test; rs = Spearman correlation.  
 
 
The above table contains scores uncorrected for multiple comparisons. Holm-
Bonferroni corrections were applied for each clinical variable and displayed in 
Supplementary Table 3. 
 
 
Table e-3. Relationship between cognition, behaviour, and clinical disease variables 
(corrected) 
 ALS Specific ALS Non-Specific ECAS Total Behaviour 
ALSFRS-R rs = .117, p = .469 rs = .041, p = .619 rs = .118, p = .469 rs = -.258, p = .009 
Bulbar involvement W = 3896.5, p = .033 W = 3605.5, p = .163 W = 3749, p = .057 W = 2061, p = .019 
HADS-D rs = -.169 , p = .122 rs = -.096 , p = .248 rs = -.168, p = .122 rs = .360, p < .001 
HADS-A rs = -.084 , p = .792 rs = -.040, p = . 792 rs = -.093, p = . 792 rs = .20 p = .075 
Note. HADS-D = Hospital Anxiety and Depression Scale (Depression Score). HADS-A = Hospital Anxiety and 






Table e-4. Cognitive and behavioural data across King’s disease stages by bulbar 
involvement 
 Stage 1  Stage 2  Stage 3  Stage 4  
Bulbar Yes     
 N 15 11 22 35 
 ALS Specific  76.33 ± 17.17 81.09 ± 7.45 74.76 ± 15.12 69.46 ± 15.88 
 ALS Non-Specific 25.60 ± 8.30 29.36 ± 3.44 27.73 ± 4.41 24.62 ± 6.55 
 ECAS Total 101.93 ± 24.95 110.45 ± 7.95 102.24 ± 18.47 95.59 ± 18.34 
 Behaviour* 0 ± 0 0 ± 0 1 ± 1.48 2.5 ± 1.48 
Bulbar No     
 N 25 34 0 19 
 ALS Specific  79.29 ± 10.51 80.65 ± 10.50 - 79.68 ± 9.28 
 ALS Non-Specific 27.84 ± 4.22 27.56 ± 4.07 - 28.42 ± 4.80 
 ECAS Total 107.04 ± 12.10 108.21 ± 13.19 - 108.11 ± 12.21 
 Behaviour* 0 ± 0 0 ± 0 - 0.5 ± 0.74 
Note. *  median and median absolute deviation. Stage 3 is defined as the presence of upper limb, lower limb, 







































































































































“What is your area of speciality?” 
 
Neurology Psychology Nursing Other 
    
 
 
If ‘other,’ please specify:  
 
 
“For how many years have you worked in your area of speciality?” 
 
Response:        
       
 
 
“For how many years have you worked with MND patients?” 
 
Response       
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SECTION B: SCREENING IN MND 
 
Say: “I’m going to ask you about cognition and behaviour in patients with MND” 
 “A screen is a brief test given to patients to see whether mental abilities, such as 
language and memory, or behaviours, are different to that of a healthy adult.”  




“In your opinion, how important is it to screen for cognitive and behaviour change in 
patients with MND?” 
 




Important Very important 
     
 
 





“Do you think all patients diagnosed with MND should routinely be screened for 
cognitive and behavioural change?” 
 












“In your practice, how frequently, if ever, do you screen for cognitive and/or 
behaviour change in MND?”  
 
Never Seldom Sometimes Often Always 
     
 
 
“If never, Why?” 











SECTION C: BARRIERS 
 
Say: “I would like to know your thoughts and opinions regarding potential barriers to 
cognitive and behavioural screening in MND. 
 
 














     
 
If ‘other’, please specify: 
 
“What, if any, are the main barriers to screening for cognitive and behavioural 
change in MND?” 




“How might these barriers be overcome?” 
 
[RECORDED ANSWER] 
 
